This page is no longer updated as of April 5th, 2021

COVID-19 Vaccine & Therapeutics Tracker

See the latest updates for vaccine and therapeutic drug developments for COVID-19. Check back for regular updates!
New addition counters are reset every Monday by 11:59 PM ET. Last updated April 5, 2021 at 11:07AM ET

Vaccines

216
TOTAL
+ 6
92
IN HUMAN
TRIALS
+ 6

Therapeutic Drugs

506
TOTAL
+ 1
419
IN HUMAN
TRIALS
+ 1
Activity Feed
Live updates on vaccine and therapeutic drug developments
Vaccine

Cadila Healthcare Limited’s DNA plasmid vaccine, ZyCoV-D, enters Phase 1/2 clinical trials in The Republic of India.

July 4, 2020
Vaccine

ZF2001, the recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters phase 3 clinical trials in China.

November 30, 2020
Vaccine

ZF2001, the recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 2 clinical trials in China.

July 10, 2020
Vaccine

The Results of Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. protein subunit vaccine phase 1/2 clinical trial published in the preprint server medRxiv reveals ZF2001 was well-tolerated and immunogenic.

December 22, 2020
Vaccine

A new recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., ZF2001, enters phase 1 clinical trials in China.

June 24, 2020
Vaccine

Vaxart’s non-replicating Ad5 vector SARS-CoV-2 vaccine VXA-CoV2-1 enters Phase I clinical trials in the United States of America.

September 24, 2020
Vaccine

Valneva Austria GmbH’s inactive vaccine, VLA2001, enters phase 1/2 clinical trials in the United Kingdom.

December 16, 2020
Drug

Vir Biotechnology, Inc and GlaxoSmithKline’s SARS-CoV-2 neutralizing antibody, VIR-7831, enters phase 2/3 clinical trials.

September 10, 2020
Drug

VIR-7831 as monotherapy demonstrated an 85% reduction in hospitalization or death in adults with early COVID-19 compared to placebo according to a press release of preliminary results from a phase 3 clinical trial.

March 10, 2021
Vaccine

VBI-2902a, a new virus-like particle vaccine developed by VBI Vaccines Inc., enters phase 1/2 clinical trials in Canada.

February 26, 2021
Vaccine

Merck’s V591, a SARS-CoV-2 vaccine candidate that uses an attenuated measles virus as a vector, enters Phase 1 clinical trials.

August 4, 2020
Vaccine

Merck Sharp & Dohme Corp.’s second COVID-19 vaccine, V590, enters Phase 1 clinical trials in the United States of America.

September 30, 2020
Vaccine

June 12th - A new Unnamed Spike Protein Candidate developed by The University of Queensland enters Phase 1 clinical trials in Australia.

June 12, 2020
Vaccine

Sanofi Pasteur’s mRNA vaccine starts phase 1/2 clinical trials in the United States of America.

March 15, 2021
Vaccine

ZHONGYIANKE Biotech Co, Ltd.’s recombinant protein vaccine enters phase 2 clinical trials in China.

March 24, 2021
Vaccine

An Unnamed Recombinant Vaccine developed by Jiangsu Province Centers for Disease Control and Prevention and West China Hospital enters Phase 1 clinical trials.

August 28, 2020
Vaccine

The Unnamed Recombinant Vaccine - Jiangsu from Jiangsu Province Centers for Disease Control and Prevention and West China Hospital enter phase 2 clinical trials in China.

November 23, 2020
Vaccine

Sanofi and GlaxoSmithKline’s unnamed protein subunit vaccine [Unnamed Protein Subunit Vaccine - Sanofi/GSK] enters phase 1/2 clinical trials in the United States.

September 3, 2020
Vaccine

A new Unnamed Inactive Vaccine SARS-CoV-2 vaccine being developed by the Chinese Academy of Medical Sciences in collaboration with West China Second University Hospital and Yunnan Center for Disease Control and Prevention enters Phase 1/2.

June 2, 2020
Vaccine

The Unnamed Inactive Vaccine - Yunnan being developed by The Chinese Academy of Medical Sciences enters Phase II of clinical trials testing.

June 20, 2020
Vaccine

The unnamed inactivated SARS-CoV-2 vaccine developed by the Chinese Academy of Medical Sciences enters phase 3 in China with an expected enrollment of over 34,000 individuals.

December 9, 2020
Vaccine

News reports indicate that the Unnamed Inactive Vaccine - Wuhan developed by the Wuhan Institute of Biological Products and Sinopharm induced neutralizing antibodies in all vaccinated individuals, and that Phase III clinical trials will start June 23rd in both China and the United Arab Emirates.

June 23, 2020
Vaccine

The Unnamed Inactive Vaccine - Wuhan developed by The Wuhan Institute of Biological Products enters Phase 3 clinical trials in The United Arab Emirates.

July 18, 2020
Vaccine

An interim report of Phase 1/2 trials of the Unnamed Inactive Vaccine - Wuhan Published in the Journal JAMA indicates that patients had a low rate of adverse reactions and demonstrated high neutralizing antibody titers.

August 13, 2020
Vaccine

Wuhan Institute of Biological Products and Sinopharm expand phase 3 clinical trials of their inactive SARS-CoV-2 vaccine to Peru.

November 3, 2020
Vaccine

COVAXX and United Biomedical Inc.’s protein subunit vaccine, UB-612 start Phase 1 clinical trials in Taiwan.

September 11, 2020
Vaccine

A novel inactivated SARS-CoV-2 vaccine, Unnamed Inactive Vaccine - Jiangsu, developed by Beijing Minhai Biotechnology Co., Shenzhen Kangtai Biological Products Co., and the Jiangsu Province Centers for Disease Control and Prevention enters phase 1/2 clinical trials in China.

February 17, 2021
Drug

Tocilzumab did not increase patients' chances of survival or help them get better faster according to two studies while a third less definitive trial did find the drug increased the chances of survival. All studies were published in the Journal of the American Medical Association.

October 20, 2020
Vaccine

COVAXX’s protein antigen vaccine, UB-612, enters phase 2/3 clinical trials.

December 24, 2020
Drug

Tocilizumab was not superior to standard care alone in patients with severe or critical COVID-19, and it might increase mortality, according to phase 3 clinical trial results published in the British Medical Journal.

January 20, 2021
Drug

Tocilizumab* failed to improved clinical status in patients with COVID-19 associated pneumonia, or reduced patient mortality in a randomized, double-blind, placebo-controlled phase 3 trial by Roche. The clinical trial program will continue to further explore the drug in other settings, including in combination with an antiviral.

July 29, 2020
Drug

Roche announced that their Phase 3 study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Tocilizumab* plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care.

September 18, 2020
Drug

The anti-interleukin-6 receptor antibody Tocilizumab* was associated with lower mortality in mechanically ventilated patients suffering from COVID-19 in a single-center, small scale study published in the journal Clinical Infectious Disease. This reduction in mortality, however, came with a higher occurrence of bacterial infections.

July 11, 2020
Drug

Preprint article in medRxiv indicates that the administration of Tocilizumab* is associated with rapid improvement in some clinical indices of those individuals not on ventilation, however, controlled clinical trials are needed to confirm its utility.

June 12, 2020
Vaccine

TMV-083, a vaccine that uses a live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of SARS-CoV-2 enters Phase 1 clinical trials.

August 4, 2020
Drug

Tocilizumab reduced the risk of death, shortened the time to hospital discharge, and reduced the need for a mechanical ventilator when given to hospitalized patients with severe COVID-19 according to the United Kingdom’s RECOVERY Trial.

February 11, 2021
Vaccine

Takeda’s TAK-919 vaccine enters phase 1/2 clinical trials in Japan.

December 21, 2020
Vaccine

The Russian Sputnik V (Gam-COVID-Vac) enters phase 3 clinical trials in Venezuela.

November 24, 2020
Vaccine

Sputnik V (Gam-COVID-Vac), a new adenoviral-based vaccine developed by Gamaleya Research Institute, starts phase 1/2 clinical trials in Russia.

June 18, 2020
Vaccine

Sputnik V (Gam-COVID-Vac) starts phase 3 clinical trials in the United Arab Emerates.

December 7, 2020
Vaccine

Sputnik V (Gam-COVID-Vac) enters Phase 3 clinical trials in Russia, with an expected enrollment of 40,000 participants.

August 28, 2020
Vaccine

Sputnik V (Gam-COVID-Vac) demonstrates 91.4% efficacy after 28 days (n=18,794) and 95% efficacy 21 days after the second dose according to the second interim analysis of clinical trials data in a press release from the Gamaleya Center team.

November 24, 2020
Vaccine

Russia becomes the first country to grant regulatory approval to a coronavirus vaccine, Sputnik V (Gam-COVID-Vac), prior to its completion of clinical trials.

August 11, 2020
Vaccine

The Russian Sputnik V (Gam-COVID-Vac) enters phase 2/3 clinical trials in the Republic of India.

November 23, 2020
Vaccine

SpFN COVID-19, a protein subunit vaccine developed by the United States Army Medical Research and Development Command, enters phase 1 clinical trial in the United States of America.

March 5, 2021
Vaccine

The European Medicines Agency starts a rolling review of the Sputnik V (Gam-COVID-Vac) COVID-19 vaccine.

March 4, 2021
Vaccine

The shingles vaccine, Shingrix, enters Phase 1 clinical trials as a preventative agent in elderly individuals for its hypothesized non-specific immunomodulatory effects.

August 21, 2020
Drug

Sinocelltech Ltd.’s recombinant anti-SARS-CoV-2 spike protein monoclonal antibody, SCTA01, enters phase 2/3 clinical trials.

November 25, 2020
Vaccine

The Scientific and Technological Research Council of Turkey’s SARS-CoV-2 VLP Vaccine enters phase 1 clinical trials.

March 26, 2021
Vaccine

The spike protein subunit vaccine by Clover Biopharmaceutical, SCB-2019, enters Phase 1 clinical trials against COVID-19.

May 28, 2020
Vaccine

Clover Biopharmaceuticals SCB-2019 vaccine enters phase 2/3 clinical trials.

December 17, 2020
Drug

The anti-IL-6 antibody, Sarilumab*, was not beneficial in COVID-19 patients requiring mechanical ventilation according to Phase 3 clinical trial results released by Sanofi and Regeneron.

July 2, 2020
Vaccine

Two new COVID-19 vaccines, ChAdV68-S and SAM-LNP-S, developed by the United States National Institute of Allergy and Infectious Diseases enter phase 1 clinical trials.

March 1, 2021
Drug

Results from Sanofi and Regeneron’s Phase 3 clinical trials indicate no statistically significant reduction in hospital stay duration or time to improved clinical outcomes in COVID-19 patients treated with Sarilumab*. The companies do not anticipate conducting further clinical studies using this drug.

September 1, 2020
Drug

No clinical benefit was observed from the use of Ritonavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.

June 29, 2020
Drug

Inhaled version of antiviral Remdesivir* to start human clinical trials in August according to Gilead Sciences.

June 22, 2020
Drug

Remdesivir, Hydroxychloroquine, Lopinavir/ Ritonavir* and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.

October 15, 2020
Drug

Results released by Gilead indicate that in a Phase III trial, Remdesivir* treatment resulted in significantly greater clinical improvement versus standard of care treatment alone.

June 1, 2020
Drug

A final report by the ACTT-1 Study Group on Remdesivir* in a double-blind, randomized, placebo-controlled trial of 1029 adults who were hospitalized with Covid-19 was published in the New England Journal of Medicine indicating a shortening of the time to recovery and evidence of lower respiratory tract infection compared to placebo control.

October 8, 2020
Drug

Remdesivir*, Gilead Sciences’ treatment found to have worked in COVID-19 clinical trials, will cost U.S. hospitals $3,120 for the typical patient with private insurance.

June 29, 2020
Drug

Gilead Sciences starts Phase 1/2 clinical trial testing of inhaled Remdesivir* in patients with early-stage SARS-CoV-2 disease.

September 4, 2020
Drug

Remdesivir* shows clinical benefit in non-human primates infected with SARS-CoV2, as published in Nature.

June 9, 2020
Drug

Health Canada authorizes the use of Remdesivir* in patients with severe COVID-19 symptoms.

July 28, 2020
Drug

The United Kingdom National Health Service follows suit behind The United States and Japan and authorizes the use of Remdesivir* for people with coronavirus infection after a publication in The New England Journal of Medicine indicates it can cut recovery time by about four days.

May 26, 2020
Drug

The European Union purchases $73.9 million worth of Remdesivir* from Gilead, enough to treat 30,000 patients.

July 29, 2020
Drug

Remdesivir*, Hydroxychloroquine, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.

October 15, 2020
Drug

Remdesivir*, which has been authorized for use on an emergency basis since spring, was officially approved by US regulators as the first treatment for COVID-19.

October 22, 2020
Drug

Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon regimens had little or no effect on hospitalized patients with COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay according to Interim WHO Solidarity Trial Results published in the New England Journal of Medicine.

December 2, 2020
Vaccine

ReCOV, the two-component recombinant protein vaccine developed by the Jiangsu Rec-Biotechnology Co., Ltd, enters phase 1 clinical trials in New Zealand.

March 26, 2021
Drug

The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Ravulizumab into Phase 4 clinical trials.

May 18, 2020
Vaccine

The Republic of Khazakstan’s QazCovid-in COVID19 vaccine enters phase 3 with an expected 3000 participants.

December 31, 2020
Vaccine

QazCovid-in, an inactive viral vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan enters Phase 1/2 clinical trials.

August 28, 2020
Vaccine

Providence Therapeutic’s mRNA vaccine, PTX-COVID19-B, enters phase 1 clinical trials in Canada.

February 21, 2021
Drug

Proxalutamide significantly accelerated viral clearance and time to clinical remission in mild to moderate COVID-19 patients versus placebo according to a randomized, double-blinded, placebo-controlled trial published in the journal Cureus.

February 22, 2021
Drug

Pfizer’s oral antiviral clinical candidate, PF-07321332, enters phase 1 clinical trial in the United States of America.

February 16, 2021
Drug

Pfizers’ SARS-CoV-2 specific antiviral [PF-07304814] enters Phase 1 clinical trials.

September 1, 2020
Vaccine

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate, NVX-CoV2373, for local production and commercialization in Japan.

August 7, 2020
Vaccine

Novavax’s protein subunit vaccine, NVX-CoV2373, starts phase 3 clinical trials in the United Kingdom in combination with the seasonal influenza vaccine.

October 12, 2020
Vaccine

NVX-CoV2373 phase 3 clinical trials expand with 30000 additional participants in The United States of America, Mexico and Puerto Rico.

November 2, 2020
Vaccine

Vaccination with NVX-CoV2373 was generally well-tolerated, induced neutralization antibody titers in 100% of participants, and elicited a robust cellular response in Novavax’s 131 participant Phase 1 clinical trial results.

August 4, 2020
Vaccine

Novavax’s protein subunit vaccine NVX-CoV2373 enters Phase 2 clinical trials in South Africa.

August 31, 2020
Vaccine

A publication in the New England Journal of Medicine indicates that Novavax’s NVX-CoV2373 appears to be safe, and elicits both a strong antibody and cellular response against SARS-CoV-2.

September 2, 2020
Vaccine

Novavax starts Phase 3 clinical trials of its COVID-19 vaccine candidate, NVX-CoV2373, in the United Kingdom.

September 11, 2020
Vaccine

Novavax secures upto $60M from the U.S. Department of Defense to support the production of their NVX-CoV2373 vaccine. The agreement includes a 2020 delivery of 10 million doses for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by the U.S. FDA.

June 4, 2020
Vaccine

SARS-CoV-2 B.1.1.7 was shown to be sensitive to neutralization by serum samples from convalescent individuals and recipients of mRNA-1273 and NVX-CoV2373 vaccines indicating that this variant is unlikely to be a major concern for current vaccines according to a publication in the journal Cell Host & Microbe.

March 3, 2021
Vaccine

Novavax administrates the NVX-CoV2373 vaccine to the first participants in Phase 1 clinical trial. Phase 2 planned to begin following successful Phase 1 results. On May 11, Novavax secured a $388M grant from CEPI (a Bill & Melinda Gates Foundation-backed vaccine development coalition).

May 25, 2020
Vaccine

Novavax’s NVX-CoV2373 demonstrated 100% protection against severe disease, 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain, and 55.4% efficacy in a region where the vast majority of strains are B1.351 escape variants according to a press release of their phase 3 U.K. and phase 2b South Africa clinical trial studies, respectively.

March 11, 2021
Vaccine

Novavax’s COVID-19 Vaccine, NVX-CoV2373, Demonstrated 89.3% Efficacy in their phase 3 clinical trial according to a company press release.

January 28, 2021
Vaccine

The Newcastle disease vector vaccine, NDV-HXP-S, enters phase 1 clinical trials in Thailand.

February 21, 2021
Vaccine

A second COVID-19 vaccine developed by SK Bioscience's, NBP2001, enters phase 1 clinical trials in the Republic of Korea.

February 18, 2021
Vaccine

A new spike protein vaccine, Nanocovax, enters phase 1/2 in Vietnam.

December 24, 2020
Vaccine

Emergent BioSolutions enters into a $628 million contract with the US government to boost manufacturing capacity for a COVID-19 vaccine.

June 1, 2020
Drug

Mabwell Bioscience Co.’s new anti-coronavirus antibody, MW33, enters Phase 1 clinical trials.

August 31, 2020
Vaccine

MVC-COV1901, a protein subunit vaccine developed by Medigen Vaccine Biologics Corp. enters Phase 1 clinical trials in Taiwan.

July 27, 2020
Vaccine

Medigen Vaccine Biologics Corp.’s COVID19 vaccine, MVC-COV1901, enters phase 2 clinical trials in Taiwan and Vietnam.

January 5, 2021
Vaccine

The Universitätsklinikum Hamburg-Eppendorf’s Modified Vaccinia Ankara virus vaccine, MVA-SARS-2-S, enters Phase 1 clinical trials in Germany.

September 29, 2020
Vaccine

MV-014-212, the live-attenuated respiratory syncytial virus vector vaccine depveloped by Meissa Vaccines, Inc., starts phase 1 clinical trials in The United States of America.

March 15, 2021
Vaccine

Moderna’s mRNA-1273 was approved by the United States Food and Drug Administration.

December 18, 2020
Vaccine

Moderna’s mRNA-1273 vaccine efficacy against COVID-19 was 94.1% overall and 100% against severe COVID-19 according to a press release detailing their primary efficacy analysis of the Phase 3 COVE study.

November 30, 2020
Vaccine

ModernaTX, Inc.’s new refrigerator-stable vaccine, mRNA-1283, starts phase 1 clinical trials in the United States of America.

March 24, 2021
Vaccines
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
216
TOTAL
+ 6
122 in preclinical development
92 in human trials
[{"sheetId":"4","name":"LV-SMENP-DC","technology":"Modified APC","technologyDetails":"LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04276896"],"organizations":["Shenzhen Geno-Immune Medical Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"The LV-SMENP-DC vaccine is made by modifying dendritic cells (DC) with lentivirus vectors expressing Covid-19 minigene SMENP and immune-modulatory genes. The COVID-19 genes expressed are selected conserved and critical structural and protease protein domains. Upon injection subcutaneously, these DCs will prime cytotoxic T lymphocytes that are specific to SARS-CoV-2. Alternatively, T cells will be primed ex vivo and intravenously infused into the patient. ","show":true,"date":"2021-04-05 11:05:10.034185","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac45ce1b981d00b29a7dd0"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac45ce1b981d00b29a7dd0-covid-19-vaccine-candidate-lv-smenp-dc-shenzhen-medical-inst","participants":["Phase 1|NA","Phase 1/2|100","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0004","nameId":"lv-smenp-dc-dendritic-cells-modified-with-lentiviral-vector-expressing-synthetic-minigene-based-on-domains-of-selected-viral-proteins-administered-with-antigen-specific-cytotoxic-t-lymphocytes"},{"sheetId":"3","name":"mRNA-1273","technology":"RNA-based vaccine","technologyDetails":"RNA; Lipid nanoparticle (LNP)-encapsulated mRNA","developmentStage":"Clinical","nextSteps":"Phase 1 started March 2020, study ends June 2021; Phase 2 to start Q2 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04283461","NCT04405076","NCT04470427","NCT04649151","NCT04748471","NCT04760132","NCT04785144","NCT04806113","NCT04805125","NCT04796896","NCT04818736","NCT04813796","NCT04811664"],"organizations":["ModernaTX, Inc.","National Institute of Allergy and Infectious Diseases","Biomedical Advanced Research and Development Authority","Assistance Publique - Hôpitaux de Paris","Institut National de la Santé Et de la Recherche Médicale, France","Ministry of the Interior and Health, Denmark","McGill University Health Centre/Research Institute of the McGill University Health Centre","CHU de Quebec-Universite Laval","Ministere de la Sante et des Services Sociaux","University Hospital, Basel, Switzerland","Swiss National Science Foundation","McMaster University","University of Alberta","University of Saskatchewan","University of Manitoba"],"funder":"Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"This vaccine is comprised of a lipid nanoparticle (LNP; proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein of SARS-CoV-2. Upon vaccination, host cells uptake the mRNA, generate the protein, and display it to the immune system. The host can thus generate an immune response against the spike protein which should be protective against infection with SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.034349","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac46971b981d00b29a822f"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac46971b981d00b29a822f-covid-19-vaccine-candidate-mrna-1273-moderna","participants":["Phase 1|440","Phase 2|780","Phase 2/3|9750","Phase 3|68100","Phase 4|14000"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"v-0003","nameId":"rna-lipid-nanoparticle-lnp-encapsulated-mrna"},{"sheetId":"9","name":"Convidicea (Ad5-nCoV)","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Adenovirus Type 5 vector","developmentStage":"Clinical","nextSteps":"Phase 2 started April 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04313127","NCT04341389","NCT04398147","NCT04526990","NCT04540419","NCT04552366","NCT04566770","ChiCTR2000031781","ChiCTR2000030906"],"organizations":["CanSino Biologics Inc.","Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China","Jiangsu Province Centers for Disease Control and Prevention","Hubei Provincial Center for Disease Control and Prevention","Zhongnan Hospital","Tongji Hospital","Canadian Center for Vaccinology","NPO Petrovax","Beijing Institute of Biotechnology"],"funder":"","publishedResults":["https://www.thelancet.com/journals/lancet/article/PIIS0140-6736|https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext"],"relatedUse":["https://www.thelancet.com/journals/lancet/article/PIIS0140-6736|https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext"],"countries":["China","Canada"],"description":"The Convidicea (Ad5-nCov) vaccine is generated by incorporating a full-length SARS-CoV-2 spike protein into a replication-defective Adenovirus Type 5 vector. It is then injected intramuscularly into patients and antibodies will be generated against the SARS-CoV-2 spike protein. ","show":true,"date":"2021-04-05 11:05:10.034457","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac4708ed090c00acd35765"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac4708ed090c00acd35765-covid-19-vaccine-candidate-ad5-ncov-cansino-biologics","participants":["Phase 1|276","Phase 1/2|696","Phase 2|989","Phase 3|40500","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0009","nameId":"non-replicating-viral-vector-adenovirus-type-5-vector"},{"sheetId":"CV1","name":"CoronaVac","technology":"Inactivated virus","technologyDetails":"Inactivated","developmentStage":"Clinical","nextSteps":"Phase 1/2 started April 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04352608","NCT04383574","NCT04456595","NCT04508075","NCT04551547","NCT04582344","NCT04617483","NCT04651790","NCT04747821","NCT04756830","NCT04754698","NCT04751695","NCT04751721","NCT04765215","NCT04775069","NCT04789356","NCT04801888","NCT04800133"],"organizations":["Sinovac Biotech Co.","Butantan Institute","PT Bio Farma","Faculty of Medicine Universitas Padjadjaran","National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia","Health Institutes of Turkey","Pontificia Universidad Catolica de Chile","Ministry of Health, Chile","D'Or Institute for Research and Education","University of Sao Paulo General Hospital","Izmir Bakircay University","Cigli Regional Training Hospital","Muğla Sıtkı Koçman University","Namik Kemal University","Humanity & Health Medical Group Limited","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","The University of Hong Kong"],"funder":"","publishedResults":["https://www.biorxiv.org/content/10.1101/2020.04.17.046375v1|https://www.biorxiv.org/content/10.1101/2020.04.17.046375v1","https://science.sciencemag.org/content/369/6499/77|https://science.sciencemag.org/content/369/6499/77"],"relatedUse":["https://www.biorxiv.org/content/10.1101/2020.04.17.046375v1|https://www.biorxiv.org/content/10.1101/2020.04.17.046375v1","https://science.sciencemag.org/content/369/6499/77|https://science.sciencemag.org/content/369/6499/77"],"countries":["China","Brazil","Republic of Indonesia","Chile"],"description":"Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) followed by inactivation using a chemical reagent (such as beta-propiolactone or formaldehyde). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive. ","show":true,"date":"2021-04-05 11:05:10.034584","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac47654ccb4800b1dd6a3d"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac47654ccb4800b1dd6a3d-covid-19-vaccine-candidate-unnamed-sinovac-biotech","participants":["Phase 1|288","Phase 2|1430","Phase 3|27730","Phase 4|42736","Phase NA|2358"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"v-0CV1","nameId":"inactivated"},{"sheetId":"5","name":"INO-4800","technology":"DNA-based","technologyDetails":"DNA plasmid","developmentStage":"Clinical","nextSteps":"Started Phase 1 April 2020; initial data expected late summer 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04336410","NCT04447781","NCT04642638"],"organizations":["Inovio Pharmaceuticals","International Vaccine Institute","Coalition for Epidemic Preparedness Innovations (CEPI)"],"funder":"Coalition for Epidemic Preparedness (CEPI) / Gates Foundation","publishedResults":["https://www.nature.com/articles/s41467-020-16505-0|https://www.nature.com/articles/s41467-020-16505-0"],"relatedUse":["https://www.nature.com/articles/s41467-020-16505-0|https://www.nature.com/articles/s41467-020-16505-0"],"countries":["United States of America","Republic of Korea","Global (CEPI)"],"description":"The INO-4800 vaccine is a double-stranded DNA plasmid that encodes antigens found in SARS-CoV-2. It is intradermally delivered into the arm of patients using proprietary CELLECTRA technology, which utilizes a small pulse of electricity (called electroporation) to form small pores in the person's cells which allows for easier uptake of the nucleic acid vaccine. Upon uptake, the cells then start to create the proteins encoded on the DNA plasmid, and the body can then create strong T cell and B cell (antibody) responses against the specific antigens. ","show":true,"date":"2021-04-05 11:05:10.034661","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac47e683330d00abddcf7f"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac47e683330d00abddcf7f-covid-19-vaccine-candidate-ino-4800-inovio-pharma","participants":["Phase 1|40","Phase 1/2|160","Phase 2/3|6578","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0005","nameId":"dna-plasmid"},{"sheetId":"CV8","name":"Unnamed Inactive Vaccine - Wuhan","technology":"Inactivated virus","technologyDetails":"Inactivated","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["ChiCTR2000031809","ChiCTR2000034780","NCT04510207","NCT04612972"],"organizations":["Wuhan Institute of Biological Products","Sinopharm","China National Biotec Group Company Limited","G42 Healthcare company","Abu Dhabi Health Services Company","Universidad Peruana Cayetano Heredia","Universidad Nacional Mayor de San Marcos"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) followed by inactivation using a chemical reagent (such as beta-propiolactone). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive.  \n","show":true,"date":"2021-04-05 11:05:10.034735","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|288","Phase 2|1168","Phase 3|60000","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0CV8","nameId":"inactivated-0"},{"sheetId":"1","name":"BBIBP-CorV","technology":"Inactivated virus","technologyDetails":"Inactivated","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["ChiCTR2000032459","ChiCTR2000034780","NCT04510207","NCT04560881","NCT04795414"],"organizations":["Beijing Institute of Biological Products","Sinopharm","China National Biotec Group Company Limited","G42 Healthcare company","Abu Dhabi Health Services Company","Laboratorio Elea Phoenix S.A.","The Huesped Foundation","Ruijin Hospital"],"funder":"","publishedResults":["https://www.sciencedirect.com/science/article/pii/S0092867420306954|https://www.sciencedirect.com/science/article/pii/S0092867420306954"],"relatedUse":["https://www.sciencedirect.com/science/article/pii/S0092867420306954|https://www.sciencedirect.com/science/article/pii/S0092867420306954"],"countries":["China"],"description":"Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) followed by inactivation using a chemical reagent (such as beta-propiolactone). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive.  \n","show":true,"date":"2021-04-05 11:05:10.034818","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eb5dd9116b6a700b01fc8fc"],"templateLink":"https://app.biorender.com/biorender-templates/t-5eb5dd9116b6a700b01fc8fc-covid-19-vaccine-candidate-unnamed-beijing-institute-of-biol","participants":["Phase 1|480","Phase 2|1648","Phase 3|63000","Phase 4|NA","Phase NA|1370"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0001","nameId":"inactivated-1"},{"sheetId":"9","name":"bacTRL-Spike","technology":"DNA-based","technologyDetails":"DNA plasmid","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04334980"],"organizations":["Symvivo Corporation","University of British Columbia","Dalhousie University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"bacTRL-Spike-1 is an oral vaccine containing the live bacterium Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2 directly to human cells. These cells can then produce the proteins and an immune response can be generated against the viral proteins.","show":true,"date":"2021-04-05 11:05:10.034884","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":["5eb5df3306b86300aee1b459"],"templateLink":"https://app.biorender.com/biorender-templates/t-5eb5df3306b86300aee1b459-covid-19-vaccine-candidate-symvivo-bactrl-spike","participants":["Phase 1|84","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|600"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-0009","nameId":"dna-plasmid-2"},{"sheetId":"8","name":"Comirnaty (BNT162b2)","technology":"RNA-based vaccine","technologyDetails":"Tozinameran","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["EudraCT 2020-001038-36","NCT04380701","NCT04368728","ChiCTR2000034825","NCT04523571","NCT04537949","EudraCT 2020-003267-26","EudraCT 2020-002641-42","NCT04588480","NCT04634760","NCT04649021","NCT04713553","NCT04754594","NCT04760132","NCT04760704","NCT04780659","NCT04775069","NCT04805125","NCT04800133","NCT04816643","NCT04816669","NCT04815031","NCT04811391","NCT04824638"],"organizations":["Biontech SE","Pfizer","Shanghai Fosun Pharmaceutical Development Co, Ltd.","Ministry of the Interior and Health, Denmark","University Hospital, Lille","Karolinska University Hospital","Karolinska Institutet","Humanity & Health Medical Group Limited","University Hospital, Basel, Switzerland","Swiss National Science Foundation","The University of Hong Kong","Institute of Public Health, Albania","World Health Organization","Centers for Disease Control and Prevention","Southeast Europe Center for Infectious Diseases Surveillance and Control","EPICONCEPT","ANRS, Emerging Infectious Diseases","Institut National de la Santé Et de la Recherche Médicale, France"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Germany","Global"],"description":"The Comirnaty (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. Upon vaccination, host cells uptake the mRNA, generate the protein, and display it to the immune system. The host can thus generate an immune response against the spike protein which will be protective against infection with SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.034982","type":"Vaccine","fdaApproved":"","updatedOrNew":"Updated","template":["5eb5e0d3763b1800af107eca"],"templateLink":"https://app.biorender.com/biorender-templates/t-5eb5e0d3763b1800af107eca-covid-19-vaccine-candidate-bnt162-a1-b1-b2-c2-biontech","participants":["Phase 1|5252","Phase 1/2|764","Phase 2|1260","Phase 2/3|33481","Phase 3|3660","Phase 4|11440","Phase NA|21750"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"v-0008","nameId":"tozinameran"},{"sheetId":"2","name":"NVX-CoV2373","technology":"Protein subunit","technologyDetails":"NVX-CoV2373; SARS-CoV-2 rS; Protein subunit; Full length S trimers/nanoparticle + Matrix M; TAK-019","developmentStage":"Clinical","nextSteps":"Start Phase 1 in May 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04368988","NCT04533399","NCT04583995","NCT04611802","NCT04712110","EudraCT 2020-004123-16"],"organizations":["Novavax","Takeda"],"funder":"Coalition for Epidemic Preparedness (CEPI)","publishedResults":[],"relatedUse":[],"countries":["United States of America","Australia","Japan"],"description":"The NVX-CoV2373 (also known as TAK-019) vaccine is an intramuscularly delivered nanoparticle vaccine. The nanoparticles are created by infecting Sf9 insect cells with baculoviruses viral vectors that express the SARS-CoV-2 spike protein. The proteins properly fold, undergo a series of programmed modifications, and are ultimately transported to the cell surface. Correctly folded and modified spike proteins are then extracted from the cell surface and purified to maintain their three-dimensional structure and biological activity, ultimately serving as the immunogenic molecule in the vaccine. The vaccine is also being tested with Matrix M adjuvant, a saponin-based adjuvant that acts in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes.","show":true,"date":"2021-04-05 11:05:10.035051","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|131","Phase 1/2|200","Phase 2|2904","Phase 3|48000","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0002","nameId":"nvx-cov2373-sars-cov-2-rs-protein-subunit-full-length-s-trimers-nanoparticle-matrix-m-tak-019"},{"sheetId":"6","name":"Covid-19/aAPC Vaccine","technology":"Modified APC","technologyDetails":"Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04299724"],"organizations":["Shenzhen Geno-Immune Medical Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"For the Covid-19/aAPC vaccine, artificial antigen presenting cells (aAPC) are altered by applying lentivirus modification including immune-modulatory genes and the viral minigenes. These cells are then inactivated for proliferation, safety tested and subjects receive multiple subcutaneous injections. The functionality of this vaccine is thought to work by priming T lymphocytes against the SARS-CoV-2 virus. \n","show":true,"date":"2021-04-05 11:05:10.035139","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5ebc087e29eaac00ada43a7f"],"templateLink":"https://app.biorender.com/biorender-templates/figures/all/t-5ebc087e29eaac00ada43a7f-covid-19-vaccine-candidate-covid-19aapc-shenzhen-medical-ins","participants":["Phase 1|100","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-0006","nameId":"artificial-antigen-presenting-cells-modified-with-lentiviral-vector-expressing-synthetic-minigene-based-on-domains-of-selected-viral-proteins"},{"sheetId":"10","name":"Unnamed","technology":"Virus Like Particle","technologyDetails":"VLP; virus-like particle, based on RBD displayed on virus-like particle","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Saiba GmbH"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035252","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0010","nameId":"vlp-virus-like-particle-based-on-rbd-displayed-on-virus-like-particle"},{"sheetId":"11","name":"CoVLP","technology":"Virus Like Particle","technologyDetails":"VLP; plant-derived VLP","developmentStage":"Clinical","nextSteps":"Start Phase 1 in July / August 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04450004","NCT04636697","NCT04662697"],"organizations":["Medicago Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada","United States of America","Japan"],"description":"The Medicago virus-like particle (VLP) vaccine is created by using plants as bioreactors to produce the SARS-CoV-2 S-spike protein. These proteins then assemble into particles that resemble the virus, without containing any of the infectious aspects. These will then be easily recognized by the host immune system, and an immune response will be generated that should protect against infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.035337","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|180","Phase 2|918","Phase 2/3|30612","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0011","nameId":"vlp-plant-derived-vlp"},{"sheetId":"12","name":"Unnamed","technology":"Virus Like Particle","technologyDetails":"VLP; ADDomerTM multiepitope display","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Imophoron Ltd","Bristol University's Max Planck Centre"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035408","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0012","nameId":"vlp-addomertm-multiepitope-display"},{"sheetId":"13","name":"Unnamed","technology":"Virus Like Particle","technologyDetails":"VLP","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Doherty Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035467","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0013","nameId":"vlp"},{"sheetId":"14","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine","Chile*"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035522","type":"Vaccine","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0014","nameId":"unknown"},{"sheetId":"15","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Emergex Vaccines","George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)*"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035575","type":"Vaccine","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0015","nameId":"unknown-3"},{"sheetId":"16","name":"Unnamed","technology":"Unknown","technologyDetails":"Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 testing by end of 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["VBI Vaccines","National Research Council of Canada"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035620","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0016","nameId":"pan-coronavirus-vaccine-candidate-targeting-covid-19-sars-and-mers-spike-protein"},{"sheetId":"17","name":"Unnamed","technology":"Unknown","technologyDetails":"Gene-encoded antibody vaccine, non-viral nanoparticle delivery","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["SmartPharm Therapeutics","Sorrento Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035693","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0017","nameId":"gene-encoded-antibody-vaccine-non-viral-nanoparticle-delivery"},{"sheetId":"18","name":"Unnamed","technology":"Unknown","technologyDetails":"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)","developmentStage":"Pre-clinical","nextSteps":"Animal study results by October 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["HaloVax (Voltron Therapeutics)","The Vaccine & Immunotherapy Center at the Massachusetts General Hospital"],"funder":"Analog Devices Foundation","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035757","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0018","nameId":"self-assembling-vaccine-fusion-protein-of-a-heat-shock-protein-and-avidin-with-biotinylated-immunogenic-peptides"},{"sheetId":"19","name":"Unnamed","technology":"Unknown","technologyDetails":"ISR-50","developmentStage":"Pre-clinical","nextSteps":"Animal study results expected in Q2 2020, Phase 1 begins Q4 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ISR Immune System Regulation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035839","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0019","nameId":"isr-50-4"},{"sheetId":"20","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ImmunoPrecise"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035881","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0020","nameId":"unknown-5"},{"sheetId":"21","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Tulane University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035925","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0021","nameId":"unknown-6"},{"sheetId":"22","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown","developmentStage":"Pre-clinical","nextSteps":"Phase 1 begins as early as September 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["SK Biosciences"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.035993","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0022","nameId":"unknown-7"},{"sheetId":"23","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vir Biotechnology","GSK"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036044","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0023","nameId":"unknown-8"},{"sheetId":"24","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Precision Vaccines Program at Boston Children's Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036087","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0024","nameId":"unknown-9"},{"sheetId":"25","name":"KBP-COVID-19","technology":"Protein subunit","technologyDetails":"In the case of developing a potential COVID-19 vaccine, KBP recently cloned a portion of COVID-19’s genetic sequence, which led to the development of a potential antigen — a substance that includes an immune response in the body and, in particular, the production of antibodies.\n\nThis antigen was inserted into tobacco plants for reproduction, and once the plants were harvested, the antigen was then purified, and is now undergoing preclinical testing.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04473690"],"organizations":["Kentucky BioProcessing","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America","United Kingdom"],"description":"The KBP-COVID-19 vaccine utilizes tobacco plants as bioreactors to produce antigens from the SARS-CoV-2 virus. Genes from the virus were transferred into the plants which then produced an abundance of the specific viral molecule. This product could then be used to immunize individuals, who would produce an immune response against the viral antigen and they would theoretically be protected against infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.036151","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|180","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0025","nameId":"in-the-case-of-developing-a-potential-covid-19-vaccine-kbp-recently-cloned-a-portion-of-covid-19s-genetic-sequence-which-led-to-the-development-of-a-potential-antigen-a-substance-that-includes-an-immu"},{"sheetId":"26","name":"Unnamed","technology":"Unknown","technologyDetails":"Unknown","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Universite Laval"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036376","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0026","nameId":"unknown-10"},{"sheetId":"27","name":"UB-612","technology":"Protein subunit","technologyDetails":"UB-612 is composed of synthetic peptides designed to mimic biology, allowing COVAXX the ability to adapt the\nproduction peptide sequence quickly to new virus strains. UB-612 has shown high immunogenicity, a robust antibody\nresponse and, through in vitro testing, the antibodies have bound the target COVID-19 spike protein antigen, blocked\nbinding to the hACE2 receptor, and neutralized the virus’s ability to replicate.\nFurthermore, unlike other vaccines that focus only on neutralizing antibodies, COVAXX activates both humoral and\ncellular immunity for greater efficacy, while avoiding vaccine-induced disease enhancement. The UBITh Vaxxine\nPlatform is proven clinically, involving no biohazard risk with minimal adverse reactions, and is a stable and highly\nscalable manufacturing process.","developmentStage":"Clinical","nextSteps":"Phase 1 to start in summer 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04545749","NCT04683224","NCT04773067"],"organizations":["United Biomedical Inc., Asia","COVAXX","Diagnósticos da América S/A (DASA)"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America","Taiwan"],"description":"UB-612 is a SARS-CoV-2 S1-receptor-binding domain (RBD)-protein based vaccine. It also incorporates a T helper cell and cytotoxic T lymphocyte epitope peptide pool, selected from the immunologically advantageous M, S2, and N sites on SARS-CoV-2, that could bind to human MHC-I and MHC-II to activate T cells. Thus, upon vaccination with this vaccine, a strong, specific T cell immune response is generated that will help to eliminate the virus before it can cause devastating disease manifestations. ","show":true,"date":"2021-04-05 11:05:10.036440","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|60","Phase 1/2|NA","Phase 2|3850","Phase 2/3|7320","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0027","nameId":"ub-612-is-composed-of-synthetic-peptides-designed-to-mimic-biology-allowing-covaxx-the-ability-to-adapt-the-production-peptide-sequence-quickly-to-new-virus-strains-ub-612-has-shown-high-immunogenicit"},{"sheetId":"28","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; LNP-encapsulated mRNA cocktail encoding VLP","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Fudan University","Shanghai JiaoTong University","RNACure Biopharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036782","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0028","nameId":"rna-lnp-encapsulated-mrna-cocktail-encoding-vlp"},{"sheetId":"29","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; LNP-encapsulated mRNA cocktail encoding RBD","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Fudan University","Shanghai JiaoTong University","RNACure Biopharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036846","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0029","nameId":"rna-lnp-encapsulated-mrna-cocktail-encoding-rbd"},{"sheetId":"30","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; Replicating defective SARS-CoV-2 derived RNAs","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Centro Nacional Biotecnologia (CNB-CSIC)","Spain"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036905","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0030","nameId":"rna-replicating-defective-sars-cov-2-derived-rnas"},{"sheetId":"31","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; LNP-encapsulated mRNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Tokyo","Daiichi-Sankyo"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.036965","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0031","nameId":"rna-lnp-encapsulated-mrna"},{"sheetId":"32","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; mRNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["China CDC","Tongji University","Stermina"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037019","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0032","nameId":"rna-mrna"},{"sheetId":"33","name":"LUNAR-COV19 (ARCT-021)","technology":"RNA-based vaccine","technologyDetails":"LUNAR-COV19; RNA; mRNA; ARCT-021","developmentStage":"Clinical","nextSteps":"Start Phase 1 in summer 2020","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04480957","NCT04668339","NCT04728347"],"organizations":["Arcturus Therapeutics, Inc.","Duke-NUS"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America","Republic of Singapore"],"description":"The LUNAR-COV19 (ARCT-021) vaccines is comprised of a lipid-mediated delivery system called Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR). When the vaccine is administered to the target tissue, it enters the host’s cells where the mRNA can be transcribed into proteins by host factors. These proteins are from the SARS-CoV-2 virus, and thus the host can induce an immune response against them and fight off an infection from the native virus.","show":true,"date":"2021-04-05 11:05:10.037069","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|85","Phase 2|706","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0033","nameId":"lunar-cov19-rna-mrna-arct-021"},{"sheetId":"34","name":"LNP-nCoVsaRNA","technology":"RNA-based vaccine","technologyDetails":"RNA; saRNA","developmentStage":"Clinical","nextSteps":"Start Phase 1 in summer 2020","customClinicalPhase":"Phase I/II","clinicalTrials":["IRAS-Number: 279315","CPMS-ID: 46068"],"organizations":["Imperial College London","Morningside Ventures"],"funder":"UK Government*","publishedResults":["https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=279315|https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=279315","http://www.isrctn.com/ISRCTN17072692|http://www.isrctn.com/ISRCTN17072692","https://www.nature.com/articles/s41467-020-17409-9#Sec7|https://www.nature.com/articles/s41467-020-17409-9#Sec7"],"relatedUse":["https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=279315|https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=279315","http://www.isrctn.com/ISRCTN17072692|http://www.isrctn.com/ISRCTN17072692","https://www.nature.com/articles/s41467-020-17409-9#Sec7|https://www.nature.com/articles/s41467-020-17409-9#Sec7"],"countries":["United Kingdom","China"],"description":"The Imperial College London vaccine is comprised of SARS-CoV-2 spike protein self-amplifying RNA that is packaged into tiny droplets of fat. Upon vaccination into muscle, host cells uptake this mixture and produce the viral spike protein. Some of these proteins are displayed on the surface of the cells, where the host’s immune system can recognize them as foreign antigens and generate an antibody response against them. The vaccinated individual will thus have circulating antibodies against the viral spike protein which will theoretically protect them from infection with the SARS-CoV-2 virus.","show":true,"date":"2021-04-05 11:05:10.037154","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|300","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0034","nameId":"rna-sarna"},{"sheetId":"35","name":"CVnCoV","technology":"RNA-based vaccine","technologyDetails":"RNA; mRNA; CV07050101","developmentStage":"Clinical","nextSteps":"Start Phase 1 in June 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04449276","NCT04515147","NCT04652102","NCT04674189"],"organizations":["CureVac AG","Coalition for Epidemic Preparedness Innovations (CEPI)"],"funder":"Coalition for Epidemic Preparedness (CEPI); European Commission","publishedResults":[],"relatedUse":[],"countries":["Germany","Global (CEPI)"],"description":"CVnCoV is an mRNA-based vaccine that encodes one protein of the SARS-CoV-2 virus. Upon delivery, it instructs the host to create the protein, which the body recognizes as something foreign and activates its immune cells to produce antibodies and T cells against it. Therefore, when the body encounters the virus naturally, it is able to fight it off.","show":true,"date":"2021-04-05 11:05:10.037226","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|168","Phase 1/2|NA","Phase 2|691","Phase 2/3|40500","Phase 3|2520","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0035","nameId":"rna-mrna-cv07050101"},{"sheetId":"36","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; BNT162","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1/2 in late April 2020*","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["BioNTech","Fosun Pharma","Pfizer"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037289","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0036","nameId":"rna-bnt162"},{"sheetId":"37","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; liposome-encapsulated mRNA","developmentStage":"Pre-clinical","nextSteps":"Animal studies begin in April 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["BIOCAD"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037336","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0037","nameId":"rna-liposome-encapsulated-mrna"},{"sheetId":"38","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; mRNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Sanofi Pasteur","Translate Bio"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037391","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0038","nameId":"rna-mrna-11"},{"sheetId":"39","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA; mRNA (cross-strain protective COV-2 mRNA) vaccine for high-risk populations","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 early 2021","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["eTheRNA Immunotherapies","EpiVax","Nexelis","REPROCELL","Centre for the Evaluation of Vaccination of the University of Antwerp"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037441","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0039","nameId":"rna-mrna-cross-strain-protective-cov-2-mrna-vaccine-for-high-risk-populations"},{"sheetId":"40","name":"Unnamed","technology":"RNA-based vaccine","technologyDetails":"RNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["GeneOne Life Science","Houston Methodist"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037512","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0040","nameId":"rna"},{"sheetId":"41","name":"Unnamed","technology":"Replicating viral vector","technologyDetails":"Replicating viral vector; measles vector","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Zydus Cadila"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037559","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0041","nameId":"replicating-viral-vector-measles-vector"},{"sheetId":"42","name":"TMV-083","technology":"Replicating viral vector","technologyDetails":"Replicating viral vector; measles vector","developmentStage":"Clinical","nextSteps":"Start animal testing in April 2020","customClinicalPhase":"Phase I","clinicalTrials":["NCT04497298"],"organizations":["Institut Pasteur","Themis Bioscience GmbH","Coalition for Epidemic Preparedness Innovations"],"funder":"Coalition for Epidemic Preparedness (CEPI)","publishedResults":[],"relatedUse":[],"countries":["France","Austral","Global"],"description":"The TMV-083 vaccine is a Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of SARS-CoV-2. Upon vaccination, the host will generate an immune response against the surface glycoprotein that will theoretically protect them from infection with the native virus. ","show":true,"date":"2021-04-05 11:05:10.037625","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|90","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-0042","nameId":"replicating-viral-vector-measles-vector-12"},{"sheetId":"43","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, capsid-lide particle (CLP)","developmentStage":"Pre-clinical","nextSteps":"Phase 1 to begin by February 2021","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["PREVENT-nCoV consortium (AdaptVac","Institute for Tropical Medicine at University of Tubingen","Leiden University Medical Center","University of Copenhagen","ExpreS2ion Biotechnologies","Wageningen University)"],"funder":"European Commission (Horizon 2020 Program)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037698","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0043","nameId":"protein-subunit-capsid-lide-particle-clp"},{"sheetId":"44","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, drosophila S2 insect cell expression system VLPs","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ExpreS2ion"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.037756","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0044","nameId":"protein-subunit-drosophila-s2-insect-cell-expression-system-vlps"},{"sheetId":"45","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; S protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["WRAIR","USAMRIID"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.038786","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0045","nameId":"protein-subunit-s-protein"},{"sheetId":"46","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, S protein + adjuvant","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["National Institute of Infectious Disease","Japan"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.038852","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0046","nameId":"protein-subunit-s-protein-adjuvant"},{"sheetId":"47","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, VLP-recombinant protein + adjuvant","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Osaka University / BIKEN / National Institutes of Biomedical Innovation","Japan"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.038910","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0047","nameId":"protein-subunit-vlp-recombinant-protein-adjuvant"},{"sheetId":"48","name":"SCB-2019","technology":"Protein subunit","technologyDetails":"Protein subunit, native like trimeric subunit spike protein","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04405908","NCT04672395"],"organizations":["Clover Biopharmaceuticals","The Coalition for Epidemic Preparedness Innovations","International Vaccine Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"The SCB-2019 vaccine is a recombinant subunit vaccine candidate for COVID-19. It is comprised of a trimer of spike proteins (S-Trimer) that resembles the native trimeric viral spike protein, however, it is produced in a mammalian cell-culture production system. This vaccine is hypothesized to work by priming a humoral immune response that will generate antibodies against the SARS-CoV-2 virus so that it cannot bind to and infect host cells.","show":true,"date":"2021-04-05 11:05:10.038985","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|150","Phase 1/2|NA","Phase 2|NA","Phase 2/3|34000","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0048","nameId":"protein-subunit-native-like-trimeric-subunit-spike-protein"},{"sheetId":"49","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; peptide","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vaxil Bio"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039070","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0049","nameId":"protein-subunit-peptide"},{"sheetId":"50","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; adjuvanted protein subunit (RBD)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Biological E Ltd"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039125","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0050","nameId":"protein-subunit-adjuvanted-protein-subunit-rbd"},{"sheetId":"51","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; S protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["AJ Vaccines"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039188","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0051","nameId":"protein-subunit-s-protein-13"},{"sheetId":"52","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; S protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vaxine Pty Ltd","Flinders University","Oracle"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039240","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0052","nameId":"protein-subunit-s-protein-14"},{"sheetId":"53","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; Ii-Key peptide","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Generex","EpiVax"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039292","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0053","nameId":"protein-subunit-ii-key-peptide"},{"sheetId":"54","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; S protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["EpiVax","University of Georgia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039349","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0054","nameId":"protein-subunit-s-protein-15"},{"sheetId":"56","name":"PittCoVacc","technology":"Protein subunit","technologyDetails":"PittCoVacc, Protein subunit, microneedle arrays S1 subunit","developmentStage":"Pre-clinical","nextSteps":"Phase 1 to start as early as June 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Pittsburgh"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"","show":true,"date":"2021-04-05 11:05:10.039406","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0056","nameId":"pittcovacc-protein-subunit-microneedle-arrays-s1-subunit"},{"sheetId":"57","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; S protein","developmentStage":"Pre-clinical","nextSteps":"Phase 1 to start as early as June 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Cambridge","DIOSynVax"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039468","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0057","nameId":"protein-subunit-s-protein-16"},{"sheetId":"58","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; COVID-19 XWG-03 truncated Spike proteins","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Innovax","Xiamen University","GSK"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039523","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0058","nameId":"protein-subunit-covid-19-xwg-03-truncated-spike-proteins"},{"sheetId":"59","name":"Unnamed Protein Subunit Vaccine - Sanofi/GSK","technology":"Protein subunit","technologyDetails":"Protein subunit; S protein, baculovirus production","developmentStage":"Clinical","nextSteps":"Start Phase 1 in second half of 2020","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04537208","NCT04762680"],"organizations":["Sanofi Pasteur","GlaxoSmithKline"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":["France","United Kingdom","Global"],"description":"This unnamed protein subunit vaccine is in development by both Sanofi and GSK. It utilizes Sanofi’s S-protein SARS-CoV-2 antigen which is based on recombinant DNA technology in a baculovirus expression platform along with GSKs proprietary adjuvant technology to help bolster an immune response against the virus using less antigen. Cumulatively, immunized individuals should be protected from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.039602","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|440","Phase 2|720","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0059","nameId":"protein-subunit-s-protein-baculovirus-production"},{"sheetId":"60","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit (gp-96 backbone)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Heat Biologics (Zolovax)","University of Miami"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039681","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0060","nameId":"protein-subunit-gp-96-backbone"},{"sheetId":"61","name":"Unnamed Spike Protein Candidate","technology":"Protein subunit","technologyDetails":"Protein subunit; molecular clamp stabilized Spike protein","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["ACTRN12620000674932","NCT04495933"],"organizations":["University of Queensland","Syneos Health","Coalition of Epidemic Preparedness Innovations"],"funder":"Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation","publishedResults":[],"relatedUse":[],"countries":["Australia","United States of America","Global"],"description":"The University of Queensland’s vaccine candidate is comprised of a SARS-CoV-2 molecular clamp-stabilized Spike protein. This is a patented technology that provides stability to the viral proteins so that the vaccinated individual can create an immune response to the protein in its native conformation. Upon vaccination, an individual will thus create antibodies to the viral spike protein that can neutralize the virus before it can cause severe disease.","show":true,"date":"2021-04-05 11:05:10.039746","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|120","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-0061","nameId":"protein-subunit-molecular-clamp-stabilized-spike-protein"},{"sheetId":"62","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; S1 or RBD protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Baylor College of Medicine"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039819","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0062","nameId":"protein-subunit-s1-or-rbd-protein"},{"sheetId":"63","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; Subunit protein, plant produced","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["iBio","CC-Pharming"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039877","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0063","nameId":"protein-subunit-subunit-protein-plant-produced"},{"sheetId":"64","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["St. Petersburg Scientific Research Institute of Vaccines and Serums"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.039936","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0064","nameId":"protein-subunit-recombinant-protein-nanoparticles-based-on-s-protein-and-other-epitopes"},{"sheetId":"65","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, adjuvanted microsphere peptide","developmentStage":"Pre-clinical","nextSteps":"Animal testing results expected in April 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["VIDO-InterVac","University of Saskatchewan"],"funder":"The Government of Saskatchewan and the Canadian Federal Government","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040013","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0065","nameId":"protein-subunit-adjuvanted-microsphere-peptide"},{"sheetId":"66","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, peptide","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Flow Pharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040074","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0066","nameId":"protein-subunit-peptide-17"},{"sheetId":"67","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["OncoGen"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040124","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0067","nameId":"protein-subunit-synthetic-long-peptide-vaccine-candidate-for-s-and-m-proteins"},{"sheetId":"68","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; oral E. coli-based protein expression system of S and N proteins","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["MIGAL Galilee Research Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040196","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0068","nameId":"protein-subunit-oral-e-coli-based-protein-expression-system-of-s-and-n-proteins"},{"sheetId":"69","name":"Unnamed","technology":"Protein subunit","technologyDetails":"Protein subunit; spike based","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Alberta"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040267","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0069","nameId":"protein-subunit-spike-based"},{"sheetId":"70","name":"DPX-COVID-19","technology":"Protein subunit","technologyDetails":"DPX-COVID-19, protein subunit, lipid-based delivery platform","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 testing by summer 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority","Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"","show":true,"date":"2021-04-05 11:05:10.040325","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0070","nameId":"dpx-covid-19-protein-subunit-lipid-based-delivery-platform"},{"sheetId":"71","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; MVA encoded VLP","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["GeoVax","BravoVax"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040391","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0071","nameId":"non-replicating-viral-vector-mva-encoded-vlp"},{"sheetId":"72","name":"Ad26.COV2.S","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Ad26 (alone or with MVA boost); JNJ-78436735","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04436276","NCT04505722","NCT04509947","NCT04614948","NCT04765384","NCT04817657","EudraCT 2020-001483-28","EudraCT 2020-002584-63"],"organizations":["Janssen Vaccines and Prevention","Beth Israel Deaconess Medical Center","Johnson & Johnson"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":["United States of America","Belgium"],"description":"Ad26.COV2.S is an adenovirus serotype 26 vector-based vaccines expressing the SARS-CoV-2 spike (S) protein. The vector is also replication-incompetent so there is no risk of infection to the vaccinated individual. Upon vaccination, the individual will generate an immune response against the spike protein and thus will have endogenous antibodies that will protect them from infection with SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.040469","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|125","Phase 1/2|1045","Phase 2|1374","Phase 3|90000","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0072","nameId":"non-replicating-viral-vector-ad26-alone-or-with-mva-boost-jnj-78436735"},{"sheetId":"73","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ReiThera"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040553","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0073","nameId":"non-replicating-viral-vector-replication-defective-simian-adenovirus-grad-encoding-sars-cov-2-s"},{"sheetId":"74","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Ad5","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ImmunityBio","NantKwest"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040638","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0074","nameId":"non-replicating-viral-vector-ad5"},{"sheetId":"75","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; MVA-S encoded","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["DZIF - German Center for Infection Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040693","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0075","nameId":"non-replicating-viral-vector-mva-s-encoded"},{"sheetId":"76","name":"AdCOVID","technology":"Non-replicating viral vector","technologyDetails":"AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein","developmentStage":"Pre-clinical","nextSteps":"Phase 1 trial to begin Q3 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Altimmune","University of Alabama at Birmingham"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"","show":true,"date":"2021-04-05 11:05:10.040758","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0076","nameId":"adcovid-single-dose-intranasal-vaccine-non-replicating-viral-vector-adenovirus-based-nasovax-expressing-spike-protein"},{"sheetId":"77","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Ad5 S (GREVAX™ platform)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Greffex"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040842","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0077","nameId":"non-replicating-viral-vector-ad5-s-grevaxtm-platform"},{"sheetId":"78","name":"VXA-CoV2-1","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Oral Vaccine\n platform","developmentStage":"Clinical","nextSteps":"Phase 1 trial to begin in the second half of 2020","customClinicalPhase":"Phase I","clinicalTrials":["NCT04563702"],"organizations":["Vaxart"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"VXA-CoV2-1 is a non-replicating adenovirus type 5 vector vaccine expressing a SARS-CoV-2 antigen adjuvanted with dsRNA in an oral tableted form. Upon vaccination, individuals are expected to develop an immune response against the SARS-CoV-2 antigen that should protect them against infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.040907","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|48","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-0078","nameId":"non-replicating-viral-vector-oral-vaccine-platform"},{"sheetId":"79","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector, MVA expressing structural proteins","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Centro Nacional Biotecnologia (CNB-CSIC)","Spain"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.040979","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0079","nameId":"non-replicating-viral-vector-mva-expressing-structural-proteins"},{"sheetId":"80","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; dendritic cell-based vaccine","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Manitoba"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041043","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0080","nameId":"non-replicating-viral-vector-dendritic-cell-based-vaccine"},{"sheetId":"81","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Live attenuated virus, measles virus (S, N targets)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["DZIF - German Center for Infection Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041103","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0081","nameId":"live-attenuated-virus-measles-virus-s-n-targets"},{"sheetId":"55","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Replicating viral vector; horsepox vector; TNX-1800","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Tonix Pharma","Southern Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041167","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0055","nameId":"replicating-viral-vector-horsepox-vector-tnx-1800"},{"sheetId":"82","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["BIOCAD","IEM"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041230","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0082","nameId":"replicating-viral-vector-live-viral-vectored-vaccine-based-on-attenuated-influenza-virus-backbone-intranasal"},{"sheetId":"83","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Replicating viral vector, VSV vector expressing S protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["IAVI","Batavia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041317","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0083","nameId":"replicating-viral-vector-vsv-vector-expressing-s-protein"},{"sheetId":"CV2","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Replicating viral vector, influenza vector expressing RBD","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["The University of Hong Kong"],"funder":"Coalition for Epidemic Preparedness (CEPI)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041379","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0CV2","nameId":"replicating-viral-vector-influenza-vector-expressing-rbd"},{"sheetId":"84","name":"Unnamed","technology":"Non-replicating viral vector","technologyDetails":"Replicating viral vector; VSV-S","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Western Ontario"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041439","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0084","nameId":"replicating-viral-vector-vsv-s"},{"sheetId":"85","name":"Unnamed","technology":"Inactivated virus","technologyDetails":"VLA2001, Inactivated*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Valneva","Dynavax*"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041497","type":"Vaccine","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0085","nameId":"vla2001-inactivated"},{"sheetId":"86","name":"Unnamed","technology":"Inactivated virus","technologyDetails":"Inactivated; PiCoVacc (inactivated + CpG 1018)","developmentStage":"Pre-Clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Sinovac","Dynavax"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041548","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0086","nameId":"inactivated-picovacc-inactivated-cpg-1018"},{"sheetId":"87","name":"Unnamed","technology":"Inactivated virus","technologyDetails":"Inactivated","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Osaka University","BIKEN","NIBIOHN"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041612","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0087","nameId":"inactivated-18"},{"sheetId":"88","name":"Unnamed","technology":"Inactivated virus","technologyDetails":"Deoptimized live attenuated virus","developmentStage":"Pre-clinical","nextSteps":"Animal data in summer 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Codagenix","Serum Institute of India"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041657","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0088","nameId":"deoptimized-live-attenuated-virus"},{"sheetId":"89","name":"CoroFlu","technology":"Inactivated virus","technologyDetails":"CoroFlu, self-limiting influenza virus","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 trial in fall 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Wisconsin-Madison","FluGen","Bharat Biotech"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America","Republic of India"],"description":"","show":true,"date":"2021-04-05 11:05:10.041712","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0089","nameId":"coroflu-self-limiting-influenza-virus"},{"sheetId":"90","name":"Unnamed","technology":"DNA-based","technologyDetails":"DNA","developmentStage":"Pre-clinical","nextSteps":"Prelinical results expected in April 2020; Phase 1 to start in fall 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Takis","Applied DNA Sciences","Evvivax"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041770","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0090","nameId":"dna"},{"sheetId":"91","name":"Unnamed","technology":"DNA-based","technologyDetails":"DNA plasmid","developmentStage":"Pre-clinical","nextSteps":"Phase 1 to start in 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["OPENCORONA - Cobra Biologics","Karolinska Institute"],"funder":"European Commission (Horizon 2020 Program)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.041813","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0091","nameId":"dna-plasmid-19"},{"sheetId":"92","name":"AG0301-COVID19","technology":"DNA-based","technologyDetails":"DNA plasmid","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04463472"],"organizations":["AnGes, Inc.","Japan Agency for Medical Research and Development"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Japan"],"description":"AG0301-COVID19 is a DNA vaccine encoding antigens from SARS-CoV-2. Upon vaccination, host cells will uptake the DNA and express the protein, which will then have an immune response made against it. The host will then have circulating antibodies that will theoretically neutralize the wild-type virus, thus protecting them from infection. ","show":true,"date":"2021-04-05 11:05:10.041864","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|30","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0092","nameId":"dna-plasmid-20"},{"sheetId":"92","name":"AG0302-COVID19","technology":"DNA-based","technologyDetails":"DNA plasmid","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04527081","NCT04655625"],"organizations":["AnGes, Inc.","Japan Agency for Medical Research and Development"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Japan"],"description":"AG0302-COVID19 is a DNA vaccine encoding antigens from SARS-CoV-2. Upon vaccination, host cells will uptake the DNA and express the protein, which will then have an immune response made against it. The host will then have circulating antibodies that will theoretically neutralize the wild-type virus, thus protecting them from infection. ","show":true,"date":"2021-04-05 11:05:10.041920","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|30","Phase 2|NA","Phase 2/3|500","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0092","nameId":"dna-plasmid-21"},{"sheetId":"93","name":"ZyCoV-D","technology":"DNA-based","technologyDetails":"DNA plasmid","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["CTRI/2020/07/026352"],"organizations":["Zydus Cadila","Cadila Healthcare Limited"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republica of India"],"description":"ZyCoV-D is a DNA plasmid-based vaccine against SARS-CoV-2. Upon vaccination, host cells will uptake the DNA and express the encoded protein of interest, which will then have an immune response made against it. The host will then have circulating antibodies that will theoretically neutralize the wild-type virus, thus protecting the individual from infection. ","show":true,"date":"2021-04-05 11:05:10.042015","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|1048","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0093","nameId":"dna-plasmid-22"},{"sheetId":"94","name":"Unnamed","technology":"DNA-based","technologyDetails":"DNA plasmid, needle-free delivery","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Immunomic Therapeutics","EpiVax","PharmaJet"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.042073","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0094","nameId":"dna-plasmid-needle-free-delivery"},{"sheetId":"95","name":"Unnamed","technology":"DNA-based","technologyDetails":"DNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["BioNet Asia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.042127","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0095","nameId":"dna-23"},{"sheetId":"96","name":"Unnamed","technology":"DNA-based","technologyDetails":"DNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["University of Waterloo"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.042170","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"v-0096","nameId":"dna-24"},{"sheetId":"CV4","name":"Measles-Mumps-Rubella Vaccine*","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III/IV","clinicalTrials":["NCT04357028","NCT04475081","EudraCT 2020-002456-21"],"organizations":["Kasr El Aini Hospital","Louisiana State University Health Sciences Center in New Orleans","Parsemus Foundation","Radboud University Medical Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Egypt","United States of America","Netherlands"],"description":"Measles, mumps, and rubella are all viral diseases that can have serious consequences. The measles-mumps-rubella (MMR) vaccine is comprised of live-attenuated strains of these viruses and is a safe and effective way to prevent these diseases, especially in young children. Interestingly, young children do not seem to be overly susceptible to COVID-19 as they generally are with other infectious diseases. One hypothesis to explain this is that antibodies formed against measles (due to the MMR vaccine) may be cross-reactive with SARS-CoV-2. Thus, vaccination with the MMR vaccine may be protective against COVID-19.","show":true,"date":"2021-04-05 11:05:10.042229","type":"Vaccine","fdaApproved":"Used worldwide to prevent the viral diseases measles, mumps, and rubella.","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 3|260","Phase 4|50"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3,4]},"inprogressClinicalTrials":[3,4],"completedClinicalTrials":[0,1,2],"phaseSortKey":6.5,"urlIdx":"v-0CV4","nameId":"-25"},{"sheetId":"CV5","name":"V-SARS","technology":"Inactivated virus","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04380532"],"organizations":["Immunitor LLC"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"The V-SARS vaccine is made from the heat-inactivated plasma of donors with COVID-19. The theory behind this vaccine is that individuals with COVID-19 will have circulating SARS-CoV-2 virus, and thus heat-inactivation of their plasma will effectively deliver an inactive virus to healthy individuals so they can mount an immune response against this pathogen. This vaccine will be administered orally in pill form.","show":true,"date":"2021-04-05 11:05:10.042270","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|20","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0CV5","nameId":"-26"},{"sheetId":"CV6","name":"AV-COVID-19","technology":"Modified APC","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04386252","NCT04690387","NCT04685603"],"organizations":["Aivita Biomedical, Inc.","PT AIVITA Biomedika Indonesia","Indonesia Ministry of Health","National Institute of Health Research and Development, Ministry of Health Republic of Indonesia","Indonesia-MoH","Faculty of Medicine University of Diponegoro, Indonesia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America","Republic of Indonesia"],"description":"The AV-COVID-19 vaccine is derived from autologous (the individual’s own) dendritic cells (DC) loaded with antigens from the SARS-CoV-2 coronavirus to prevent COVID-19. To generate this vaccine, a healthy, naive individual will have their blood drawn and monocytes isolated. Those monocytes will be differentiated into DCs using the cytokines interleukin (IL)-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by incubated with antigens from SARS-CoV-2 to create AV-COVID-19. This vaccine will be administered subcutaneously with or without additional GM-CSF. ","show":true,"date":"2021-04-05 11:05:10.042315","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|54","Phase 1/2|180","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-0CV6","nameId":"-27"},{"sheetId":"7","name":"AZD1222 (ChAdOx1 nCoV-19)","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Covishield","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04324606","EudraCT 2020-001072-15","EudraCT 2020-001228-32","NCT04400838","NCT04444674","PACTR202006922165132","ISRCTN89951424","NCT04516746","NCT04536051","NCT04540393","NCT04568031","NCT04686773","NCT04684446","NCT04760132","NCT04760730","NCT04775069","NCT04800133","NCT04794946","NCT04816019","NCT04811391","NCT04809948"],"organizations":["Consortium of the Jenner Institute, Oxford Biomedica","University of Oxford, Vaccines Manufacturing and Innovation Centre","AstraZeneca","University of Witwatersrand, South Africa","Medical Research Council, South Africa","Bill and Melinda Gates Foundation","Iqvia Pty Ltd","Covance","R-Pharm","Ministry of the Interior and Health, Denmark","Humanity & Health Medical Group Limited","The University of Hong Kong","Institute of Liver and Biliary Sciences, India","Institute of Public Health, Albania","World Health Organization","Centers for Disease Control and Prevention","Southeast Europe Center for Infectious Diseases Surveillance and Control","EPICONCEPT","Assiut University"],"funder":"Coalition for Epidemic Preparedness (CEPI) / UK Government","publishedResults":[],"relatedUse":[],"countries":["United Kingdom"],"description":"AZD1222 (formerly ChAdOx1 nCoV-19) is an attenuated adenovirus that displays the SARS-CoV-2 spike protein on its surface. Since the virus is attenuated, it is safe to inject it into humans. Upon vaccination, the individual will generate an immune response against the spike protein and thus will have endogenous antibodies that will protect them from infection with SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.042375","type":"Vaccine","fdaApproved":"N/A","updatedOrNew":"None","template":["5eb5d9b409888100b11021ee"],"templateLink":"https://app.biorender.com/biorender-templates/t-5eb5d9b409888100b11021ee-covid-19-vaccine-candidate-chadox1-ncov-19-university-of-oxf","participants":["Phase 1|30","Phase 1/2|3302","Phase 2|100","Phase 2/3|10260","Phase 3|36000","Phase 4|15400"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"v-0007","nameId":"non-replicating-viral-vector-covishield"},{"sheetId":"CV3","name":"Bacille Calmette-Guerin*","technology":"Repurposed","technologyDetails":"Bacille Calmette Guerin; BCG","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04328441","NCT04362124","NCT04379336","NCT04350931","NCT04417335","NCT04327206","NCT04369794","NCT04414267","NCT04373291","NCT04384549","NCT04348370","NCT04387409","NCT04435379","NCT04439045","NCT04461379","NCT04475302","NCT04534803","NCT04537663","NCT04542330","NCT04632537","NCT04641858","NCT04648800","NCT04659941","EudraCT 2020-001678-31","EudraCT 2020-001783-28","EudraCT 2020-001888-90","EudraCT 2020-002111-22","EudraCT 2020-002448-21","EudraCT 2020-000919-69","EudraCT 2020-002456-21"],"organizations":["University Medical Center Utrecht","Radboud University","Universidad de Antioquia","TASK Applied Science","Ain Shams University","Assiut University","Murdoch Childrens Research Institute","Royal Children's Hospital","BATTLE","Bandim Health Project","University of Southern Denmark","Texas A&M University","Baylor College of Medicine","M.D. Anderson Cancer Center","Cedars-Sinai Medical Center","Harvard University","Vakzine Projekt Management GmbH","FGK Clinical Research GmbH","Assistance Publique - Hôpitaux de Paris","National Korányi Institute of Pulmonology","Hellenic Institute for the Study of Sepsis","University of Rzeszów","University Health Network, Toronto","Serum Institute of India Pvt. Ltd.","Max Planck Institute for Infection Biology","Verity Pharmaceuticals","Hospital Universitario Dr. Jose E. Gonzalez","Tuberculosis Research Centre, India","ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu","All India Institute of Medical Sciences, New Delhi","National Institute for Research in Environmental Health, Bhopal, Madhya Pradesh","National Institute of Occupational Health, Ahmedabad, Gujarat","King Edward Memorial Hospital","National Institute for Implementation Research on Non-Communicable Disease","Harvard Medical School","Texas Medical Research Associates, L.L.C.","Odense Patient Data Explorative Network","Odense University Hospital","Municipality of Odense","Henry M. Jackson Foundation for the Advancement of Military Medicine","Harvard Medical School","Uniformed Services University of the Health Sciences","United States Department of Defense","Institute of Hygiene and Tropical Medicine, NOVA University, Lisbon, Portugal","University of Cape Verde, Praia, Cape Verde","National Institute of Public Health of Cape Verde, Praia, Cape Verde","Centro de Investigacao em Saude de Manhica","European and Developing Countries Clinical Trials Partnership (EDCTP)","Bandim Health Project, Bissau, Guinea-Bissau","Medical Research Agency - Agencja Badań Medycznych","Universidade Federal do Rio de Janeiro","Ministry of Science and Technology, Brazil"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Netherlands","Colombia","South Africa","Egypt","Australia","Brazil","Denmark","United States of America","France","Republic of India","Hungary","Greece","Poland","Canada","Germany","Mexico","Cape Verde","Republic of Guinea-Bissau","Mozambique"],"description":"The Bacille Calmette-Guerin is a live attenuated vaccine comprised of the bacteria that causes bovine tuberculosis (Mycobacterium bovis). It was generated approximately 100 years ago and when administered under the skin (intradermally) to a newborn child, it protects them from the severe and disseminating disease manifestations of human tuberculosis (caused by Mycobacterium tuberculosis infection). Amazingly, BCG vaccination seems to not only protect against childhood severe tuberculosis but has non-specific protective effects against other respiratory tract infections in in vitro and in vivo studies, and thus this vaccine is being repurposed to see if it can reduce morbidity and mortality associated with SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.042499","type":"Vaccine","fdaApproved":"Used worldwide to prevent tuberculosis (infection with Mycobacterium tuberculosis) in neonates.","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|1000","Phase 3|33095","Phase 4|12014"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"v-0CV3","nameId":"bacille-calmette-guerin-bcg"},{"sheetId":"CV7","name":"Unnamed Inactive Vaccine - Yunnan","technology":"Inactivated virus","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04412538","NCT04470609","NCT04659239"],"organizations":["Chinese Academy of Medical Sciences","West China Second University Hospital","Yunnan Center for Disease Control and Prevention"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) followed by inactivation using a chemical reagent (such as beta-propiolactone). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive. ","show":true,"date":"2021-04-05 11:05:10.042569","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|192","Phase 1/2|NA","Phase 2|750","Phase 3|34020","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-0CV7","nameId":"-28"},{"sheetId":"CV9","name":"COVAX-19","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04428073","NCT04453852"],"organizations":["GeneCure Biotechnologies","Vaxine","Medytox","Central Adelaide Local Health Network Incorporated","Flinders University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America","Australia","Republic of Korea"],"description":"COVAX-19 is a protein subunit vaccine that combines recombinant SARS-CoV-2 spike protein with ADVAX adjuvant. This adjuvant is comprised of a novel polysaccharide that enhances antibody and T-cell immune responses. Upon vaccination, the individual will generate both a humoral and cell-based immune response against the spike protein and thus will have protection against SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.042616","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|72","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-0CV9","nameId":"-29"},{"sheetId":"CV10","name":"Sputnik V (Gam-COVID-Vac)","technology":"Non-replicating viral vector","technologyDetails":"rAd26-S","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04437875","NCT04436471","NCT04530396","NCT04564716","NCT04587219","NCT04642339","NCT04640233","NCT04656613","NCT04713488","NCT04741061","NCT04684446","NCT04760730"],"organizations":["Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","Acellena Contract Drug Research and Development","Government of the city of Moscow","Crocus Medical BV","Russian Direct Investment Fund","iPharma","Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela","Dr. Reddy's Laboratories Limited","Russian Direct Investment Fund","CRO: JSS Medical Research India Pvt. Ltd","PDC-CRO","AstraZeneca","R-Pharm","The Russian Direct Investment Fund",""],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Russia"],"description":"Sputnik V (Gam-COVID-Vac) is a is an adenoviral-based vaccine that displays the SARS-CoV-2 glycoprotein S molecule on its surface. Upon vaccination, the individual will generate an immune response against the glycoprotein S molecule and thus will have endogenous antibodies that will protect them from infection with SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.042682","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|386","Phase 2|110","Phase 2/3|1600","Phase 3|49100","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-CV10","nameId":"rad26-s"},{"sheetId":"CV11","name":"AlloStim","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04441047"],"organizations":["Immunovative Therapies, Ltd.","Mirror Biologics, Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Israel","United States of America"],"description":"AlloStim is a bioengineered living-cell vaccine that is comprised of SARS-CoV-2-specific modified cells from healthy donors that elicit both memory and effector cell functions. The vaccine works by surveying the host, and upon encounter with the native virus, an immune response is elicited that leads to rapid viral clearance and viral-specific memory that will protect against future infections as well.","show":true,"date":"2021-04-05 11:05:10.042747","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|40","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV11","nameId":"-30"},{"sheetId":"CV12","name":"IMM-101","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04442048"],"organizations":["Canadian Cancer Trials Group","Immodulon Therapeutics Ltd","BioCan Rx","Canadian Cancer Society Research Institute (CCSRI)","ATGen Canada Inc","Canadian Centre for Applied Research in Cancer Control (ARCC)"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada","United Kingdom"],"description":"IMM-101 is a vaccine comprised of heat-killed Mycobacterium obuense. It is currently being studied as a chemotherapy, and has been shown to activate and generate immune memory that may also be beneficial to fighting off viral infections in a non-specific manner. Since it is a heat-killed vaccine, there is less risk than those comprised of live or attenuated organisms.","show":true,"date":"2021-04-05 11:05:10.042791","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 3|1500","Phase 4|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"v-CV12","nameId":"-31"},{"sheetId":"CV13","name":"NasoVAX","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04442230"],"organizations":["Altimmune","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"NasoVAX is an intranasal flu vaccine comprised of a replication-deficient adenovirus vector. It has been shown to induce strong humoral and cellular immune responses at mucosal surfaces and thus may be beneficial for those suffering from the early stages of COVID-19.","show":true,"date":"2021-04-05 11:05:10.042828","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|96","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"v-CV13","nameId":"-32"},{"sheetId":"CV14","name":"GX-19","technology":"DNA-based","technologyDetails":"DNA vaccine expressing SARS-CoV-2 S-protein antigen","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04445389","NCT04715997"],"organizations":["Genexine","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Korea"],"description":"GX-19 is a DNA vaccine expressing the SARS-CoV-2 S-protein antigen. Upon vaccination, host cells will uptake the DNA and express the protein, which will then have an immune response made against it. The host will then have circulating antibodies that will theoretically neutralize the wild-type virus, thus protecting them from infection. ","show":true,"date":"2021-04-05 11:05:10.042870","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|380","Phase 2|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV14","nameId":"dna-vaccine-expressing-sars-cov-2-s-protein-antigen"},{"sheetId":"CV15","name":"Oral Polio Vaccine*","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III/IV","clinicalTrials":["NCT04445428","NCT04540185","NCT04639375"],"organizations":["Bandim Health Project","NeuroActiva, Inc.","Biomed Industries, Inc.","E-MO Biology Inc"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Guinea-Bissau","United States of America","New Zealand","United States of America"],"description":"The oral polio vaccine is an attenuated strain of the virus that causes poliomyelitis. It is generated by the passage of the virus through non-human cells at sub physiological temperatures which produce random mutations in the virus and attenuates it. Studies have shown that this vaccine may confer non-specific effects, reducing morbidity and mortality from other infections than polio. It is thus being tested to determine whether these effects are observed in SARS-CoV-2 infections.","show":true,"date":"2021-04-05 11:05:10.042955","type":"Vaccine","fdaApproved":"Used worldwide since 1961 to prevent poliomyelitis.","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 3|3600","Phase 4|3425"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3,4]},"inprogressClinicalTrials":[3,4],"completedClinicalTrials":[0,1,2],"phaseSortKey":6.5,"urlIdx":"v-CV15","nameId":"-33"},{"sheetId":"CV16","name":"BACMUNE (MV130)","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04452643"],"organizations":["Inmunotek S.L.","BioClever 2005 S.L."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Spain","Mexico"],"description":"BACMUNE (MV130) is a polyvalent preparation of heat-inactivated Gram-positive and -negative bacteria that is administered via oral spray. It has been shown to activate numerous facets of the immune system that may also be beneficial to fighting off infections in a non-specific manner. It thus may be beneficial in preventing infection with SARS-CoV-2. Since it is a heat-killed vaccine, there is less risk than those comprised of live or attenuated organisms.","show":true,"date":"2021-04-05 11:05:10.042999","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 3|3312","Phase 4|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"v-CV16","nameId":"-34"},{"sheetId":"CV17","name":"oeh","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04453488"],"organizations":["Fundació Institut Germans Trias i Pujol"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Spain"],"description":"RUTI is a vaccine comprised of purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli. It is currently being tested as a tuberculosis vaccine candidate, but it has also been shown to activate numerous facets of the immune system that may also be beneficial to fighting off infections in a non-specific manner. It thus may be beneficial in preventing infection with SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.043036","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|368"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"v-CV17","nameId":"-35"},{"sheetId":"CV18","name":"Covaxin","technology":"Inactivated virus","technologyDetails":"BBV152","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04471519","NCT04641481"],"organizations":["Bharat Biotech International Limited","Indian Council of Medical Research","Iqvia Pty Ltd"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of India"],"description":"Covaxin is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum adjuvant. Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) and/or by inactivation using a chemical reagent (such as beta-propiolactone or formaldehyde). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive.","show":true,"date":"2021-04-05 11:05:10.043075","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|375","Phase 1/2|NA","Phase 2|750","Phase 3|25800","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-CV18","nameId":"bbv152"},{"sheetId":"CV19","name":"MVC-COV1901","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04487210","NCT04695652","NCT04822025"],"organizations":["Medigen Vaccine Biologics Corp."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Taiwan"],"description":"The MVC-COV1901 vaccine is comprised of the SARS-CoV-2 Spike protein and two adjuvants, CpG 1018 and Aluminium. Upon vaccination, the individual will generate an immune response against the spike protein and thus will have protection against SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.043135","type":"Vaccine","fdaApproved":"","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|45","Phase 1/2|NA","Phase 2|4100","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV19","nameId":"-36"},{"sheetId":"CV20","name":"ZF2001","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04445194","NCT04466085","NCT04550351","NCT04646590"],"organizations":["Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","The Second Affiliated Hospital of Chongqing Medical University","Beijing Chao Yang Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"The Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. vaccine, ZF2001, is a recombinant protein vaccine that involves using a specific piece of the virus, such as the spike protein of the antigen, to trigger a protective immune response. When the host then encounters a virus naturally that has that protein, it is able to fight it off.","show":true,"date":"2021-04-05 11:05:10.043177","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|50","Phase 1/2|50","Phase 2|900","Phase 3|29000","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-CV20","nameId":"-37"},{"sheetId":"CV21","name":"Unnamed mRNA vaccine","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["ChiCTR2000034112"],"organizations":["Yunnan Walvax Biotechnology Co., Ltd.","Shulan (Hangzhou) Hospital","Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"mRNA-based vaccines function by instructing the host to create the protein-of-interest, which the body recognizes as a foreign entity and activates the immune system to produce antibodies and T cells against it. When the host then encounters a virus naturally that has that protein, it is able to fight it off.","show":true,"date":"2021-04-05 11:05:10.043219","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|168","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV21","nameId":"-38"},{"sheetId":"CV22","name":"V591","technology":"Replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04498247"],"organizations":["Merck Sharp & Dohme Corp."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"V591 is a SARS-CoV-2 vaccine candidate that uses an attenuated measles virus as a vector. The measles virus is genetically modified to express a coronavirus protein, that upon vaccination elicits an immune response that will be protective against infection with the native coronavirus and prevent COVID-19 disease from developing.","show":true,"date":"2021-04-05 11:05:10.043256","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|260","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV22","nameId":"-39"},{"sheetId":"CV23","name":"AdimrSC-2f","technology":"Protein subunit","technologyDetails":"Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04522089"],"organizations":["Adimmune Corporation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Taiwan"],"description":"AdimrSC-2f is a protein subunit vaccine. The recombinant receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is created using a baculovirus-insect cell expression system. Once purified, the protein can be used to immunize an individual, with or without alum adjuvant, to bolster an immune response that should protect them from infection with the native virus. ","show":true,"date":"2021-04-05 11:05:10.043290","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|70","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV23","nameId":"using-the-baculovirus-insect-cells-expression-system-the-recombinant-receptor-binding-domain-rbd-of-sars-cov-2-spike-s-protein-is-amplified-and-purified"},{"sheetId":"CV24","name":"Shingrix","technology":"Repurposed","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04523246"],"organizations":["Oklahoma Medical Research Foundation","University of Oklahoma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"Shingrix is a lyophilized, trunked form of the recombinant varicella zoster virus glycoprotein E antigen that is reconstituted using the adjuvant AS01B. Not only does this vaccine protect against shingles, but there is evidence to suggest that there are non-specific immune-modulating properties that may assist in protection against infection with other viruses such as SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.043408","type":"Vaccine","fdaApproved":"FDA-approved since 2006, approved to prevent shingles (Herpes zoster) in adults.","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|250","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV24","nameId":"-40"},{"sheetId":"CV25","name":"EpiVacCorona","technology":"Protein subunit","technologyDetails":"EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04527575","NCT04780035"],"organizations":["Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\""],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Russia"],"description":"The EpiVacCorona vaccine is a protein subunit vaccine that is comprised of chemically synthesized peptide antigens of SARS-CoV-2 conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). Upon vaccination, an individual will create an immune response against those viral-specific antigens which then should theoretically protect them again infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.043446","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|100","Phase 2|NA","Phase 3|3000","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-CV25","nameId":"epivaccorona-vaccine-is-intended-to-prevent-covid-19-the-vaccine-relies-on-chemically-synthesized-peptide-antigens-of-sars-cov-2-proteins-conjugated-to-a-carrier-protein-and-adsorbed-on-an-aluminum-co"},{"sheetId":"CV26","name":"QazCovid-in","technology":"Inactivated virus","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04530357","NCT04691908"],"organizations":["Research Institute for Biological Safety Problems","National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan","City polyclinic No. 4 of the UZO of Almaty","Clinic of the International Institute of Postgraduate Education","City Multidisciplinary Hospital of the Health Department of the Akimat of Zhambyl Region"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Kazakhstan"],"description":"The QazCovid-in vaccine is an inactivated vaccine. Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) and/or by inactivation using a chemical reagent (such as beta-propiolactone or formaldehyde). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive. ","show":true,"date":"2021-04-05 11:05:10.043656","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|44","Phase 1/2|NA","Phase 2|200","Phase 3|3000","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-CV26","nameId":"-41"},{"sheetId":"CV27","name":"GRAd-COV2","technology":"Non-replicating viral vector","technologyDetails":"GRAd-COV2 is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04528641","NCT04791423"],"organizations":["ReiThera Srl","Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Italy"],"description":"GRAd-COV2 is a non-replicating viral vector based on a novel replication-defective gorilla adenovirus. This vaccine encodes for a SARS-CoV-2 full-length prefusion stabilized Spike protein, which upon immunization, allows the recipient to generate an immune response that should be protective against the native SARS-CoV-2 virus.","show":true,"date":"2021-04-05 11:05:10.043700","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|90","Phase 1/2|NA","Phase 2|NA","Phase 2/3|10300","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"v-CV27","nameId":"grad-cov2-is-based-on-a-novel-replication-defective-gorilla-adenovirus-and-encodes-for-sars-cov-2-full-length-prefusion-stabilized-spike-protein"},{"sheetId":"CV28","name":"Unnamed Recombinant Vaccine - Jiangsu","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04530656","NCT04640402","NCT04718467"],"organizations":["Jiangsu Province Centers for Disease Control and Prevention","West China Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"This protein subunit vaccine is created by inducing Sf9 insect cells to produce SARS-CoV-2 proteins. Individuals can then be immunized with these proteins and the host will create an immune response against them, which should protect the host from an infarction with the native virus.","show":true,"date":"2021-04-05 11:05:10.043811","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|168","Phase 1/2|NA","Phase 2|4960","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV28","nameId":"-42"},{"sheetId":"CV29","name":"CoVac-1","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04546841"],"organizations":["University Hospital Tuebingen"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Germany"],"description":"The CoVac-1 vaccine is comprised of multiple SARS-CoV-2 peptides which are sized to fit within human major histocompatibility complex II molecules for optimal immune cell presentation. This vaccine is delivered with the XS15 emulsified in Montanide ISA 51 adjuvant which stimulates toll-like receptors 1/2, specifically stimulating a strong T cell immune response. Upon vaccination, this vaccine should elicit a strong cellular immune response that should protect the recipient from infection with the SARS-CoV-2 virus.","show":true,"date":"2021-04-05 11:05:10.043849","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|36","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV29","nameId":"-43"},{"sheetId":"CV30","name":"ChulaCov19","technology":"RNA-based vaccine","technologyDetails":"An mRNA vaccine carries an mRNA sequence that is coded for a viral-specific antigen; novel lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 investigational vaccine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04566276"],"organizations":["Chulalongkorn University","Center of Excellence in Vaccine Research and Development, Chulalongkorn University","Center of Excellence for Vaccine Trial (Vaccine Trial Centre), Faculty of Tropical Medicine, Mahidol University","Chula Clinical Research Center (ChulaCRC), Faculty of Medicine, Chulalongkorn University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Thailand"],"description":"ChulaCov19 is a novel lipid nanoparticles-encapsulated vaccine that carries an mRNA sequence that encodes a viral-specific antigen. Upon immunization, host cells take up the nucleic acid and express the viral antigen so that an immune response can be made against it and protect the host against native virus infection.","show":true,"date":"2021-04-05 11:05:10.043885","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|96","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV30","nameId":"an-mrna-vaccine-carries-an-mrna-sequence-that-is-coded-for-a-viral-specific-antigen-novel-lipid-nanoparticles-lnps-encapsulated-mrna-based-chulacov19-investigational-vaccine"},{"sheetId":"CV31","name":"Covigenix VAX-001","technology":"DNA-based","technologyDetails":"DNA Plasmid; DNA vaccine for the coronavirus. Most other genetic vaccines carry the gene for the spike protein on the surface of the virus. Entos instead chose the gene for nucleocapsid, a protein that sits inside the virus’s membrane","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04591184"],"organizations":["Entos Pharmaceuticals Inc.","Canadian Institutes of Health Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"Covigenix VAX-001 is a DNA plasmid vaccine candidate against SARS-CoV-2. It carries the gene for the viral nucleocapsid protein that sits inside the virus’s membrane. Upon vaccination, the host will take up the DNA and produce the vaccine antigen itself, which it will then be able to produce a robust immune response against in hope of being able to fight off infection from the native virus.","show":true,"date":"2021-04-05 11:05:10.044004","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|72","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV31","nameId":"dna-plasmid-dna-vaccine-for-the-coronavirus-most-other-genetic-vaccines-carry-the-gene-for-the-spike-protein-on-the-surface-of-the-virus-entos-instead-chose-the-gene-for-nucleocapsid-a-protein-that-si"},{"sheetId":"CV33","name":"hAd5-S-Fusion+N-ETSD","technology":"Non-replicating viral vector","technologyDetails":"The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04591717","NCT04710303","NCT04732468"],"organizations":["ImmunityBio","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"The hAd5-S-Fusion+N-ETSD vaccine is a replication-deficient human adenovirus serotype 5 vector that expresses the SARS-CoV-2 spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain. Upon vaccination the host will ideally develop a robust antibody and cellular-mediated immune response that will protect the recipient from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044152","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|135","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV33","nameId":"the-had5-s-fusion-n-etsd-vaccine-is-a-human-adenovirus-serotype-5-had5-vector-with-e1-e2b-e3-deletions-expressing-sars-cov-2-viral-antigen-spike-fusion-protein-and-nucleocapsid-with-an-enhanced-t-cell"},{"sheetId":"CV31","name":"MVA-SARS-2-S","technology":"Replicating viral vector","technologyDetails":"The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein (S)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04569383"],"organizations":["Universitätsklinikum Hamburg-Eppendorf","German Center for Infection Research","Philipps University Marburg Medical Center","Ludwig-Maximilians - University of Munich"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Germany"],"description":"The MVA-SARS-2-S vaccine utilizes a modified Vaccinia Ankara virus that expresses the SARS-CoV-2 spike protein. Upon vaccination, the host will create an immune response against the spike protein and protect the vaccine-recipient against a SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.044285","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|30","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV31","nameId":"the-vaccine-contains-a-modified-vaccinia-virus-ankara-mva-vector-expressing-the-sars-cov-2-spike-protein-s"},{"sheetId":"CV34","name":"IIBR-100","technology":"Replicating viral vector","technologyDetails":"rVSV-SARS-CoV-2-S Vaccine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04608305"],"organizations":["Israel Institute for Biological Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Israel"],"description":"IIBR-100 is a replicating viral vector vaccine based on a recombinant vesicular stomatitis virus expressing the SARS-CoV-2 spike protein. Upon vaccination, the host will produce an immune response against the spike protein which will theoretically protect individuals from infection with the native virus. ","show":true,"date":"2021-04-05 11:05:10.044383","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|1040","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV34","nameId":"rvsv-sars-cov-2-s-vaccine"},{"sheetId":"CV35","name":"COVI-VAC","technology":"Replicating viral vector","technologyDetails":"Live attenuated; CodaVax-COVID","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04619628"],"organizations":["Codagenix","Inc"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United Kingdom"],"description":"COVI-VAC is a live-attenuated vaccine against COVID-19. It is designed to produce immunity against all SARS-CoV-2 proteins, not just the spike surface protein. It is given by intranasal administration, and upon vaccination, individuals will create a robust antibody and cellular response that should protect the host from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044449","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|48","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV35","nameId":"live-attenuated-codavax-covid"},{"sheetId":"CV36","name":"CORVax","technology":"DNA-based","technologyDetails":"SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04627675"],"organizations":["Providence Health & Services","OncoSec Medical Incorporated"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"CORVax is a DNA plasmid vaccine that encodes the SARS-CoV-2 spike protein. It is electroporated into a host using a Cliniporator, whose cells then uptake the plasmid and produce the foreign protein antigen. An immune response can then be made against this non-self entity, which should protect the host from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044513","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|36","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV36","nameId":"sars-cov-2-spike-s-protein-plasmid-dna-vaccine"},{"sheetId":"CV37","name":"Unnamed Recombinant Vaccine - ZHONGYIANKE","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04636333","NCT04813562"],"organizations":["Jiangsu Province Centers for Disease Control and Prevention","Academy of Military Medical Sciences, Academy of Military Sciences, PLA","ZHONGYIANKE Biotech Co, Ltd.","LIAONINGMAOKANGYUAN Biotech Co, Ltd"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"The Unnamed Recombinant Vaccine - ZHONGYIANKE is a recombinant vaccine produced in Chinese hamster ovary cells. Upon vaccination with the protein cocktail, a host will generate an immune response that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044588","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|216","Phase 1/2|NA","Phase 2|480","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV37","nameId":"-44"},{"sheetId":"CV38","name":"Unnamed Ad5 Vaccine - Jiangsu","technology":"Non-replicating viral vector","technologyDetails":"Non-replicating viral vector; Adenovirus Type 5 vector","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04568811"],"organizations":["Jiangsu Province Centers for Disease Control and Prevention"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"The Unnamed Ad5 Vaccine - Jiangsu is created using a type 5 adenovirus backbone and incorporating viral sequences from SARS-CoV-2. It is then injected into patients and antibodies will be generated against the SARS-CoV-2 virus which should protect the recipient from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044626","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|89","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV38","nameId":"non-replicating-viral-vector-adenovirus-type-5-vector-45"},{"sheetId":"CV39","name":"COH04S1","technology":"Replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04639466"],"organizations":["City of Hope Medical Center","National Cancer Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"COH04S1 is a synthetic modified vaccinia Ankara-based SARS-CoV-2 vaccine that was created by placing small pieces of SARS-CoV-2 DNA into the vaccine backbone. Upon vaccination, the host will be able to induce immunity to the native virus which should protect them upon exposure.","show":true,"date":"2021-04-05 11:05:10.044693","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|129","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV39","nameId":"-46"},{"sheetId":"CV40","name":"GLS-5310","technology":"DNA-based","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04673149"],"organizations":["GeneOne Life Science","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Korea"],"description":"GLS-5310 is a DNA vaccine encoding the spike protein and a second antigenic target of SARS-CoV-2. Upon vaccination, the DNA is uptaken by host cells, and the corresponding viral antigens are produced from the DNA. The host can then create both a cellular and humoral response to the antigens which should protect the individual from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044732","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|345","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV40","nameId":"-47"},{"sheetId":"CV41","name":"VLA2001","technology":"Inactivated virus","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04671017"],"organizations":["Valneva Austria GmbH","National Institute for Health Research, United Kingdom"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Austria","United Kingdom"],"description":"VLA2001 is a whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide. Upon vaccination, the host will create a robust immune response against numerous viral components, and since it is inactive, the vaccine itself will be unable to replicate within the host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to eradicate the infection before signs or symptoms prevent, as well as transmission of the virus is possible.","show":true,"date":"2021-04-05 11:05:10.044781","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|150","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV41","nameId":"-48"},{"sheetId":"CV42","name":"AdCLD-CoV19","technology":"Non-replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04666012"],"organizations":["Cellid Co.","Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Korea"],"description":"AdCLD-CoV19 is a replication-defective human adenovirus type 5/35 vector based vaccine expressing the SARS-CoV-2 S protein. Upon vaccination, the host will create a robust immune response against this antigen, and since the vaccine vector is replication-defective, the vaccine itself will be unable to infect its host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to protect the host.","show":true,"date":"2021-04-05 11:05:10.044819","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|150","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV42","nameId":"-49"},{"sheetId":"CV43","name":"Nanocovax","technology":"Protein subunit","technologyDetails":"Recombinant Protein spike (s) SARS-CoV-2 and adjuvant","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04683484"],"organizations":["Nanogen Pharmaceutical Biotechnology Joint Stock Company"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Vietnam"],"description":"Nanocovax is a recombinant SARS-CoV-2 spike protein vaccine administered with aluminum phosphate adjuvant. Upon vaccination the host will generate an immune response against the spike protein that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.044859","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|620","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV43","nameId":"recombinant-protein-spike-s-sars-cov-2-and-adjuvant"},{"sheetId":"CV44","name":"AKS-452","technology":"Protein subunit","technologyDetails":"AKS-452 is a novel, biologically engineered SARS-CoV-2-RBD-Fc fusion protein designed to induce and/or augment antibody titers in patients against the novel SARS-CoV-2 coronavirus that causes COVID-19.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04681092"],"organizations":["University Medical Center Groningen","Akston Biosciences Corporation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Netherlands"],"description":"AKS-452 is a biologically engineered SARS-CoV-2-RBD-Fc fusion protein vaccine. It was designed to induce and/or augment antibody titers in patients against the novel SARS-CoV-2 coronavirus that causes COVID-19. These induced antibodies should protect an individual from the native virus.","show":true,"date":"2021-04-05 11:05:10.044933","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|130","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV44","nameId":"aks-452-is-a-novel-biologically-engineered-sars-cov-2-rbd-fc-fusion-protein-designed-to-induce-and-or-augment-antibody-titers-in-patients-against-the-novel-sars-cov-2-coronavirus-that-causes-covid-19"},{"sheetId":"CV45","name":"AdCOVID","technology":"Non-replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04679909"],"organizations":["Altimmune","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"AdCOVID is a replication-deficient adenovirus type 5 based vaccine. Upon vaccination, the host will create a robust immune response against this vaccine and since the vector is replication-defective, the vaccine itself will be unable to infect the host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to provide protection to the host.","show":true,"date":"2021-04-05 11:05:10.045063","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|180","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV45","nameId":"-50"},{"sheetId":"CV46","name":"TAK-919","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04677660"],"organizations":["Takeda"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Japan"],"description":"TAK-919 is a vaccine against SARS-CoV-2. Upon immunization, the host will create a robust immune response against this vaccine that should be sufficient to provide protection to the host against native virus.","show":true,"date":"2021-04-05 11:05:10.045100","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|200","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV46","nameId":"-51"},{"sheetId":"CV47","name":"ERUCOV-VAC","technology":"Inactivated virus","technologyDetails":"Inactivated COVID-19 Vaccine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04691947","NCT04824391"],"organizations":["Health Institutes of Turkey","TC Erciyes University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Turkey"],"description":"ERUCOV-VAC is an inactivated SARS-CoV-2 vaccine. Upon vaccination, the host will create a robust immune response against numerous viral components, and since it is inactive, the vaccine itself will be unable to replicate within the host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to eradicate the infection before signs or symptoms prevent, as well as transmission of the virus is possible.","show":true,"date":"2021-04-05 11:05:10.045139","type":"Vaccine","fdaApproved":"","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|44","Phase 1/2|NA","Phase 2|250","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV47","nameId":"inactivated-covid-19-vaccine"},{"sheetId":"CV48","name":"COVAC-2","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04702178"],"organizations":["University of Saskatchewan","Government of Canada\nGovernment of Saskatchewan","Vaccine Formulation Institute","SEPPIC"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"COVAC-2 is a COVID-19 vaccine comprised of a portion of the SARS-CoV-2 spike protein, called S1 and SWE adjuvant. Upon vaccination, the host will generate an immune response against the spike protein that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045205","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|108","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV48","nameId":"-52"},{"sheetId":"CV50","name":"GBP510","technology":"Protein subunit","technologyDetails":"SK Bioscience’s GBP510 is a recombinant protein nanoparticle vaccine. It is developed based on an optimal COVID-19 antigen adjuvanted with ","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04750343","NCT04742738"],"organizations":["SK Bioscience Co., Ltd.","Coalition for Epidemic Preparedness Innovations","GlaxoSmithKline","SK Chemicals Co., Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Korea"],"description":"GBP510 is a recombinant protein nanoparticle COVID-19 vaccine that was developed based on an optimal COVID-19 antigen. Upon vaccination, the host will generate an immune response against the spike protein that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045296","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|580","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV50","nameId":"sk-biosciences-gbp510-is-a-recombinant-protein-nanoparticle-vaccine-it-is-developed-based-on-an-optimal-covid-19-antigen-adjuvanted-with"},{"sheetId":"CV51","name":"COVIGEN","technology":"DNA-based","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04742842"],"organizations":["Bionet Co., Ltd","University of Sydney","Technovalia","Telethon Kids Institute","Institute for Clinical Pathology and Medical Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Thailand","Australia"],"description":"COVIGEN is a needle-free SARS-CoV-2 Recombinant DNA vaccine. Upon vaccination, the DNA is uptaken by host cells, and the corresponding viral antigens are produced from the DNA. The host can then create both a cellular and humoral response to the antigens which should protect the individual from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045413","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|150","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV51","nameId":"-53"},{"sheetId":"CV52","name":"Unnamed Inactive Vaccine - Jiangsu","technology":"Inactivated virus","technologyDetails":"Inactivated COVID-19 Vaccine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04758273","NCT04756323"],"organizations":["Beijing Minhai Biotechnology Co., Ltd","Shenzhen Kangtai Biological Products Co., LTD","Jiangsu Province Centers for Disease Control and Prevention"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"This is an inactivated SARS-CoV-2 vaccine. Upon vaccination, the host will create a robust immune response against numerous viral components, and since it is inactive, the vaccine itself will be unable to replicate within the host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to eradicate the infection before signs or symptoms prevent, as well as transmission of the virus is possible.","show":true,"date":"2021-04-05 11:05:10.045462","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|180","Phase 1/2|NA","Phase 2|1000","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV52","nameId":"inactivated-covid-19-vaccine-54"},{"sheetId":"CV53","name":"CoV2 SAM (LNP)","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04758962"],"organizations":["GlaxoSmithKline"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"The CoV2 SAM (LNP) vaccine is a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike antigen. Upon immunization, host cells take up the nucleic acid and express the viral antigen so that an immune response can be made against it and protect the host against native virus infection.","show":true,"date":"2021-04-05 11:05:10.045528","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|40","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV53","nameId":"-55"},{"sheetId":"CV54","name":"BBV154","technology":"Non-replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04751682"],"organizations":["Bharat Biotech International Limited"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of India"],"description":"BBV154 is a replication-deficient adenoviral vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein delivered intranasally. Upon vaccination, the host will create a robust immune response against this antigen, and since the vaccine vector is replication-defective, the vaccine itself will be unable to infect its host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to protect the host.","show":true,"date":"2021-04-05 11:05:10.045567","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|175","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV54","nameId":"-56"},{"sheetId":"CV55","name":"NBP2001","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04760743"],"organizations":["SK Bioscience Co.","Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Korea"],"description":"NBP2001 is a receptor-binding domain protein subunit vaccine adjuvanted with alum. Upon vaccination, the host will generate an immune response against this antigen that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045605","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|50","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV55","nameId":"-57"},{"sheetId":"CV56","name":"NDV-HXP-S vaccine","technology":"Replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04764422"],"organizations":["Mahidol University","The Government Pharmaceutical Organization"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Thailand"],"description":"NDV-HXP-S is a Newcastle disease virus vector-based vaccine expressing the SARS-CoV-2 spike protein. Upon vaccination, the host will create a robust immune response against this spike protein, and since the vaccine vector does not normally infect humans, the vaccine itself will not be dangerous. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to protect the host.","show":true,"date":"2021-04-05 11:05:10.045638","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|460","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV56","nameId":"-58"},{"sheetId":"CV57","name":"PTX-COVID19-B","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04765436"],"organizations":["Providence Therapeutics Holdings Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"PTX-COVID19-B is an mRNA vaccine that encodes a viral-specific antigen. Upon immunization, host cells take up the nucleic acid and express the viral antigen so that an immune response can be made against it and protect the host against native virus infection.","show":true,"date":"2021-04-05 11:05:10.045676","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|60","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV57","nameId":"-59"},{"sheetId":"CV58","name":"ChAdV68-S","technology":"Non-replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04776317"],"organizations":["National Institute of Allergy and Infectious Diseases"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"ChAdV68-S is a chimpanzee adenovirus serotype 68 vaccine vector expressing the SARS-CoV-2 spike alone, or spike plus additional SARS-CoV-2 T cell epitopes. Upon vaccination, the host will create a robust immune response against this vaccine and since the vector is replication-defective, the vaccine itself will be unable to infect the host. Upon infection with the native SARS-CoV-2 virus, the immune response generated from the vaccine should be sufficient to provide protection to the host.","show":true,"date":"2021-04-05 11:05:10.045709","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|130","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV58","nameId":"-60"},{"sheetId":"CV58","name":"SAM-LNP-S","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04776317"],"organizations":["National Institute of Allergy and Infectious Diseases"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"SAM-LNP-S is a self-amplifying mRNA liquid nanoparticle vaccine vector expressing either the SARS-CoV-2 spike alone or spike plus additional SARS-CoV-2 T cell epitopes. Upon immunization, host cells take up the nucleic acid and express the viral antigen so that an immune response can be made against it and protect the host against native virus infection.","show":true,"date":"2021-04-05 11:05:10.045752","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|130","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV58","nameId":"-61"},{"sheetId":"CV57","name":"VBI-2902a","technology":"Virus Like Particle","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04773665"],"organizations":["VBI Vaccines Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Canada"],"description":"VBI-2902a is an enveloped virus-like particle vaccine that expresses a modified version of the SARS-CoV-2 spike glycoprotein. It is designed to induce neutralizing antibody and cell-mediated immune responses against the SARS-CoV-2 spike protein so that upon infection with the native COVID-19 virus, an immunized host will be protected from associated morbidity and mortality.","show":true,"date":"2021-04-05 11:05:10.045787","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|780","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV57","nameId":"-62"},{"sheetId":"CV58","name":"COVID-eVax","technology":"DNA-based","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04788459"],"organizations":["Takis","Rottapharm Biotech"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Italy"],"description":"COVID-eVax is a DNA plasmid-based vaccine encoding a portion of the S protein of SARS-CoV-2 virus (the Receptor Binding Domain located in the CTD1 of the S1 region of the S protein). It is administered using the Cliniporator and EPSGun devices, and upon vaccination, the DNA is uptaken by host cells, and the corresponding viral antigens are produced from the DNA. The host can then create both a cellular and humoral response to the antigens which should protect the individual from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045822","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|160","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV58","nameId":"-63"},{"sheetId":"CV59","name":"EuCorVac-19","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04783311"],"organizations":["EuBiologics Co.,Ltd"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Republic of Korea"],"description":"EuCorVac-19 is a coronavirus spike protein subunit vaccine. Upon vaccination, the host will generate an immune response against this antigen that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045861","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|280","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV59","nameId":"-64"},{"sheetId":"CV60","name":"SpFN COVID-19","technology":"Protein subunit","technologyDetails":"SpFN_1B-06-PL","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04784767"],"organizations":["U.S. Army Medical Research and Development Command","Walter Reed Army Institute of Research","Henry M. Jackson Foundation for the Advancement of Military Medicine"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"SpFN COVID-19 is a Spike-Ferritin-Nanoparticle (SpFN) Vaccine administered with Army Liposomal Formulation QS21 adjuvant. Upon vaccination, the host will generate an immune response against the SARS-CoV-2 spike protein that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045927","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|72","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV60","nameId":"spfn-1b-06-pl"},{"sheetId":"CV61","name":"MV-014-212","technology":"Replicating viral vector","technologyDetails":"Live-attenuated Respiratory syncytial virus","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04798001"],"organizations":["Meissa Vaccines","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"MV-014-212 is a live-attenuated respiratory syncytial virus vaccine that is expressing the spike protein of SARS-CoV-2. Administered intranasally by drops or spray and it is designed to produce immunity against the SARS-CoV-2 spike protein. Upon vaccination, individuals will create a robust immune response that should protect the host from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.045985","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|130","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV61","nameId":"live-attenuated-respiratory-syncytial-virus"},{"sheetId":"CV62","name":"Unnamed SARS-CoV-2 mRNA vaccine","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04798027"],"organizations":["Sanofi Pasteur"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"This Sanofi vaccine is comprised of mRNA encoding a specific SARS-CoV-2 viral antigen. Upon immunization, host cells take up the nucleic acid and express the antigen so that an immune response can be made against it and protect the host against native virus infection.","show":true,"date":"2021-04-05 11:05:10.046055","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|415","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV62","nameId":"-65"},{"sheetId":"CV63","name":"SARS-CoV-2 VLP Vaccine","technology":"Virus Like Particle","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04818281"],"organizations":["Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital","The Scientific and Technological Research Council of Turkey","MonitorCRO"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Turkey"],"description":"This is a virus-like particle vaccine that is adjuvanted with alum and CpGODN-K3. It is designed to induce neutralizing antibody and cell-mediated immune responses against SARS-CoV-2 so that upon infection with the native COVID-19 virus, an immunized host will be protected from associated morbidity and mortality.","show":true,"date":"2021-04-05 11:05:10.046093","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|36","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV63","nameId":"-66"},{"sheetId":"CV64","name":"ReCOV","technology":"Protein subunit","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04818801"],"organizations":["Jiangsu Rec-Biotechnology Co.","Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China","New Zealand"],"description":"ReCOV is a recombinant protein two-component COVID-19 vaccine made in Chinese hamster ovary cells. It is comprised of the receptor-binding domain of the spike protein which is involved in entry into host cells by binding to angiotensin-converting enzyme 2. Upon vaccination, the host will generate neutralizing antibodies against the spike protein that should protect them from infection with the native virus.","show":true,"date":"2021-04-05 11:05:10.046127","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|160","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV64","nameId":"-67"},{"sheetId":"CV65","name":"mRNA-1283","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04813796"],"organizations":["ModernaTX","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"mRNA-1283 is a next-generation vaccine candidate against COVID-19 that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the receptor-binding domain and N-terminal domain. It is being developed as a potentially refrigerator-stable mRNA vaccine that will facilitate distribution and administration by healthcare providers. Upon vaccination, host cells uptake the mRNA, generate the protein, and display it to the immune system. The host can thus generate an immune response against the spike protein which should be protective against infection with SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.046163","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|125","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV65","nameId":"-68"},{"sheetId":"CV66","name":"DelNS1-nCoV-RBD LAIV","technology":"Replicating viral vector","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04809389"],"organizations":["The University of Hong Kong"],"funder":"","publishedResults":[],"relatedUse":[],"countries":["China"],"description":"DelNS1-nCoV-RBD LAIV is a genetically engineered live attenuated influenza virus that expresses the receptor-binding domain of SARS-CoV-2's spike protein. Because it is an attenuated virus, vaccination with this entity will not cause a severe infection of the host. Upon vaccination, individuals will create a robust immune response that should protect them from infection with the native COVID-19 causing virus.","show":true,"date":"2021-04-05 11:05:10.046200","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|115","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV66","nameId":"-69"},{"sheetId":"CV67","name":"DS-5670a","technology":"RNA-based vaccine","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04821674"],"organizations":["Daiichi Sankyo Co.","Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["Japan"],"description":"DS-5670a is a vaccine comprised of mRNA encoding SARS-CoV-2 viral antigens. Upon immunization, host cells take up the nucleic acid and express the antigen so that an immune response can be made against it and protect the host against native virus infection.","show":true,"date":"2021-04-05 11:05:10.046236","type":"Vaccine","fdaApproved":"","updatedOrNew":"New","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|NA","Phase 1/2|152","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"v-CV67","nameId":"-70"},{"sheetId":"CV32","name":"V590","technology":"Replicating viral vector","technologyDetails":"recombinant vesicular stomatitis virus (rVSV) technology","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04569786"],"organizations":["Merck Sharp & Dohme Corp."],"funder":"","publishedResults":[],"relatedUse":[],"countries":["United States of America"],"description":"The V590 vaccine is composed of a recombinant vesicular stomatitis virus expressing SARS-CoV-2 antigens. An additional benefit is that this vaccine can be administered using a ‘swish and swallow’ oral protocol which may lower the barrier to vaccination should it be effective. Upon vaccination, the individual will generate an immune response that should be protective against infection from the native SARS-CoV-2 virus.","show":true,"date":"2021-04-05 11:05:10.046270","type":"Vaccine","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5ea83be2d3420200adea0b6a-clinical-phase-vaccine-candidates-for-covid-19","participants":["Phase 1|252","Phase 1/2|NA","Phase 2|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"v-CV32","nameId":"recombinant-vesicular-stomatitis-virus-rvsv-technology"}]

Vaccine Candidates Development Progress

VACCINE CANDIDATES
Legend
Completed
In trials

PRECLINICAL

122

PHASE I

87

PHASE II

55

PHASE III

27

PHASE IV

7

Vaccine Candidates

↑/↓

Name ↑/↓

Organization ↑/↓

Technology ↑/↓

Stage ↑/↓

Countries ↑/↓

Clinical Trial #

Therapeutic Drugs
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
506
TOTAL
+ 1
87 in preclinical development
419 in human trials
[{"sheetId":"CD17","name":"Fluvoxamine","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04342663","NCT04668950","NCT04711863","NCT04727424","NCT04718480"],"organizations":["Washington University School of Medicine","Covid-19 Early Treatment Fund","Asan Medical Center","Cardresearch"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Fluvoxamine is a selective serotonin reuptake inhibitor antidepressant. This drug has also been shown to prevent overreactions by the immune system, which is a common pathological event in severe cases of COVID-19.","show":true,"date":"2021-04-05 11:05:09.991342","type":"Treatment","fdaApproved":"FDA-approved since 1994, approved to treat obsessive compulsive disorder","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|152","Phase 2/3|NA","Phase 3|1100","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD17","nameId":""},{"sheetId":"CD18","name":"Tranexamic Acid","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04338126","NCT04338074","NCT04550338"],"organizations":["University of Alabama at Birmingham"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Tranexamic Acid is a synthetic analog of the amino acid lysine which, upon binding to plasminogen, prevents its conversion to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure. There is recent evidence that plasmin acts on SARS-CoV-2 by cleaving a newly inserted furin site in the S protein portion of the virus resulting in increased infectivity and virulence. Therefore, a drug that reduces plasminogen conversion to plasmin may be beneficial to patients with COVID-19.","show":true,"date":"2021-04-05 11:05:09.991445","type":"Treatment","fdaApproved":"FDA-approved since 1986, approved to treat cyclic heavy menstrual bleeding","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|160","Phase 2/3|NA","Phase 3|100","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD18","nameId":"-0"},{"sheetId":"CD19","name":"Valsartan","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"Phase 4 trials recruiting May 2020","customClinicalPhase":"Phase IV","clinicalTrials":["NCT04335786","x-NCT04330300"],"organizations":["Radboud Universit","National University of Ireland, Galway, Ireland"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Valsartan is an angiotensin II receptor blocker that functions by binding to the angiotensin II type 1a receptor (AT1R). It is hypothesized that a buildup of angiotensin II interacting with its receptor (AT1R) drives COVID-19 pathology by increasing pulmonary vascular permeability. Blocking the angiotensin II/AT1R interaction would help mitigate this facet of COVID-19 disease, and thus this therapeutic is currently being tested in clinical trials.","show":true,"date":"2021-04-05 11:05:09.991497","type":"Treatment","fdaApproved":"FDA-approved since 1996, approved to treat hypertension, treat heart failure, and reduce cardiovascular mortality in patients after myocardial infarction","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|3065","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2,3],"inprogress":[4]},"inprogressClinicalTrials":[4],"completedClinicalTrials":[0,1,2,3],"phaseSortKey":8,"urlIdx":"d-CD19","nameId":"-1"},{"sheetId":"CD19","name":"TJ003234","technology":"Antibodies","technologyDetails":"TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody; lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody; Otilimab","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04341116"],"organizations":["I-Mab Biopharma Co. Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"TJ003234 is a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody that targets granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that helps create more white blood cells such as neutrophils, macrophages, and eosinophils. Recent scientific evidence suggests that GM-CSF may contribute to the immunopathology of COVID-19, and thus neutralizing this factor with an antibody may prove beneficial to those suffering from the disease. ","show":true,"date":"2021-04-05 11:05:09.991541","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|144","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD19","nameId":"tjm2-tj003234-anti-granulocyte-macrophage-colony-stimulating-factor-antibody-lenzilumab-anti-granulocyte-macrophage-colony-stimulating-factor-antibody-otilimab"},{"sheetId":"CD20","name":"Lenzilumab","technology":"Antibodies","technologyDetails":"lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody; Otilimab","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04351152","NCT04534725","NCT04583969"],"organizations":["Humanigen, Inc.","Peter MacCallum Cancer Centre, Australia","National Institute of Allergy and Infectious Diseases"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Lenzilumab is a humanized monoclonal antibody (class IgG1 kappa) that targets granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that helps create more white blood cells such as neutrophils, macrophages, and eosinophils. Recent scientific evidence suggests that GM-CSF may contribute to the immunopathology of COVID-19, and thus neutralizing this factor with an antibody may prove beneficial to those suffering from the disease.","show":true,"date":"2021-04-05 11:05:09.991662","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|200","Phase 2/3|NA","Phase 3|238","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD20","nameId":"lenzilumab-anti-granulocyte-macrophage-colony-stimulating-factor-antibody-otilimab"},{"sheetId":"CD21","name":"Otilimab","technology":"Antibodies","technologyDetails":"Otilimab is a human monoclonal anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody. GM-CSF is a cytokine that helps create more white blood cells such as neutrophils, macrophages, and eosinophils. Recent scientific evidence suggests that GM-CSF may contribute to the immunopathology of COVID-19, and thus neutralizing this factor with an antibody may prove beneficial to those suffering from the disease. ","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04376684"],"organizations":["GlaxoSmithKline"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that helps create more white blood cells such as neutrophils, macrophages, and eosinophils. Recent scientific evidence suggests that GM-CSF may contribute to the immunopathology of COVID-19, and thus neutralizing this factor with an antibody may prove beneficial to those suffering from the disease. ","show":true,"date":"2021-04-05 11:05:09.991754","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|800","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD21","nameId":"otilimab-is-a-human-monoclonal-anti-granulocyte-macrophage-colony-stimulating-factor-gm-csf-antibody-gm-csf-is-a-cytokine-that-helps-create-more-white-blood-cells-such-as-neutrophils-macrophages-and-e"},{"sheetId":"CD22","name":"Artemisinin*","technology":"Other","technologyDetails":"Artemisinin; artesunate; and ArtemiC","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04387240","NCT04382040","NCT04475107","NCT04532931","NCT04701606","NCT04801017"],"organizations":["Princess Nourah Bint Abdulrahman University","MGC Pharmaceuticals","Shin Poong Pharmaceutical Co. Ltd.","Medicines for Malaria Venture","Oncotelic Inc.","Mateon Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Artemisinin, and one if its semisynthetic derivatives Artesunate, are anti-malarial drugs that have also demonstrated anti-viral properties.  Chemically, their endoperoxide 1,2,4-trioxane ring along with a peroxide bridge is responsible for the drug's therapeutic effects, however, the mechanism of action of these compounds is hotly debated. They are both a prodrug of the biologically active dihydroartemisinin, and it is hypothesized that this molecule can generate many free radicals which would be detrimental to both malaria and numerous viruses, including coronaviruses and SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:09.991956","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|148","Phase 2/3|402","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD22","nameId":"artemisinin-artesunate-and-artemic"},{"sheetId":"CD23","name":"Telmisartan","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04355936","NCT04360551","NCT04359953","NCT04356495","NCT04394117","NCT04466241","NCT04510662","NCT04715763","EudraCT 2020-001435-27","EudraCT 2020-001303-16","x-NCT04330300"],"organizations":["Laboratorio Elea Phoenix S.A.","University of Hawaii","University Hospital, Strasbourg, France","University Hospital, Bordeaux","University of Bordeaux","National University of Ireland","The George Institute","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Université de Bordeaux","Programme PACCI","Abraham Edgar Gracia-Ramos","National Polytechnic Institute, Mexico","Hospital Regional de Alta Especialidad de Zumpango","Queens Medical Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Telmisartan is an angiotensin II receptor blocker that shows high affinity for the angiotensin II receptor type 1 (AT1R). It is hypothesized that a buildup of angiotensin II interacting with its receptor (AT1R) drives COVID-19 pathology by increasing pulmonary vascular permeability. Blocking the angiotensin II/AT1R interaction would help mitigate this facet of COVID-19 disease, and thus this therapeutic is currently being tested in clinical trials.","show":true,"date":"2021-04-05 11:05:09.992028","type":"Treatment","fdaApproved":"FDA-approved since 1998, approved to treat hypertension and reduce cardiovascular risk in patients unable to take ACE inhibitors","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-CD23","nameId":"-2"},{"sheetId":"1","name":"Fecal Microbiota Transplantation","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04824222"],"organizations":["Medical University of Warsaw","Human Biome Institute, Poland"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.992230","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"New","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|366","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0001","nameId":"-3"},{"sheetId":"2","name":"Recombinant ACE2","technology":"Other","technologyDetails":"Recombinant ACE2 (angiotensin-converting enzyme 2)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04382950","NCT04375046","NCT04335136","X-NCT04287686"],"organizations":["Kafrelsheikh University","Apeiron Biologics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.992281","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0002","nameId":"recombinant-ace2-angiotensin-converting-enzyme-2"},{"sheetId":"112","name":"(Hydroxy)Chloroquine*","technology":"Other","technologyDetails":"Chloroquine/ Hydroxychloroquine, antimalarial/TLC19","developmentStage":"Clinical","nextSteps":"Results from the University of Washington/New York University trial expected in summer 2020; RECOVERY trial results expected by June 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04261517","NCT04303507","NCT04303299","NCT04304053","NCT04316377","NCT04365764","NCT04315948","NCT04321993","EudraCT 2020-001113-21","EudraCT 2020-001246-18","EudraCT 2015-002340-14","EudraCT 2020-001357-52","NCT04323527","NCT04333732","NCT04332991","NCT04345419","NCT04345289","NCT02735707","NCT04351347","NCT04341493","NCT04359615","NCT04350684","NCT04372628","NCT04376814","NCT04373733","NCT04330690","NCT04346147","NCT04328285","NCT04359095","NCT04286503","NCT04328012","NCT04331470","NCT04364022","NCT04350671","NCT04351724","NCT04366245","NCT04343768","NCT04373044","NCT04380818","NCT04350281","NCT04370782","NCT04343092","NCT04338906","NCT04355052","NCT04374019","NCT04395768","NCT04321616","NCT04397328","NCT04400019","NCT04383717","NCT04403555","NCT04405921","NCT04334928","NCT04408456","NCT04410562","NCT04411433","NCT04414241","NCT04394182","NCT04429867","NCT04355026","NCT04434118","NCT04434144","NCT04435587","NCT04437693","NCT04438837","NCT04443270","NCT04443725","NCT04446104","NCT04447534","NCT04354428","NCT04328961","NCT04458948","NCT04459702","NCT04460547","NCT04461353","NCT04466280","NCT04466540","NCT04471649","NCT04477083","NCT04483960","NCT04491994","NCT04497519","NCT04501965","NCT04502342","NCT04554979","NCT04573153","NCT04575064","NCT04597775","NCT04590274","NCT04605588","NCT04621461","NCT04627467","NCT04652648","NCT04668469","NCT04697654","NCT04715295","NCT04714515","NCT04712279","NCT04731051","NCT04746365","NCT04779047","NCT04788355","x-NCT04421664","x-NCT04528927","x-NCT04420247","x-NCT04341727","x-NCT04333654","x-NCT04334967","x-NCT04329572","x-NCT04348474","x-NCT04341870","x-NCT04307693","x-NCT04350450","x-NCT04371926","x-NCT04369742","x-NCT04363203","x-NCT04361461","x-NCT04362332","x-NCT04354441","x-NCT04345861","x-NCT04347512","x-NCT04344379","x-NCT04329611","x-NCT04323631","x-NCT04522466","x-NCT04575558","x-NCT04392128","x-NCT04379492","x-NCT04365582","x-NCT04360759","Over 22 trials registered in China","Over 180 trials listed at clinicaltrials.gov"],"organizations":["Numerous trials with global research sponsors","(hydroxychloroquine)","University of Minnesota","University of Washington","New York University","University of Oxford","IHU-Méditerranée Infection and others","World Health Organization SOLIDARITY trial","Vanderbilt University Medical Center","AbbVie","Chelsea and Westminster NHS Foundation Trust","Hospital Universitario de Fuenlabrada","Centro Nacional de Investigaciones Oncologicas CARLOS III","Groupe Hospitalier Paris Saint Joseph","Centre Hospitalier Universitaire de Saint Etienne","Institut Pasteur","Universidad Nacional de Colombia","Bassett Healthcare","Fasa University of Medical Sciences","Calmy Alexandra","University Hospital, Geneva","Shahid Beheshti University of Medical Sciences","Andalusian Network for Design and Translation of Advanced Therapies","Shahid Beheshti University of Medical Sciences","University of Southern California","National Cancer Institute (NCI)","Grupo de Investigación Clínica en Oncología Radioterapia","The University of Hong Kong","St. Francis Hospital, New York","National Institute of Integrative Medicine, Australia","Catholic Health Initiatives","Lawson Health Research Institute","Postgraduate Institute of Medical Education and Research","Universidad Peruana Cayetano Heredia","COVID-19 PEP Canada","WellStar Health System","UHFPO","Mahidol University","Hamad Medical Corporation","Rambam Health Care Campus","Cairo University","National University Hospital, Singapore","Bill and Melinda Gates Foundation","University of New Mexico","ProgenaBiome","Big Corona Ltd.","Qassim University","Pulmoquine Therapeutics, Inc","Rockefeller University","Baqiyatallah Medical Sciences University","Brazilian Research In Intensive Care Network","Mansoura University","University of Melbourne","The Peter Doherty Institute for Infection and Immunity","Australasian Society for Infectious Diseases","UNICEF","Pak Emirates Military Hospital Rawalpindi","University Medical Center Groningen","Institute for Research and Development of Medicinal and Food Plants of Guinea","ScandiBio Therapeutics AB","Istanbul Medipol University Hospital","Istanbul Umraniye Training andResearch Hospital","INSERM","Dept. of Statistics and Medical Biometry, University of Bremen","Regional Center for Disease Control and Prevention, Jordan","Farhat Hached Hospital, Tunisia","Fattouma Bourguiba, Tunisia","International Brain Research Foundation","Rutgers, The State University of New Jersey","SynaVir","Bryn Mawr Hospital","Sharpe-Strumia Research Foundation","Cotswold Foundation","Benha University","Taiwan Liposome Company","Yaounde Central Hospital","University of Sargodha","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","Shaukat Khanum Memorial Cancer Hospital & Research Centre","Teesside University","Corpometria Institute","King Hussein Cancer Center","Amman Pharmaceutical Industries","Sana Pharmaceutical Industry","ACDIMA Center for Bioequivalence and Pharmaceutical Studies","Elaraby Hospital","Shebin-Elkom Teaching Hospital","October 6 University","Beni-Suef University","Universidade do Vale do Sapucai","Apsen Farmaceutica S.A.","Pfizer","Dermadia","Methodos Laboratory","Biofarma\n\n(chloroquine)","New York State Department of Health","Beijing YouAn Hospital","CMN \"20 de Noviembre\"","Tanta University","Fundacion Clinica Valle del Lili\n\n(hydroxychloroquine with zithromax)","Mahidol Oxford Tropical Medicine Research Unit","Tanta University\n\n(hydroxychloroquine and chloroquine)","ORCHID Trial with National Heart, Lung, and Blood Institute (NHLBI)","REMAP-CAP global trial","Novartis","PRINCIPLE trial*","THDMS-COVID-19","Baqiyatallah Medical Sciences University","ACOVACT"],"funder":"COVID-19 Treatment Accelerator (University of Washington/New York University trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial)*","publishedResults":["NCT04261517|https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29","IHU-Méditerranée Infection|https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf","Journal of ZheJiang University|http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03","medRxiv|https://doi.org/10.1101/2020.03.22.20040758","Int'l Journal of Antimicrobial Agents|https://doi.org/10.1016/j.ijantimicag.2020.105949","medRxiv|https://doi.org/10.1101/2020.04.10.20060558","medRxiv|https://doi.org/10.1101/2020.03.22.20040949","medRxiv|https://doi.org/10.1101/2020.04.02.20047050","medRxiv|https://doi.org/10.1101/2020.03.31.20048777","medRxiv|https://doi.org/10.1101/2020.03.24.20042366","medRxiv|https://doi.org/10.1101/2020.04.07.20056424","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.08.20054551","ScienceDirect|https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub","ISAC|https://www.isac.world/news-and-publications/official-isac-statement","ScienceDirect|https://www.sciencedirect.com/science/article/pii/S0924857920300996","medRxiv|https://doi.org/10.1101/2020.04.10.20060699","medRxiv|https://doi.org/10.1101/2020.04.10.20060558","medRxiv|https://doi.org/10.1101/2020.04.14.20065276","medRxiv|https://doi.org/10.1101/2020.04.16.20065920","medRxiv|https://doi.org/10.1101/2020.04.16.20068205"],"relatedUse":["NCT04261517|https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29","IHU-Méditerranée Infection|https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf","Journal of ZheJiang University|http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03","medRxiv|https://doi.org/10.1101/2020.03.22.20040758","Int'l Journal of Antimicrobial Agents|https://doi.org/10.1016/j.ijantimicag.2020.105949","medRxiv|https://doi.org/10.1101/2020.04.10.20060558","medRxiv|https://doi.org/10.1101/2020.03.22.20040949","medRxiv|https://doi.org/10.1101/2020.04.02.20047050","medRxiv|https://doi.org/10.1101/2020.03.31.20048777","medRxiv|https://doi.org/10.1101/2020.03.24.20042366","medRxiv|https://doi.org/10.1101/2020.04.07.20056424","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.08.20054551","ScienceDirect|https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub","ISAC|https://www.isac.world/news-and-publications/official-isac-statement","ScienceDirect|https://www.sciencedirect.com/science/article/pii/S0924857920300996","medRxiv|https://doi.org/10.1101/2020.04.10.20060699","medRxiv|https://doi.org/10.1101/2020.04.10.20060558","medRxiv|https://doi.org/10.1101/2020.04.14.20065276","medRxiv|https://doi.org/10.1101/2020.04.16.20065920","medRxiv|https://doi.org/10.1101/2020.04.16.20068205"],"countries":[],"description":"Both hydroxychloroquine and chloroquine are common antimalarial drugs. Although no scientific consensus has been reached, this function has been attributed to the lowering of endosomal pH and the ultimate formation and accumulation of free cytotoxic heme that kills the malaria parasite. Again, no scientific consensus has been reached, but it is thought that this lowering of endosomal pH may also have antiviral properties as increased pH is generally required for uncoating and replication of many viruses.\n\nNote: The FDA has revoked this drug's emergency authorization for the treatment of COVID-19 due to observed side effects in clinical trials studies (June 15, 2020).","show":true,"date":"2021-04-05 11:05:09.992624","type":"Treatment","fdaApproved":"FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)","updatedOrNew":"None","template":["5e8f25b213f46000ab9f89ed"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f25b213f46000ab9f89ed-chloroquine-potential-mechanisms-of-action-against-coronavir","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|440","Phase 2/3|NA","Phase 3|800","Phase 4|202","Phase NA|40040"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0112","nameId":"chloroquine-hydroxychloroquine-antimalarial-tlc19"},{"sheetId":"57","name":"Remdesivir*","technology":"Antivirals","technologyDetails":"remdesivir, nucleotide analog","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04292730","NCT04292899","NCT04280705","EudraCT 2020-000936-23","EudraCT 2020-000982-18","NCT04315948","NCT04302766","NCT04323761","NCT04321616","NCT04330690","NCT04373044","NCT04365725","NCT04401579","NCT04410354","NCT04409262","NCT04365764","NCT04431453","NCT04480333","NCT04488081","NCT04492475","NCT04492501","NCT04501952","NCT04501978","NCT04539262","NCT04546581","NCT04560231","NCT04578158","NCT04582266","NCT04583956","NCT04583969","NCT04593940","NCT04596839","NCT04610541","NCT04640168","NCT04647669","NCT04669990","NCT04678739","NCT04693026","NCT04694612","NCT04727775","NCT04728880","NCT04738045","NCT04745351","NCT04779047","NCT04784559","x-NCT04257656","x-NCT04252664"],"organizations":["Gilead","World Health Organization SOLIDARITY trial","National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial","Feinstein Institutes","University of Southern California","National Cancer Institute (NCI)","Assistance Publique - Hôpitaux de Paris","Hoffmann-La Roche","NeuroActiva, Inc.","National Institute of Allergy and Infectious Diseases","UNICEF","Pak Emirates Military Hospital Rawalpindi","International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)","University of Copenhagen","Medical Research Council","Kirby Institute","Washington D.C. Veterans Affairs Medical Center","AIDS Clinical Trials Group","National Heart, Lung, and Blood Institute (NHLBI)","US Department of Veterans Affairs","Prevention and Early Treatment of Acute Lung Injury (PETAL)","Cardiothoracic Surgical Trials Network (CTSN)","University of Minnesota","National Institutes of Health","The International Network for Strategic Initiatives in Global HIV Trials","Lahore General Hospital","Liaquat University of Medical & Health Sciences","University of Milano Bicocca","University of Pavia","International Maternal Pediatric Adolescent AIDS Clinical Trials Group","National Center for Advancing Translational Science","Biomedical Advanced Research and Development Authority","Duke University","Beximco Pharmaceuticals Ltd.","University of Pecs","HECRIN Consortium","Hungarian Ministry of Innovation and Technology","The University of The West Indies","Nepal Health Research Council","M Abdur Rahim Medical College and Hospital","First affiliated Hospital of Xi'an Jiaoting University","M Abdur Rahim Medical College and Hospital","First affiliated Hospital Xi'an Jiaoting University","Astana Medical University","Mansoura University","Beni-Suef University","October 6 University","PharmaMar"],"funder":"","publishedResults":["NEJM|https://www.nejm.org/doi/full/10.1056/NEJMoa2007016","NEJM|https://www.nejm.org/doi/full/10.1056/NEJMoa2001191","Stat News|https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/","Reuters|https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326","Stat|https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/"],"relatedUse":["NEJM|https://www.nejm.org/doi/full/10.1056/NEJMoa2007016","NEJM|https://www.nejm.org/doi/full/10.1056/NEJMoa2001191","Stat News|https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/","Reuters|https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326","Stat|https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/"],"countries":[],"description":"Remdesivir is an antiviral prodrug under the nucleotide analog category. It functions post-metabolism in its active form (GS-441524) by mimicking adenosine and interfering with the RNA-dependent RNA polymerase. This interaction causes premature termination and a decrease in viable viral progeny.   ","show":true,"date":"2021-04-05 11:05:09.992829","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":["5e8f2617bbf15200b1d93310"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0057","nameId":"remdesivir-nucleotide-analog"},{"sheetId":"56","name":"Lopinavir*","technology":"Antivirals","technologyDetails":"Kaletra (lopinavir)","developmentStage":"Clinical","nextSteps":"RECOVERY trial results expected by June 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04303299","NCT04255017","ChiCTR2000029548","ChiCTR2000029539","ChiCTR2000029541","EudraCT 2020-000936-23","NCT04315948","NCT04252885","NCT04276688","NCT02735707","NCT04321993","EudraCT 2020-001113-21","EudraCT 2015-002340-14","ChiCTR2000030535","NCT04261907","ChiCTR2000029496","NCT04350684","NCT04372628","NCT04376814","NCT04330690","NCT04346147","NCT04328285","NCT04359095","NCT04286503","NCT04328012","NCT04331470","NCT04321174","NCT04364022","NCT04350671","NCT04295551","NCT04351724","NCT04366245","NCT04343768","NCT04373044","NCT04275388","NCT04380818","NCT04365764","NCT04425382","NCT04455958","NCT04459702","NCT04466241","NCT04483960","NCT04499677","NCT04521400","NCT04611243","NCT04738045","x-NCT04307693","x-NCT04409483","x-NCT04365582"],"organizations":["Global hospital testing (AbbVie)","World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta)","University of Oxford RECOVERY trial","REMAP-CAP global trial","INSERM","Mianyang Central Hospital","Ascletis Pharmaceuticals Co., Ltd.","First Affiliated Hospital of Zhejiang University","Zhongnan Hospital of Wuhan University","Vanderbilt University Medical Center","Baqiyatallah Medical Sciences University","Hospital Universitario de Fuenlabrada","Centro Nacional de Investigaciones Oncologicas CARLOS III","Groupe Hospitalier Paris Saint Joseph","Centre Hospitalier Universitaire de Saint Etienne","Institut Pasteur","Universidad Nacional de Colombia","Beijing YouAn Hospital","Bassett Healthcare","Fasa University of Medical Sciences","St. Michael's Hospital, Toronto","Calmy Alexandra","University Hospital, Geneva","Shahid Beheshti University of Medical Sciences","ACOVACT","Andalusian Network for Design and Translation of Advanced Therapies","Shahid Beheshti University of Medical Sciences","University of Southern California","National Cancer Institute (NCI)","Grupo de Investigación Clínica en Oncología Radioterapia","Université Abdou Moumouni","Centre de Recherche Médicale et Sanitaire","Ministry of Public Health, Republic of Niger","Hamad Medical Corporation","OHSU Knight Cancer Institute","Oregon Health and Science University","National Cancer Institute","ProgenaBiome","Big Corona Ltd.","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Université de Bordeaux","Programme PACCI","University of Melbourne","The Peter Doherty Institute for Infection and Immunity","Australasian Society for Infectious Diseases","University College, London","LifeArc","Chinese University of Hong Kong","The University of Hong Kong","Health and Medical Research Fund","Beni-Suef University","October 6 University"],"funder":"UK Government (University of Oxford RECOVERY trial)","publishedResults":["NEJM|https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","medRxiv|https://doi.org/10.1101/2020.03.19.20038984","Chinese Journal of Infectious Diseases|http://rs.yiigle.com/yufabiao/1182592.htm","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.21.20066761","medRxiv|https://doi.org/10.1101/2020.04.25.20079079","medRxiv|https://doi.org/10.1101/2020.04.24.20077735"],"relatedUse":["NEJM|https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","medRxiv|https://doi.org/10.1101/2020.03.19.20038984","Chinese Journal of Infectious Diseases|http://rs.yiigle.com/yufabiao/1182592.htm","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.21.20066761","medRxiv|https://doi.org/10.1101/2020.04.25.20079079","medRxiv|https://doi.org/10.1101/2020.04.24.20077735"],"countries":[],"description":"Lopinavir is an antiretroviral that functions by binding viral proteases.","show":true,"date":"2021-04-05 11:05:09.993013","type":"Treatment","fdaApproved":"FDA-approved since 2000, approved to treat HIV-1 infection","updatedOrNew":"None","template":["5eac4ad94ccb4800b1dd839b"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac4ad94ccb4800b1dd839b-lopinavir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0056","nameId":"kaletra-lopinavir"},{"sheetId":"62","name":"ASC09*","technology":"Antivirals","technologyDetails":"ASC09, HIV protease inhibitor","developmentStage":"Clinical","nextSteps":"Primary trial ends May 2020","customClinicalPhase":"Phase III","clinicalTrials":["NCT04261907","NCT04261270"],"organizations":["Ascletis Pharmaceuticals Co., Ltd.","First Affiliated Hospital of Zhejiang University","Tongji Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"ASC09 is an antiretroviral protease inhibitor related to darunavir.","show":true,"date":"2021-04-05 11:05:09.993075","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac4c941b981d00b29aaa29"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac4c941b981d00b29aaa29-asc-09-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|60","Phase 4|NA","Phase NA|40"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0062","nameId":"asc09-hiv-protease-inhibitor"},{"sheetId":"55","name":"Favipiravir*","technology":"Antivirals","technologyDetails":"Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza","developmentStage":"Clinical","nextSteps":"Phase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04303299","NCT04310228","ChiCTR2000029548","ChiCTR2000029544","ChiCTR2000030254","NCT04336904","NCT04333589","NCT04345419","NCT04358549","NCT04346628","NCT04349241","NCT04319900","NCT04359615","NCT04351295","NCT04356495","NCT04376814","NCT04373733","NCT04373733","NCT04400682","NCT04402203","NCT04411433","NCT04425460","NCT04434248","NCT04445467","NCT04464408","NCT04468087","NCT04471662","NCT04474457","NCT04475991","NCT04499677","NCT04501783","NCT04529499","NCT04532931","NCT04542694","NCT04558463","NCT04600895","NCT04600999","NCT04613271","NCT04651959","NCT04694612","NCT04715360","NCT04727775","NCT04718285","NCT04818320","NCT04828564"],"organizations":["Fujifilm Toyama Chemical/Pharmaceuticals","Zhejiang Hisun Pharmaceuticals","Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School","Rajavithi Hospital","Peking University First Hospital","The First Affiliated Hospital, Zhejiang University School of Medicine","Zhongnan Hospital of Wuhan University","ASST Fatebenefratelli Sacco","Tanta University","Stanford University","Ain Shams University","Beijing Chao Yang Hospital","Shahid Beheshti University of Medical Sciences","University Hospital, Bordeaux","Baqiyatallah Medical Sciences University","Chelsea and Westminster NHS Foundation Trust","Novelfarma Ilaç San. ve Tic. Ltd. Sti.","Novagenix Bioanalytical Drug R&D Center","Farmagen Ar-Ge Biyot. Ltd. Sti","Bangladesh Medical Research Council","Ministry of Health, Turkey","Opera CRO, a TIGERMED Group Company","Chromis LLC","Chemical Diversity Research Institute","Bayside Health","Appili Therapeutics Inc.","MOUNT SINAI HOSPITAL","Applied Health Research Centre","Sunnybrook Health Sciences Centre","University Health Network, Toronto","University of Toronto","King Abdullah International Medical Research Center","Ministry of Health, Saudi Arabia","Hospital do Coracao","Ministry of Health, Turkey","Hospital General de México Dr. Eduardo Liceaga","CCINSHAE. Secretaría de Salud. México","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Centro de Investigación en. Enfermedades Infecciosas, Mexico","University College, London","LifeArc","R-Pharm","Dr. Reddy's Laboratories Limited","Shin Poong Pharmaceutical Co. Ltd.","Medicines for Malaria Venture","Promomed, LLC","Solyur-pharm","Indonesia University","University of Pecs","HECRIN Consortium","Hungarian Ministry of Innovation and Technology","Ina-Respond","Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia","Pharma Plant","Nepal Health Research Council","Hayandra Peduli Foundation","Koja Regional Public Hospital","Astana Medical University","Bahcesehir University","Medipol University","The Scientific and Technological Research Council of Turkey","Penang Hospital, Malaysia","Ankara City Hospital Bilkent","Istanbul Umraniye Training and Research Hospital","Koç University","Monitor CRO"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.17.20037432","medRxiv|https://doi.org/10.1101/2020.04.21.20066761"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.17.20037432","medRxiv|https://doi.org/10.1101/2020.04.21.20066761"],"countries":[],"description":"Favipiravir is the prodrug of a purine nucleotide, that upon conversion to its active form (favipiravir-ribofuranosyl-5'-triphosphate [favipiravir-RTP]), is thought to selectively inhibit viral RNA-dependent RNA-polymerase, but not impact host (mammalian) polymerases. Other research suggests that the mode of action may be the induction of lethal RNA transversion mutations which leads to non-viable viral progeny. ","show":true,"date":"2021-04-05 11:05:09.993209","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":["5eac4dbb1b981d00b29ab1b1"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac4dbb1b981d00b29ab1b1-favipiravir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|170","Phase 2/3|290","Phase 3|1192","Phase 4|20","Phase NA|490"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0055","nameId":"favilavir-favipiravir-t-705-avigan-licensed-in-japan-to-treat-influenza"},{"sheetId":"58","name":"Darunavir*","technology":"Antivirals","technologyDetails":"Prezcobix (darunavir, HIV-1 protease inhibitor)","developmentStage":"Clinical","nextSteps":"Primary study ends August 2020","customClinicalPhase":"Phase III/IV","clinicalTrials":["ChiCTR2000029541","NCT04252274","NCT04303299","NCT04425382","NCT04435587"],"organizations":["Shanghai Public Health Clinical Center","Rajavithi Hospital","Zhongnan Hospital of Wuhan University","Hamad Medical Corporation","Mahidol University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Darunavir is a nonpeptidic protease inhibitor that functions by using numerous hydrogen bonds to lodge itself into their active sites.","show":true,"date":"2021-04-05 11:05:09.993299","type":"Treatment","fdaApproved":"FDA-approved since 2015, approved to treat HIV-1 infection","updatedOrNew":"None","template":["5eac4e664ccb4800b1dd9b61"],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5eac4e664ccb4800b1dd9b61-darunavir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|190","Phase 4|NA","Phase NA|40"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3,4]},"inprogressClinicalTrials":[3,4],"completedClinicalTrials":[0,1,2],"phaseSortKey":6.5,"urlIdx":"d-0058","nameId":"prezcobix-darunavir-hiv-1-protease-inhibitor"},{"sheetId":"13","name":"Sarilumab*","technology":"Antibodies","technologyDetails":"Kevzara (sarilumab), interleukin-6 receptor antagonist","developmentStage":"Clinical","nextSteps":"Started phase 2/3 in March 2020; preliminary Phase 2 results released April 27, 2020, trial continuing for only critical patients, Phase 3 (US) results expected June 2020, Phase 3 (ex-US) results expected 3Q 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04357808","NCT04315298","NCT04357860","NCT04327388","NCT04324073","NCT04345289","NCT04322773","NCT02735707","NCT04386239","EudraCT 2020-001246-18","EudraCT 2015-002340-14","NCT04365764","NCT04661527","x-NCT04341870","x-NCT04359901"],"organizations":["Sanofi/Regeneron","REMAP-CAP","Westyn Branch-Elliman","Maria del Rosario Garcia de Vicuña Pinedo","Instituto de Investigación Sanitaria Hospital Universitario de la Princesa","Maimónides Biomedical Research Institute of Córdoba","Consejería de Salud y Familias - Junta de Andalucía","Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)","Assistance Publique - Hôpitaux de Paris","CCAP","Hvidovre University Hospital","Frederiksberg University Hospital","ASST Fatebenefratelli Sacco","Clinica Universidad de Navarra, Universidad de Navarra","Hospital Universitario Infanta Leonor"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":["ChinaXiv|http://www.chinaxiv.org/abs/202003.00026","medRxiv|https://doi.org/10.1101/2020.04.23.20076612","Regeneron|https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive"],"relatedUse":["ChinaXiv|http://www.chinaxiv.org/abs/202003.00026","medRxiv|https://doi.org/10.1101/2020.04.23.20076612","Regeneron|https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive"],"countries":[],"description":"Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. Interleukin 6 is a cytokine relevant to many inflammatory diseases including COVD-19, and thus blocking its effects may be beneficial to those suffering from the disease.","show":true,"date":"2021-04-05 11:05:09.993417","type":"Treatment","fdaApproved":"FDA-approved since 2017, approved to treat rheumatoid arthritis","updatedOrNew":"None","template":["5eb1a6072288cf00ab0143d5"],"templateLink":"https://app.biorender.com/biorender-templates/t-5eb1a6072288cf00ab0143d5-sarilumab-antibody-against-il-6r","participants":["Phase 1|NA","Phase 2|370","Phase 2/3|939","Phase 3|500","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0013","nameId":"kevzara-sarilumab-interleukin-6-receptor-antagonist"},{"sheetId":"14","name":"Tocilizumab*","technology":"Antibodies","technologyDetails":"Actemra (tocilizumab), interleukin-6 receptor antagonist; ROACTEMRA","developmentStage":"Clinical","nextSteps":"Phase 2 open label study in Italy active (April 2020), Phase 3 studies recruiting April 2020, some results from open label study in France released April 2020","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04317092","NCT04320615","NCT04310228","ChiCTR2000030894","NCT04306705","ChiCTR2000029765","NCT04322773","NCT02735707","NCT04330638","NCT04345445","NCT04331795","NCT04377750","NCT04332094","NCT04377659","NCT04359667","NCT04335071","NCT04356937","NCT04347031","NCT04365764","NCT04331808","NCT04315480","NCT04339712","NCT04335305","NCT04363736","NCT04361032","NCT04363853","NCT04377503","NCT04332913","NCT04372186","NCT04380818","EudraCT 2020-001246-18","NCT04409262","EudraCT 2020-001500-41","EudraCT 2020-001039-29","EudraCT 2015-002340-14","NCT04412291","NCT04412772","NCT04424056","NCT04423042","NCT04394182","NCT04435717","NCT04445272","NCT04476979","NCT04479358","NCT04486521","NCT04492501","NCT04519385","NCT04560205","NCT04577534","NCT04600141","NCT04678739","NCT04693026","NCT04690920","NCT04734678","NCT04730323","NCT04779047","x-NCT04403685","x-NCT04361552","x-NCT04346355","x-NCT04333914","x-NCT04370834"],"organizations":["Roche","Genentech, Inc.","National Cancer Institute, Naples","Hoffmann-La Roche","Peking University First Hospital","Tongji Hospital","The First Affiliated Hospital of University of science and technology of China","REMAP-CAP","University Hospital, Ghent","Centre Leon Berard","University of Malaya","University of Chicago","Hadassah Medical Organization","Sheba Medical Center","Wolfson Medical Center","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","Instituto de Salud Carlos III","Memorial Sloan Kettering Cancer Center","Azienda Unità Sanitaria Locale Reggio Emilia","University Hospital for Infectious Diseases, Croatia","University Hospital Inselspital, Berne","Massachusetts General Hospital","Burnasyan Federal Medical Biophysical Center","Groupe Hospitalier Pitie-Salpetriere","Centre Hospitalier Intercommunal Robert Ballanger","Centre Hospitalier Intercommunal Montfermeil-Le Raincy","CMC Ambroise Paré","Assistance Publique - Hôpitaux de Paris","Emory University","National Cancer Institute (NCI)","Università Politecnica delle Marche","Azienda Ospedaliera Ospedali Riuniti Marche Nord","Hellenic Institute for the Study of Sepsis","MedSIR","Abderrahmane Mami Hospital","Eshmoun Clinical Research Centre","Datametrix","Instituto Nacional de Cancerologia de Mexico","Hospital Sao Domingos","University of L'Aquila","Grupo de Investigación Clínica en Oncología Radioterapia","Beneficência Portuguesa de São Paulo","Gilead Sciences","Queen's Medical Centre","Assistance Publique Hopitaux De Marseille","University of Calgary","Hospital Universitario Ramon y Cajal","Fundacion SEIMC-GESIDA","Dynamic Science S.L.","King Faisal Specialist Hospital & Research Center","Society of Critical Care Medicine","UNICEF","Pak Emirates Military Hospital Rawalpindi","South Valley University","Lahore General Hospital","Turku University Hospital","University of Sao Paulo","Conselho Nacional de Desenvolvimento Científico e Tecnológico","M Abdur Rahim Medical College and Hospital","First affiliated Hospital of Xi'an Jiaoting University","M Abdur Rahim Medical College and Hospital","First affiliated Hospital Xi'an Jiaoting University","University of Lahore","Ain Shams University","Misr International University","FMH College of Medicine and Dentistry","October 6 University","Beni-Suef University"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":["ChinaXiv|http://www.chinaxiv.org/abs/202003.00026","medRxiv|https://doi.org/10.1101/2020.04.20.20061861","medRxiv|https://doi.org/10.1101/2020.04.23.20076612","Assistance Publique Hopitaux De Paris|https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid","PNAS|https://www.pnas.org/content/early/2020/04/27/2005615117#T1"],"relatedUse":["ChinaXiv|http://www.chinaxiv.org/abs/202003.00026","medRxiv|https://doi.org/10.1101/2020.04.20.20061861","medRxiv|https://doi.org/10.1101/2020.04.23.20076612","Assistance Publique Hopitaux De Paris|https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid","PNAS|https://www.pnas.org/content/early/2020/04/27/2005615117#T1"],"countries":[],"description":"Tocilizumab is an inhibitor of the receptor of interleukin 6 (IL-6). IL-6 is a cytokine relevant to many inflammatory diseases including COVD-19, and thus blocking its effects may be beneficial to those suffering from the disease.","show":true,"date":"2021-04-05 11:05:09.993698","type":"Treatment","fdaApproved":"FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome","updatedOrNew":"None","template":["5eb1a99de0132000ae367f4b"],"templateLink":"https://app.biorender.com/biorender-templates/t-5eb1a99de0132000ae367f4b-tocilizumab-humanized-antibody-against-il-6r","participants":["Phase 1|NA","Phase 2|2402","Phase 2/3|NA","Phase 3|1800","Phase 4|1117","Phase NA|518"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0014","nameId":"actemra-tocilizumab-interleukin-6-receptor-antagonist-roactemra"},{"sheetId":"9","name":"Bevacizumab","technology":"Antibodies","technologyDetails":"Avastin (bevacizumab), vascular endothelial growth factor inhibitor","developmentStage":"Clinical","nextSteps":"Phase 2/3 studies recruiting April 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04275414","NCT04305106","NCT04344782","NCT04822818","EudraCT 2020-001246-18"],"organizations":["Roche","Assistance Publique - Hôpitaux de Paris","Qilu Hospital of Shandong University","Renmin Hospital of Wuhan University","Ialy Moriggia Pelascini Gravedona Hospital S.p.A\nWuhan University","Jiangbei Union Hospital of Huazhong University of science and technology","Shandong Provincial Chest Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Bevacizumab is a whole recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).","show":true,"date":"2021-04-05 11:05:09.993800","type":"Treatment","fdaApproved":"FDA-approved since 2004, approved to treat certain types of cancer","updatedOrNew":"Updated","template":["5ebc019b5c475700aea9e3ef"],"templateLink":"https://app.biorender.com/biorender-templates/figures/all/t-5ebc019b5c475700aea9e3ef-bevacizumab-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 2|NA","Phase 2/3|20","Phase 3|NA","Phase 4|NA ","Phase NA|140"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0009","nameId":"avastin-bevacizumab-vascular-endothelial-growth-factor-inhibitor"},{"sheetId":"10","name":"Anti-PD-1 Antibody","technology":"Antibodies","technologyDetails":"anti-programmed cell death protein (PD)-1 antibody - camrelizumab; Nivolumab; Pembrolizumab","developmentStage":"Clinical","nextSteps":"Phase 2 primary trial ends April 30, 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04268537","NCT04356508","","ChiCTR2000030028","ChiCTR2000029806","NCT04335305","NCT04343144","NCT04413838","x-NCT04333914"],"organizations":["Southeast University, China","Wuhan Infectious Diseases Hospital","West China Hospital, Sichuan University","The University of Hong Kong","Queen Mary Hospital, Hong Kong","Centre Leon Berard","Assistance Publique - Hôpitaux de Paris","Hospices Civils de Lyon"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Programmed death (PD)-1 is a marker on active T cells that, upon being bound to its ligand (PD-L1/2) results in that T cell becoming inactive. Antibodies against PD-1 prevent this interaction and allow T cells (including immunoregulatory T cells, which may be important in controlling overactive immune responses) to remain functional. ","show":true,"date":"2021-04-05 11:05:09.993887","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":["5ebbff395c475700aea9cd37"],"templateLink":"https://app.biorender.com/biorender-templates/figures/all/t-5ebbff395c475700aea9cd37-pd-1-blocking-antibodies-potential-repurposed-drug-candidate","participants":["Phase 1|NA","Phase 2|255","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|120"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0010","nameId":"anti-programmed-cell-death-protein-pd-1-antibody-camrelizumab-nivolumab-pembrolizumab"},{"sheetId":"10","name":"Thymosin","technology":"Other","technologyDetails":"Thymosin; Thymalfasin","developmentStage":"Clinical","nextSteps":"Phase 2 study not yet recruiting","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04268537","NCT04320238","ChiCTR2000029806","NCT04428008","NCT04487444"],"organizations":["Southeast University, China","Wuhan Infectious Diseases Hospital","Shanghai Jiao Tong University School of Medicine","Inova Health System","Nephrology Associates of Northern Virginia, Inc.","Davita Clinical Research","Rhode Island Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Thymosins are a family of small proteins that are found in many animal (and human) tissues and have a wide array of functions. One such function is their ability to regulate cellular immunity in sepsis patients. ","show":true,"date":"2021-04-05 11:05:09.993984","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|240","Phase 2|80","Phase 2/3|NA","Phase 3|1472","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0010","nameId":"thymosin-thymalfasin"},{"sheetId":"11","name":"Leronlimab (PRO 140)","technology":"Antibodies","technologyDetails":"leronlimab (PRO 140), a CCR5 antagonist","developmentStage":"Clinical","nextSteps":"Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04343651","","NCT04347239","NCT04678830"],"organizations":["CytoDyn","Amarex Clinical Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Leronlimab (PRO 140) is a humanized IgG4 monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5) found on the surface of T lymphocytes. It functions by preventing viral entry to the cell by steric hindrance.","show":true,"date":"2021-04-05 11:05:09.994041","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 2|465","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0011","nameId":"leronlimab-pro-140-a-ccr5-antagonist"},{"sheetId":"18","name":"Siltuximab*","technology":"Antibodies","technologyDetails":"Sylvant (siltuximab), interleukin-6 targeted monoclonal","developmentStage":"Clinical","nextSteps":"Interim data shared April 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04322188","NCT04329650","NCT04330638","NCT04486521"],"organizations":["EUSA Pharma/The Papa Giovanni XXII Hospital","Fundacion Clinic per a la Recerca Biomédica","University Hospital, Ghent","King Faisal Specialist Hospital & Research Center","Society of Critical Care Medicine"],"funder":"","publishedResults":["EUSA Pharma|https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/","medRxiv|https://doi.org/10.1101/2020.04.01.20048561","medRxiv|https://doi.org/10.1101/2020.04.23.20076612"],"relatedUse":["EUSA Pharma|https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/","medRxiv|https://doi.org/10.1101/2020.04.01.20048561","medRxiv|https://doi.org/10.1101/2020.04.23.20076612"],"countries":[],"description":"A human-mouse chimeric monoclonal antibody that binds the proinflammatory cytokine, interleukin (IL)-6.","show":true,"date":"2021-04-05 11:05:09.994129","type":"Treatment","fdaApproved":"FDA-approved since 2014, approved to treat multicentric Castleman disease","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 2|100","Phase 2/3|NA","Phase 3|171","Phase 4|NA","Phase NA|50"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0018","nameId":"sylvant-siltuximab-interleukin-6-targeted-monoclonal"},{"sheetId":"19","name":"Eculizumab","technology":"Antibodies","technologyDetails":"Soliris (eculizumab), complement inhibitor","developmentStage":"Clinical","nextSteps":"Phase 2 recruiting May 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04288713","NCT04355494","NCT04346797","NCT04802083","EudraCT 2020-001246-18"],"organizations":["Alexion Pharmaceuticals","Hudson Medical","Assistance Publique - Hôpitaux de Paris"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Eculizumab is a humanized whole antibody that targets the proinflammatory complement component 5 molecule.","show":true,"date":"2021-04-05 11:05:09.994197","type":"Treatment","fdaApproved":"FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 2|120","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0019","nameId":"soliris-eculizumab-complement-inhibitor"},{"sheetId":"20","name":"Canakinumab","technology":"Antibodies","technologyDetails":"Ilaris (canakinumab), interleukin-1beta blocker","developmentStage":"Clinical","nextSteps":"Novartis Phase 3 to start and trial top-line results expected late summer 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04362813","NCT04365153","NCT04348448","NCT04476706","NCT04510493"],"organizations":["Novartis Pharmaceuticals","The Cleveland Clinic","AUSL Romagna Rimini","University Hospital, Basel, Switzerland","Swiss National Science Foundation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Canakinumab is a human monoclonal antibody that targets the important inflammatory molecule interleukin (IL)-1 beta, which is elevated in people suffering from COVID-19.  ","show":true,"date":"2021-04-05 11:05:09.994256","type":"Treatment","fdaApproved":"FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|45","Phase 2/3|NA","Phase 3|450","Phase 4|NA","Phase NA|100"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0020","nameId":"ilaris-canakinumab-interleukin-1beta-blocker"},{"sheetId":"21","name":"Emapalumab","technology":"Antibodies","technologyDetails":"Gamifant (emapalumab), anti-interferon gamma antibody","developmentStage":"Clinical","nextSteps":"Phase 2/3 recruiting April 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04324021"],"organizations":["Swedish Orphan Biovitrum"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Emapalumab is a whole antibody of human origin that binds to the proinflammatory cytokine interferon-gamma. ","show":true,"date":"2021-04-05 11:05:09.994315","type":"Treatment","fdaApproved":"FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 2|NA","Phase 2/3|54","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0021","nameId":"gamifant-emapalumab-anti-interferon-gamma-antibody"},{"sheetId":"22","name":"Meplazumab","technology":"Antibodies","technologyDetails":"meplazumab, anti-CD147 antibody","developmentStage":"Clinical","nextSteps":"Phase 1/2 recruiting April 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04275245","NCT04586153"],"organizations":["Tang-Du Hospital","Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.21.20040691"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.21.20040691"],"countries":[],"description":"Meplazumab is a humanized antibody that binds and blocks cluster of differentiation (CD)147 (also known as basigin). This molecule may interact with the spike protein of SARS-CoV-2 and facilitate host cell invasion, and thus meplazumab may prevent this from occurring. ","show":true,"date":"2021-04-05 11:05:09.994387","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|20","Phase 2|NA","Phase 2/3|456","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0022","nameId":"meplazumab-anti-cd147-antibody"},{"sheetId":"23","name":"LY3127804","technology":"Antibodies","technologyDetails":"LY3127804, anti-Angiopoietin 2 (Ang2) antibody","developmentStage":"Clinical","nextSteps":"Phase 2 to start in April 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04342897"],"organizations":["Eli Lilly and Company"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"LY3127804 is an antibody that targets human angiopoietin (Ang) 2. Ang2 is a growth factor that assists in the formation of new blood vessels (a process known as angiogenesis. ","show":true,"date":"2021-04-05 11:05:09.994440","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|200","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0023","nameId":"ly3127804-anti-angiopoietin-2-ang2-antibody"},{"sheetId":"25","name":"IFX-1","technology":"Antibodies","technologyDetails":"IFX-1, anti-C5a antibody","developmentStage":"Clinical","nextSteps":"Phase 2/3 recruiting in April 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04333420"],"organizations":["InflaRx GmbH","University Amsterdam","University Maastricht"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"IFX-1 is a monoclonal antibody that targets the proinflammatory complement component C5a.","show":true,"date":"2021-04-05 11:05:09.994505","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|130","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0025","nameId":"ifx-1-anti-c5a-antibody"},{"sheetId":"41","name":"Convalescent plasma","technology":"Antibodies","technologyDetails":"Convalescent plasma (blood plasma from recovered patients)","developmentStage":"Clinical","nextSteps":"Phase 2 and Phase 3 trials not yet recruiting as of April 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04321421","","NCT04292340","","NCT04316728","","NCT04338360","","NCT04345289","","NCT04321421","","NCT04292340","","NCT04316728","","NCT04338360","","NCT04345289","","NCT04349410","","NCT04346589","","NCT04333251","","NCT04361253","","NCT04323800","","NCT04359810","","NCT04362176","","NCT04354831","","NCT04360486","NCT04264858","NCT04355897","NCT04395170","NCT04393727","NCT04397757","NCT04342182","NCT04385186","NCT04405310","NCT04408040","NCT04408209","NCT04412486","NCT04411602","NCT04415086","NCT04418518","NCT04421404","NCT04420988","NCT04425915","NCT04425837","NCT04428021","NCT04429854","NCT04432103","NCT04433910","NCT04434131","NCT04432272","NCT04438694","NCT04438057","NCT04441424","NCT04442191","NCT04442958","NCT04445207","NCT04452812","NCT04456413","NCT04460547","NCT04458363","NCT04462848","NCT04467151","NCT04468009","NCT04472572","NCT04474340","NCT04476888","NCT04479163","NCT04480632","NCT04483960","NCT04492501","NCT04497324","NCT04502472","NCT02735707","NCT04513158","NCT04516811","NCT04516954","NCT04521036","NCT04524507","NCT04530370","NCT04528368","NCT04535063","NCT04539275","NCT04542941","NCT04542967","NCT04545047","NCT04547127","NCT04547660","NCT04554992","NCT04558476","NCT04565197","NCT04567173","NCT04569188","NCT04570982","NCT04589949","NCT04600440","NCT04616976","NCT04622826","NCT04621123","NCT04616976","NCT04634422","NCT04644198","NCT04642014","NCT04649879","NCT04669990","NCT04681430","NCT04716556","NCT04712344","NCT04721236","NCT04730401","NCT04747158","NCT04769245","NCT04803370","NCT04816942","x-NCT04325672","Over 90 clinical trial studies listed in clincialtrials.gov"],"organizations":["Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes","CORIPLASM","CCAP","Mayo Clinic","Erasmus Medical Center","Sanquin Plasma Products BV","Hamilton Health Sciences Corporation","Canadian Blood Services","Héma-Québec","University of Toronto","Université de Montréal","The Christ Hospital","Lifefactors Zona Franca, SAS","University of Pennsylvania","Erasmus Medical Center","Sanquin Plasma Products BV","National Blood Center Foundation, Hemolife","Universidad de Antioquia","Grupo Mexicano para el Estudio de la Medicina Intensiva","Hospital General Naval de Alta Especialidad - Escuela Medico Naval","National Institute of Pediatrics, Mexico Instituto Nacional de Enfermedades Respiratorias","National and Kapodistrian University of Athens","Hellenic Society of Hematology","University of Mississippi Medical Center","Ascension South East Michigan","Weill Medical College of Cornell University","Hamilton Health Sciences Corporation","University of California, San Francisco","Rutgers, The State University of New Jersey","University Hospital - Newark, NJ","Institute of Liver and Biliary Sciences, India","Fundación Santa Fe de Bogota","Universitaire Ziekenhuizen Leuven","Centro Medico ABC","Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","University of New Mexico","William Beaumont Hospitals","Cairo University","Metro Infectious Disease Consultants","Alkarkh Health Directorate-Baghdad","University of Illinois at Chicago","University of Massachusetts","Universidad Autonoma de Coahuila","National Council of Science and Technology, Mexico","Hackensack Meridian Health","Qassim University","Emory University","University of California, Los Angeles","University of Southern California","Hospital de Infecciosas Francisco Javier Muniz","Ministry of Health, Kuwait","Aga Khan University","Fundacion Infant","Fundación Cardiovascular de Colombia","University of Melbourne","The Peter Doherty Institute for Infection and Immunity","Australasian Society for Infectious Diseases","UNICEF","Pak Emirates Military Hospital Rawalpindi","Universidad Peruana Cayetano Heredia","Inova Health Care Services","UMC Utrecht","Australian and New Zealand Intensive Care Research Centre","Medical Research Institute of New Zealand","Unity Health","Berry Consultants","Global Coalition for Adaptive Research","University of Pittsburgh Medical Center","Norton Healthcare","South African National Blood Service","Vinmec Research Institute of Stem Cell and Gene Technology","National Institute of Hygiene and Epidemiology, Vietnam","National Hospital for Tropical Diseases, Hanoi, Vietnam","National Institute of Hematology and Blood Transfusion, Vietnam","Vinmec Research Institute of Stem Cell and Gene Technology","National Institute of Hygiene and Epidemiology, Vietnam","National Hospital for Tropical Diseases, Hanoi, Vietnam","National Institute of Hematology and Blood Transfusion, Vietnam","University of North Carolina, Chapel Hill","South Valley University","D'Or Institute for Research and Education","Hospital do Coracao","Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","Makerere University","Uganda Blood Transfusion Services","Joint Clinical Research Center","Hospital CentralMilitar","Instituto Grifols, S.A.","Grifols Therapeutics LLC","Hospital de Clinicas de Porto Alegre","Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil","Instituto Cultural Floresta","The Methodist Hospital System","University of Liege","KCE","Lahore General Hospital","University of the Philippines","Azienda Socio Sanitaria Territoriale di Mantova","Ministry of Health and Population, Nepal","Nepal Health Research Council","Erasmus Medical Center","Sanquin Plasma Products BV","ZonMw: The Netherlands Organisation for Health Research and Development","Leiden University Medical Center","Skane University Hospital","Southeast University, China","Azienda USL Toscana Nord Ovest","Aalborg University Hospital","Aarhus University Hospital","Odense University Hospital","Zealand University Hospital","The University of The West Indies","Wroclaw Medical University","Medical Research Agency","Karolinska Institutet","Danderyd Hospital","Falu Hospital","Heinrich-Heine University, Duesseldorf","The Federal Ministry of Health, Germany","Istituto Superiore di Sanità","Gruppo Italiano Malattie EMatologiche dell'Adulto","Agenzia Italiana del Farmaco","University of Erlangen-Nürnberg Medical School","Policlinico San Matteo Pavia Fondazione IRCCS","Helsinki University Central Hospital","Finnish Red Cross","Consejo Nacional de Ciencias y Tecnología, Paraguay","Ministerio de Salud Pública y Bienestar Social, Paraguay","Acibadem University","Acıbadem Labcell","Hospital Son Llatzer","Fundació d'investigació Sanitària de les Illes Balears","Ministry of Health and Population, Egypt"],"funder":"Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.16.20036145","JAMA|https://jamanetwork.com/journals/jama/fullarticle/2763983","medRxiv|https://doi.org/10.1101/2020.04.07.20056440","JAMA Network|https://jamanetwork.com/journals/jama/fullarticle/2763982"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.16.20036145","JAMA|https://jamanetwork.com/journals/jama/fullarticle/2763983","medRxiv|https://doi.org/10.1101/2020.04.07.20056440","JAMA Network|https://jamanetwork.com/journals/jama/fullarticle/2763982"],"countries":[],"description":"Convalescent plasma is the opaque liquid part of the blood from individuals who have recovered from SARS-CoV-2 infection. It contains antibodies, enzymes, and other proteins that may be protective against COVID-19. \n","show":true,"date":"2021-04-05 11:05:09.994706","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0041","nameId":"convalescent-plasma-blood-plasma-from-recovered-patients"},{"sheetId":"53","name":"Intravenous Immunoglobulin","technology":"Antibodies","technologyDetails":"Intraenous Immunoglobulin (IVIG); Octagam; Kamada; GC5131; OCTAPLAS","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04261426","NCT04350580","NCT04400058","NCT04403269","NCT04411667","NCT04432324","NCT04480424","NCT04500067","NCT04521309","NCT04546581","NCT04548557","NCT04550325","NCT04555148","NCT04616001","NCT04826588","EudraCT 2020-001696-32","EudraCT 2020-001768-27","EudraCT 2020-001570-30"],"organizations":["Peking Union Medical College Hospital","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Centre Hospitalier St Anne","Octapharma","Sharp HealthCare","Instituto Grifols, S.A","CH Versailles","GHU PARIS PSYCHIATRIE ET NEUROSCIENCES","Instituto Grifols, S.A.","Grifols Therapeutics LLC","Grifols Therapeutics LLC","Biopharma Plasma LLC","Dow University of Health Sciences","Higher Education Commission (Pakistan)","University of Minnesota","National Institute of Allergy and Infectious Diseases","National Institutes of Health","The International Network for Strategic Initiatives in Global HIV Trials","University of Health Sciences Lahore","University of Lahore","Amson Vaccine and Pharma (Pvt) Limited","Kamada, Ltd.","Green Cross Corporation","University Children's Hospital Basel"],"funder":"","publishedResults":["Open Forum Infectious Diseases|https://academic.oup.com/ofid/article/7/3/ofaa102/5810740"],"relatedUse":["Open Forum Infectious Diseases|https://academic.oup.com/ofid/article/7/3/ofaa102/5810740"],"countries":[],"description":"Intravenous Immunoglobulin (IVIG) is a treatment methodology that involved the intravenous administration of antibodies from healthy blood donors. This differs from convalescent serum in that the blood donation is not from individuals who have recovered from SARS-CoV-2 infection, however, IVIG is still able to have immunomodulatory effects that may be beneficial to people suffering from COVID-19. \n","show":true,"date":"2021-04-05 11:05:09.994792","type":"Treatment","fdaApproved":"FDA-approved to treat primary humoral immunodeficiency","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|80","Phase 3|192","Phase 4|40","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0053","nameId":"intraenous-immunoglobulin-ivig-octagam-kamada-gc5131-octaplas"},{"sheetId":"56","name":"Ritonavir*","technology":"Antivirals","technologyDetails":"Aluvia (ritonavir)","developmentStage":"Clinical","nextSteps":"RECOVERY trial results expected by June 2021","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04303299","NCT04255017","ChiCTR2000029548","ChiCTR2000029539","EudraCT 2020-000936-23","EudraCT 2015-002340-14","NCT04315948","NCT04252885","NCT04276688","NCT02735707","NCT04321993","EudraCT 2020-001113-21","NCT04291729","NCT04261907","NCT04261270","ChiCTR2000029496","NCT04350684","ChiCTR2000029541","NCT04372628","NCT04346147","NCT04330690","NCT04328285","NCT04359095","NCT04286503","NCT04328012","NCT04331470","NCT04321174","NCT04364022","NCT04350671","NCT04295551","NCT04351724","NCT04366245","NCT04343768","NCT04373044","NCT04275388","NCT04380818","NCT04365764","NCT04394182","NCT04425382","NCT04435587","NCT04455958","NCT04459286","NCT04459702","NCT04466241","NCT04483960","NCT04499677","NCT04521400","NCT04738045","x-NCT04307693","x-NCT04409483","x-NCT04365582"],"organizations":["Global hospital testing (AbbVie)","World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta)","University of Oxford RECOVERY trial","REMAP-CAP global trial","INSERM","Ascletis Pharmaceuticals Co., Ltd.","First Affiliated Hospital of Zhejiang University","Tongji Hospital","Vanderbilt University Medical Center","Hospital Universitario de Fuenlabrada","Centro Nacional de Investigaciones Oncologicas CARLOS III","Groupe Hospitalier Paris Saint Joseph","Centre Hospitalier Universitaire de Saint Etienne","Institut Pasteur","Universidad Nacional de Colombia","Beijing YouAn Hospital","Bassett Healthcare","Fasa University of Medical Sciences","St. Michael's Hospital, Toronto","Calmy Alexandra","University Hospital, Geneva","Shahid Beheshti University of Medical Sciences","ACOVACT","Andalusian Network for Design and Translation of Advanced Therapies","Shahid Beheshti University of Medical Sciences","University of Southern California","National Cancer Institute (NCI)","Grupo de Investigación Clínica en Oncología Radioterapia","Université Abdou Moumouni","Centre de Recherche Médicale et Sanitaire","Ministry of Public Health, Republic of Niger","Mahidol University","OHSU Knight Cancer Institute","Oregon Health and Science University","National Cancer Institute","Obafemi Awolowo University","University of Liverpool","African Centre of Excellence for Genomics of Infectious Diseases","Oyo State Ministry of Health","ProgenaBiome","Big Corona Ltd.","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Université de Bordeaux","Programme PACCI","University of Melbourne","The Peter Doherty Institute for Infection and Immunity","Australasian Society for Infectious Diseases","University College, London","LifeArc","Beni-Suef University","October 6 University"],"funder":"UK Government (University of Oxford RECOVERY trial)","publishedResults":["NEJM|https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","medRxiv|https://doi.org/10.1101/2020.03.19.20038984","Chinese Journal of Infectious Diseases|http://rs.yiigle.com/yufabiao/1182592.htm","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.21.20066761","medRxiv|https://doi.org/10.1101/2020.04.25.20079079","medRxiv|https://doi.org/10.1101/2020.04.24.20077735"],"relatedUse":["NEJM|https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","medRxiv|https://doi.org/10.1101/2020.03.19.20038984","Chinese Journal of Infectious Diseases|http://rs.yiigle.com/yufabiao/1182592.htm","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.21.20066761","medRxiv|https://doi.org/10.1101/2020.04.25.20079079","medRxiv|https://doi.org/10.1101/2020.04.24.20077735"],"countries":[],"description":"Ritonavir is a protease inhibitor. Not only does it function to inhibit viral proteases (and is thus an antiretroviral), it also inhibits host proteases that degrade antivirals, and thus is generally used in tandem with other drugs so that they can be more efficacious.","show":true,"date":"2021-04-05 11:05:09.994976","type":"Treatment","fdaApproved":"FDA-approved since 2000, approved to treat HIV-1 infection","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0056","nameId":"aluvia-ritonavir"},{"sheetId":"59","name":"Galidesivir","technology":"Antivirals","technologyDetails":"galidesivir","developmentStage":"Clinical","nextSteps":"Phase 1b to start April 2020","customClinicalPhase":"Phase I","clinicalTrials":["NCT03891420"],"organizations":["BioCryst Pharmaceuricals"],"funder":"National Institute of Allergy and Infectious Diseases (NIAID)","publishedResults":[],"relatedUse":[],"countries":[],"description":"Galidesivir is an adenosine analog antiretroviral drug.","show":true,"date":"2021-04-05 11:05:09.995025","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|66","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|40"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-0059","nameId":"galidesivir"},{"sheetId":"60","name":"Ebastine*","technology":"Antivirals","technologyDetails":"ebastine","developmentStage":"Clinical","nextSteps":"Primary trial ends March 31, 2020","customClinicalPhase":"Phase IV","clinicalTrials":["ChiCTR2000030535"],"organizations":["Mianyang Central Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ebastine is an antihistamine and second-generation H1 receptor agonist. It thus provides relief from common allergy symptoms such as sneezing and nasal congestion.  ","show":true,"date":"2021-04-05 11:05:09.995176","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|100","Phase NA|40"],"clinicalPhases":{"completed":[0,1,2,3],"inprogress":[4]},"inprogressClinicalTrials":[4],"completedClinicalTrials":[0,1,2,3],"phaseSortKey":8,"urlIdx":"d-0060","nameId":"ebastine"},{"sheetId":"61","name":"Danoprevir*","technology":"Antivirals","technologyDetails":"Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase IV","clinicalTrials":["NCT04291729"],"organizations":["Ascletis Pharmaceuticals Co., Ltd.","The Ninth Hospital of Nanchang"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.22.20034041"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.22.20034041"],"countries":[],"description":"Danoprevir is a 15-membered macrocyclic peptidomimetic inhibitor of the hepatitis C NS3/4A protease.","show":true,"date":"2021-04-05 11:05:09.995287","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|11","Phase NA|40"],"clinicalPhases":{"completed":[0,1,2,3],"inprogress":[4]},"inprogressClinicalTrials":[4],"completedClinicalTrials":[0,1,2,3],"phaseSortKey":8,"urlIdx":"d-0061","nameId":"ganovo-danoprevir-hepatitis-c-virus-ns3-protease-inhibitor"},{"sheetId":"63","name":"Truvada*","technology":"Antivirals","technologyDetails":"Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["ChiCTR2000029468","NCT04334928","NCT04405271","EudraCT 2020-001385-11","NCT04519125","NCT04685512","NCT04712357"],"organizations":["Gilead","Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital","Plan Nacional sobre el Sida (PNS)","Effice Servicios Para la Investigacion S.L.","Hospital Italiano de Buenos Aires","Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)","Plan Nacional Sobre SIDA","Hospital Universitario San Ignacio","Pontificia Universidad Javeriana","Hospital Universitario Nacional de Colombia","Hospital de la Samaritana, Sede Bogotá y Sede Zipaquirá","Hospital Universitario San Jorge, Pereira.","Fundación Universitaria Autónoma de Las Américas","Universidad Tecnológica de Pereira","Colsanitas","University Hospital, Caen","Universidade Federal do Ceara","Conselho Nacional de Desenvolvimento Científico e Tecnológico","São José Hospital for Infectious Diseases - HSJ","Central Laboratory of Public Health of Ceará - Lacen-CE"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Truvada is a combination of two nucleoside analog reverse transcriptase inhibitors (emtricitabine and tenofovir).  ","show":true,"date":"2021-04-05 11:05:09.995376","type":"Treatment","fdaApproved":"FDA-approved since 2004, approved to treat and prevent HIV-1 infection","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|950","Phase 3|5378","Phase 4|NA","Phase NA|60"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0063","nameId":"truvada-emtricitabine-and-tenofovir-both-hiv-1-nucleoside-analog-reverse-transcriptase-inhibitors"},{"sheetId":"64","name":"Umifenovir*","technology":"Antivirals","technologyDetails":"Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/IV","clinicalTrials":["NCT04252885","NCT04350684","NCT04286503","NCT04255017","NCT04273763","NCT04260594","NCT04476719"],"organizations":["Guangzhou 8th People's Hospital","Beijing YouAn Hospital","Tongji Hospital","Jieming QU","Ruijin Hospital","Second Affiliated Hospital of Wenzhou Medical University","WanBangDe Pharmaceutical Group Co.,Ltd.","Atabay Kimya Sanayi Ticaret A.S.","Novagenix Bioanalytical Drug R&D Center","Farmagen Ar-Ge Biyot. Ltd. Sti"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.19.20038984","Chinese Journal of Infectious Diseases|http://rs.yiigle.com/yufabiao/1182592.htm","medRxiv|https://doi.org/10.1101/2020.03.17.20037432","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.06.20042580","medRxiv|https://doi.org/10.1101/2020.04.11.20056523"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.19.20038984","Chinese Journal of Infectious Diseases|http://rs.yiigle.com/yufabiao/1182592.htm","medRxiv|https://doi.org/10.1101/2020.03.17.20037432","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.08.20057539","medRxiv|https://doi.org/10.1101/2020.04.06.20042580","medRxiv|https://doi.org/10.1101/2020.04.11.20056523"],"countries":[],"description":"Umifenovir is an indole-based, hydrophobic antiviral drug that has broad-spectrum activity, including prevention of the fusion between the viral envelope and host cells, as well as direct interactions with some viral proteins.","show":true,"date":"2021-04-05 11:05:09.995515","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|115","Phase NA|NA"],"clinicalPhases":{"completed":[0,2,3],"inprogress":[1,4]},"inprogressClinicalTrials":[1,4],"completedClinicalTrials":[0,2,3],"phaseSortKey":7.5,"urlIdx":"d-0064","nameId":"arbidol-umifenovir-licensed-in-russia-and-china-for-treatment-of-respiratory-viral-infections"},{"sheetId":"65","name":"Baloxavir Marboxil","technology":"Antivirals","technologyDetails":"Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["ChiCTR2000029544","ChiCTR2000029548"],"organizations":["Roche","The First Affiliated Hospital of Zhejiang University Medical School"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Baloxavir marboxil is an antiviral enzyme inhibitor that targets the cap-dependent endonuclease activity of the polymerase complex.","show":true,"date":"2021-04-05 11:05:09.995596","type":"Treatment","fdaApproved":"FDA-approved since 2018, approved to treat influenza","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|30"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-0065","nameId":"xofluza-baloxavir-marboxil-polymerase-acidic-endonuclease-inhibitor"},{"sheetId":"66","name":"Azvudine","technology":"Antivirals","technologyDetails":"azvudine, reverse transcriptase inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["ChiCTR2000030487","ChiCTR2000030424","ChiCTR2000029853","NCT04425772","NCT04668235"],"organizations":["He'nan Sincere Biotechnology Co., Ltd","HRH Holdngs Limited","GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil","SANTA CASA DE MISERICORDIA DE CAMPOS HOSPITAL (SCMCH), Brazil","UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE, Brazil"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Azuvidine is an antiviral reverse transcriptase inhibitor.","show":true,"date":"2021-04-05 11:05:09.995667","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|60"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0066","nameId":"azvudine-reverse-transcriptase-inhibitor"},{"sheetId":"69","name":"Oseltamivir*","technology":"Antivirals","technologyDetails":"Tamiflu (oseltamivir), neuraminidase inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/III/IV","clinicalTrials":["NCT04303299","NCT04255017","NCT04261270","NCT02735707","EudraCT 2015-002340-14","NCT04365764","NCT04457609","NCT04516915","NCT04558463"],"organizations":["Roche","REMAP-CAP global trial","Rajavithi Hospital","Tongji Hospital","Groupe Hospitalier Pitie-Salpetrier","Centre Hospitalier Intercommunal Robert Ballanger","Centre Hospitalier Intercommunal Montfermeil-Le Raincy","CMC Ambroise Paré","Indonesia University","University Hospitals Coventry and Warwickshire NHS Trust","Immunic AG","University of Warwick","MODEPHARMA"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.11.20056523"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.11.20056523"],"countries":[],"description":"Oseltamivir, more commonly known as Tamiflu, is an antiviral competitive inhibitor of the enzyme neuraminidase. Upon binding, it prevents new viral particles from budding off of an infected cell. ","show":true,"date":"2021-04-05 11:05:09.995746","type":"Treatment","fdaApproved":"FDA-approved since 1999, approved to treat and prevent influenza","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|220","Phase 4|1126","Phase NA|NA"],"clinicalPhases":{"completed":[0,2],"inprogress":[1,3,4]},"inprogressClinicalTrials":[1,3,4],"completedClinicalTrials":[0,2],"phaseSortKey":6,"urlIdx":"d-0069","nameId":"tamiflu-oseltamivir-neuraminidase-inhibitor"},{"sheetId":"73","name":"Ribavirin","technology":"Antivirals","technologyDetails":"Virazole (ribavirin for inhalation solution)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04356677","NCT04276688","NCT04276688","NCT04460443","NCT04494399","NCT04497649","NCT04551768","NCT04563208","NCT04605588","NCT04828564"],"organizations":["Bausch Health Americas, Inc.","The University of Hong Kong","Tanta University","Hospital Authority, Hong Kong","University of Witwatersrand, South Africa","Rutgers, The State University of New Jersey","SynaVir","The Scientific and Technological Research Council of Turkey","Ankara City Hospital Bilkent","Istanbul Umraniye Training and Research Hospital","Koç University","Monitor CRO"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ribavirin is a nucleoside analog antiviral medication that mimics adenosine and guanosine. Upon incorporation into the viral genome, it induces mutations that can be lethal.  ","show":true,"date":"2021-04-05 11:05:09.995818","type":"Treatment","fdaApproved":"FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|50","Phase 1/2|NA","Phase 2|42","Phase 2/3|60","Phase 3|138","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0073","nameId":"virazole-ribavirin-for-inhalation-solution"},{"sheetId":"1","name":"Polyclonal Hyperimmune Globulin","technology":"Antibodies","technologyDetails":"Polyclonal hyperimmune globulin (H-IG), CSL760","developmentStage":"Clinical","nextSteps":"Phase 1 trials start in summer 2020. To patients between December 2020 and December 2021","customClinicalPhase":"Phase I","clinicalTrials":["NCT04638634"],"organizations":["CSL Behring"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.995876","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|24","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-0001","nameId":"polyclonal-hyperimmune-globulin-h-ig-csl760"},{"sheetId":"2","name":"REGN3048-3051","technology":"Antibodies","technologyDetails":"Antibodies from mice, REGN3048-3051, against the spike protein","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 June 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Regeneron"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.995930","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0002","nameId":"antibodies-from-mice-regn3048-3051-against-the-spike-protein"},{"sheetId":"3","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 in July 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Celltrion"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.995989","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0003","nameId":"antibodies-from-recovered-covid-19-patients"},{"sheetId":"4","name":"Unnamed","technology":"Antibodies","technologyDetails":"Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Celltrion"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996037","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0004","nameId":"super-antibody-or-antibody-cocktail-to-target-potential-mutations-of-sars-cov-2"},{"sheetId":"5","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Kamada","Kedrion Biopharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996099","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0005","nameId":"antibodies-from-recovered-covid-19-patients-7"},{"sheetId":"6","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 ~ July 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vir Biotech","WuXi Biologics","Biogen"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996148","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0006","nameId":"antibodies-from-recovered-covid-19-patients-9"},{"sheetId":"7","name":"VIR-7832","technology":"Antibodies","technologyDetails":"VIR-7831 and VIR-7832, antibodies from recovered SARS patients","developmentStage":"Pre-clinical","nextSteps":"Start Phase 2 ~ July-September 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vir Biotechnology","GSK","Samsung","WuXi Biologics","Biogen"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996196","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0007","nameId":"vir-7831-and-vir-7832-antibodies-from-recovered-sars-patients"},{"sheetId":"CD219","name":"VIR-7831","technology":"Antibodies","technologyDetails":"VIR-7831 (GSK4182136) is a monoclonal antibody that has shown the ability to neutralise SARS-CoV-2 live virus in vitro","developmentStage":"Clinical","nextSteps":"Start Phase 2 ~ July-September 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04545060","NCT04634409","NCT04501978","NCT04779879"],"organizations":["Vir Biotechnology, Inc.","GlaxoSmithKline","Eli Lilly and Company","AbCellera Biologics Inc.","Shanghai Junshi Bioscience Co., Ltd.","National Institute of Allergy and Infectious Diseases (NIAID)","International Network for Strategic Initiatives in Global HIV Trials","University of Copenhagen","Medical Research Council","Kirby Institute","Washington D.C. Veterans Affairs Medical Center","AIDS Clinical Trials Group","National Heart, Lung, and Blood Institute (NHLBI)","US Department of Veterans Affairs","Prevention and Early Treatment of Acute Lung Injury (PETAL)","Cardiothoracic Surgical Trials Network (CTSN)","Brii Biosciences Limited","AstraZeneca"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996262","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|1360","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD219","nameId":"vir-7831-gsk4182136-is-a-monoclonal-antibody-that-has-shown-the-ability-to-neutralise-sars-cov-2-live-virus-in-vitro"},{"sheetId":"8","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"Start Phase 1 in late July 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Eli Lilly","Ab-Cellera (NIH Vaccines Research Center)"],"funder":"Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996350","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0008","nameId":"antibodies-from-recovered-covid-19-patients-12"},{"sheetId":"75","name":"Clevudine","technology":"Antivirals","technologyDetails":"Levovir (clevudine)*","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04347915"],"organizations":["Bukwang Pharmaceutical"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Clevudine is an antiviral nucleoside analog drug. Upon entry into the cell, it is phosphorylated to its active state where it is incorporated into viral DNA in competition with the common nucleotide thymidine. Incorporation by viral polymerase leads to early DNA chain termination and thus non-viable viral progeny.","show":true,"date":"2021-04-05 11:05:09.996403","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|30","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0075","nameId":"levovir-clevudine"},{"sheetId":"81","name":"Multipotent Adult Progenitor Cells","technology":"Cell-based therapies","technologyDetails":"MultiStem, bone marrow stem cells","developmentStage":"Clinical","nextSteps":"Phase 2/3 trial to start 2Q 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04367077"],"organizations":["Athersys","Inc."],"funder":"Medical Technology Enterprise Consortium (MTEC)","publishedResults":[],"relatedUse":[],"countries":[],"description":"Multipotent adult progenitor cells are a type of stem cell that is derived from the bone marrow. They differ from mesenchymal stem cells in that they are expanded outside of the body (ex vivo) to yield large quantities that can be banked for future use. When administered therapeutically, they can reduce inflammation and protect damaged tissue. ","show":true,"date":"2021-04-05 11:05:09.996452","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|400","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0081","nameId":"multistem-bone-marrow-stem-cells"},{"sheetId":"84","name":"CYNK-001","technology":"Cell-based therapies","technologyDetails":"CYNK-001, allogeneic, natural killer cell therapy","developmentStage":"Clinical","nextSteps":"Phase 1/2 study to start in April 2020","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04365101"],"organizations":["Celularity Incorporated","Infectious Disease Research Institute, Seattle","Lung Biotechnology PBC"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"CYNK-001 is a cell-based therapy comprised of natural killer (NK) cells derived from placental stem cells. These cells can be frozen, culture-expanded, and administered to patients. NK cells play a major role in the body getting rid of virally infected cells, including those infected with SARS-CoV-2. \n","show":true,"date":"2021-04-05 11:05:09.996508","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|86","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0084","nameId":"cynk-001-allogeneic-natural-killer-cell-therapy"},{"sheetId":"26","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibody","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Erasmus MC","Utrecht University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996564","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0026","nameId":"antibody"},{"sheetId":"27","name":"Unnamed","technology":"Antibodies","technologyDetails":"Monoclonal antibody cocktail*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ImmunoPrecise Antibodies"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996599","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0027","nameId":"monoclonal-antibody-cocktail"},{"sheetId":"28","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibody","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Harbour BioMed","Erasmus MC","Utrecht University","Mount Sinai Health System"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996641","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0028","nameId":"antibody-16"},{"sheetId":"29","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display","developmentStage":"Pre-clinical","nextSteps":"Phase 1 trials begin in summer 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["AstraZeneca","US Army Medical Research Institute of Infectious Diseases (USAMRIID)","University of Maryland School of Medicine"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996680","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0029","nameId":"antibodies-targeting-the-s-protein-from-convalescent-serum-humanized-mice-and-phage-display"},{"sheetId":"30","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibody","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Distributed Bio"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996816","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0030","nameId":"antibody-19"},{"sheetId":"31","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Chelsea and Westminster Hospital","Imperial College London"],"funder":"UK Government","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996855","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0031","nameId":"antibodies"},{"sheetId":"32","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibody","developmentStage":"Pre-clinical","nextSteps":"Phase 1 trial begins in summer 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vanderbilt Vaccine Center","AstraZeneca"],"funder":"Defense Advanced Research Projects Agency","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996890","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0032","nameId":"antibody-22"},{"sheetId":"33","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Medicago","Laval University's Infectious Disease Research Centre"],"funder":"Canadian Institutes for Health Research (CIHR)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996923","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0033","nameId":"antibodies-24"},{"sheetId":"34","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["FairJourney Biologics","Iontas"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996960","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0034","nameId":"antibodies-26"},{"sheetId":"35","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies (OmniChicken platform)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Ligand Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.996994","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0035","nameId":"antibodies-omnichicken-platform"},{"sheetId":"36","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies (OmniRat platform)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Ligand Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997036","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0036","nameId":"antibodies-omnirat-platform"},{"sheetId":"37","name":"Unnamed","technology":"Antibodies","technologyDetails":"Moncloncal antibodies, TLR4 antagonist","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Edesa Biotech","Light Chain Bioscience (NovImmune)"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997081","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0037","nameId":"moncloncal-antibodies-tlr4-antagonist"},{"sheetId":"38","name":"Unnamed","technology":"Antibodies","technologyDetails":"Moncloncal antibodies, CXC10 antagonist","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Edesa Biotech","Light Chain Bioscience (NovImmune)"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997126","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0038","nameId":"moncloncal-antibodies-cxc10-antagonist"},{"sheetId":"39","name":"COVID-HIG","technology":"Antibodies","technologyDetails":"Polyclonal hyperimmune globulin (H-IG); Anti-SARS-CoV-2 Immunoglobulin; COVID-HIGIV; NP-028","developmentStage":"Clinical","nextSteps":"Phase 2 trials begin ~ August 2020","customClinicalPhase":"Preclinical","clinicalTrials":["NCT04661839"],"organizations":["Emergent BioSolutions","United States Department of Defense"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997175","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|56","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0039","nameId":"polyclonal-hyperimmune-globulin-h-ig-anti-sars-cov-2-immunoglobulin-covid-higiv-np-028"},{"sheetId":"40","name":"Unnamed","technology":"Antibodies","technologyDetails":"Horse plasma product (COVID-EIG)","developmentStage":"Pre-clinical","nextSteps":"Phase 2 trials begin ~ August 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Emergent BioSolutions"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997246","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0040","nameId":"horse-plasma-product-covid-eig"},{"sheetId":"85","name":"Cardiosphere-Derived Cells","technology":"Cell-based therapies","technologyDetails":"CAP-1002, allogenic cardiosphere-derived cells","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04338347","NCT04623671"],"organizations":["Capricor Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Cardiosphere-derived cells are stem cells that are derived from donor cardiac (heart) tissue. These cells have demonstrated potent immunomodulatory and regenerative properties.","show":true,"date":"2021-04-05 11:05:09.997290","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|60","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0085","nameId":"cap-1002-allogenic-cardiosphere-derived-cells"},{"sheetId":"42","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"Phase 1 trial begins Q3 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Tsinghua University","Third People's Hospital of Shenzhen","Brii Biosciences"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997345","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0042","nameId":"antibodies-from-recovered-covid-19-patients-34"},{"sheetId":"43","name":"Unnamed","technology":"Antibodies","technologyDetails":"Polyclonal hyperimmune globulin (H-IG)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Grifols"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997395","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0043","nameId":"polyclonal-hyperimmune-globulin-h-ig"},{"sheetId":"44","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Grifols"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997440","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0044","nameId":"antibodies-from-recovered-covid-19-patients-37"},{"sheetId":"45","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Amgen","Adaptive Biotechnologies"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997486","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0045","nameId":"antibodies-from-recovered-covid-19-patients-39"},{"sheetId":"46","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Innovent Biologics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997533","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0046","nameId":"antibodies-from-recovered-covid-19-patients-41"},{"sheetId":"47","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Xbiotech","BioBridge Global"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997583","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0047","nameId":"antibodies-from-recovered-covid-19-patients-43"},{"sheetId":"48","name":"Unnamed","technology":"Antibodies","technologyDetails":"Antibodies from recovered COVID-19 patients","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Costa Rican Social Security Fund (CCSS)","The University of Costa Rica (UCR)","Clodomiro Picado Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997636","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0048","nameId":"antibodies-from-recovered-covid-19-patients-45"},{"sheetId":"49","name":"SAB-185","technology":"Antibodies","technologyDetails":"SAB-185, Polyclonal hyperimmune globulin (H-IG)","developmentStage":"Clinical","nextSteps":"Phase 1 starts early summer 2020","customClinicalPhase":"Phase I","clinicalTrials":["NCT04468958","NCT04469179"],"organizations":["SAb Biotherapeutics, Inc.","Department of Health and Human Services","Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997684","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|28","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-0049","nameId":"sab-185-polyclonal-hyperimmune-globulin-h-ig"},{"sheetId":"50","name":"Unnamed","technology":"Antibodies","technologyDetails":"Non-viral gene therapy to produce monoclonal antibodies","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Generation Bio","Vir Biotechnology"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997741","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0050","nameId":"non-viral-gene-therapy-to-produce-monoclonal-antibodies"},{"sheetId":"51","name":"Unnamed","technology":"Antibodies","technologyDetails":"rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["GigaGen"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.997793","type":"Treatment","fdaApproved":"N//A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0051","nameId":"rcig-recombinant-anti-coronavirus-19-hyperimmune-gammaglobulin-polyclonal-antibodies"},{"sheetId":"111","name":"Corticosteroid Therapy*","technology":"Other","technologyDetails":"Methylprednisolone / ciclesonide/ hydrocortisone/glucocorticoids/mineralocorticoids/Budesonide/Prednisone","developmentStage":"Clinical","nextSteps":"Primary study ends April 2020 (Peking) / June 2020 (Tongji)/ RECOVERY trial results expected by June 2020","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04484493","NCT04359511","NCT04344288","NCT04374071","NCT04451174","NCT04345445","NCT04355247","NCT04329650","NCT04273321","NCT04355637","NCT04486521","NCT04416399","NCT04381936","NCT04361474","NCT04374474","NCT04348305","NCT03852537","NCT04456439","NCT04380818","NCT02735707","NCT04394182","NCT04381364","NCT04343729","NCT04528888","NCT04534478","NCT04551781","NCT04559113","NCT04569825","NCT04586114","NCT04603729","NCT04636671","NCT04657484","NCT04654416","NCT04673162","NCT04765371","NCT04782700","NCT04780581","NCT04795583","NCT04826588"],"organizations":["University of Oxford","Benha University","University Hospital, Tours","Hospices Civils de Lyon","Henry Ford Health System","University of Chile","University of Malaya","Auxilio Mutuo Cancer Center","Fundacion Clinic per a la Recerca Biomédica","Beijing Chao Yang Hospital","Fundacion Clinic per a la Recerca Biomédica","King Faisal Specialist Hospital & Research Center","Society of Critical Care Medicine","UK Research and Innovation","National Institute for Health Research, United Kingdom","Wellcome","Bill and Melinda Gates Foundation","Department for International Development, United Kingdom","Health Data Research UK","Medical Research Council Population Health Research Unit","NIHR Clinical Trials Unit Support Funding","Fondation Ophtalmologique Adolphe de Rothschild","Hopital Lariboisière","Lawson Health Research Institute","Scandinavian Critical Care Trials Group","Rigshospitalet, Denmark","Copenhagen Trial Unit, Center for Clinical Intervention Research","University of Copenhagen","Aarhus University Hospital","Mayo Clinic","Mesoblast, Ltd.","Grupo de Investigación Clínica en Oncología Radioterapia","Hospital Universitario Madrid Sanchinarro","Hospital del Mar","Hospital Universitari Sant Joan de Reus","UMC Utrecht","Australian and New Zealand Intensive Care Research Centre","Medical Research Institute of New Zealand","Unity Health","Berry Consultants","Global Coalition for Adaptive Research","University of Pittsburgh Medical Center","Fundacion GenesisCare","Hospital La Milagrosa","Hospital Vithas Valencia Consuelo","Karolinska University Hospital","Danderyd Hospital","Centrallasarettet Västerås","Fundação de Medicina Tropical","University of Modena","Hospital Universitari Vall d'Hebron Research Institute","South Valley University","Lahore General Hospital","University Of Anbar","Central Hospital, Nancy, France","Fatima Memorial Hospital","University of Trieste","Centro di Riferimento Oncologico - Aviano","National Institute for the Infectious Diseases (L. Spallanzani) - Rome","Postgraduate Institute of Medical Education and Research","Clínica Medellín - Grupo Quirónsalud","Azienda Unità Sanitaria Locale Reggio Emilia","Centre Hospitalier René Dubos","Northwell Health","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","Instituto de Investigación Biomédica de Salamanca","University of Alberta","University Children's Hospital Basel"],"funder":"UK Government (University of Oxford RECOVERY trial)","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.06.20032342","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.07.20056390","medRxiv|https://doi.org/10.1101/2020.04.17.20064469","medRxiv|https://doi.org/10.1101/2020.04.17.20069773"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.06.20032342","medRxiv|https://doi.org/10.1101/2020.03.28.20045955","medRxiv|https://doi.org/10.1101/2020.04.07.20056390","medRxiv|https://doi.org/10.1101/2020.04.17.20064469","medRxiv|https://doi.org/10.1101/2020.04.17.20069773"],"countries":[],"description":"Glucocorticoids are a class of steroid hormones that are synthesized in the adrenal gland. They play an important feedback role for the immune system, and can thus modulate overactive immune responses. Examples include: methylprednisolone, ciclesonide, hydrocortisone, and corticosteroids.","show":true,"date":"2021-04-05 11:05:09.997940","type":"Treatment","fdaApproved":"FDA-approved since at least the 1950s, approved to treat many diseases, including anti-iflammatory conditions and some cancers","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|70","Phase 2/3|80","Phase 3|NA","Phase 4|100","Phase NA|148"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0111","nameId":"methylprednisolone-ciclesonide-hydrocortisone-glucocorticoids-mineralocorticoids-budesonide-prednisone"},{"sheetId":"113","name":"Camostat Mesylate*","technology":"Other","technologyDetails":"camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis; DWJ1248; FOY-305","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04321096","NCT04338906","NCT04353284","NCT04355052","NCT04374019","NCT04435015","NCT04455815","NCT04470544","NCT04521296","NCT04524663","NCT04530617","NCT04583592","NCT04608266","NCT04625114","NCT04652765","NCT04657497","NCT04662073","NCT04681430","NCT04713176","NCT04721535","NCT04730206","NCT04750759"],"organizations":["University of Aarhus","Yale University","Heinrich-Heine University, Duesseldorf","Universitätsklinikum Hamburg-Eppendorf","University Hospital, Frankfurt","St. Georg Hospital Leipzig, Germany","Hospital Schwabing Munich, Germany","Missioklinik, Wuerzburg, Germany","University of Kentucky","Ono Pharmaceutical Co. Ltd","Cancer Research UK","Latus Therapeutics","Academic and Community Cancer Research United","Daewoong Pharmaceutical Co. LTD.","Stanford University","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Instituto Nacional de Cardiologia Ignacio Chavez","Hospital General de Mexico","Hospital General Dr. Manuel Gea González","Sagent Pharmaceuticals Inc.","Assistance Publique - Hôpitaux de Paris","University Hospital, Ghent","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","The Federal Ministry of Health, Germany","KU Leuven","Universiteit Antwerpen","University Ghent","Université de Liège","Vrije Universiteit Brussel","Charité Research Organisation GmbH","Bayer"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"camostat mesylate is a serine protease inhibitor. SARS-CoV-2 cell entry is thought to require the transmembrane protease serine 2 (TMPRSS2), and thus inhibition of this serine protease may impact COVID-19 disease.","show":true,"date":"2021-04-05 11:05:09.998049","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|180","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0113","nameId":"camostat-mesylate-transmembrane-protease-serine-2-tmprss2-inhibitor-approved-in-japan-to-treat-multiple-conditions-including-pancreatitis-dwj1248-foy-305"},{"sheetId":"54","name":"Unnamed","technology":"Antibodies","technologyDetails":"Purified ovine immunoglobulin from immunized sheep","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Public Health England (Stuart Dowall)"],"funder":"UK Government","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998153","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0054","nameId":"purified-ovine-immunoglobulin-from-immunized-sheep"},{"sheetId":"67","name":"Unnamed","technology":"Antivirals","technologyDetails":"Vicromax, broad spectrum antiviral","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ViralClear Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998205","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0067","nameId":"vicromax-broad-spectrum-antiviral"},{"sheetId":"68","name":"Unnamed","technology":"Antivirals","technologyDetails":"ISR-50","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ISR Immune System Regulation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998253","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0068","nameId":"isr-50_Treatment"},{"sheetId":"70","name":"Unnamed","technology":"Antivirals","technologyDetails":"antiviral Fc conjugates","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Cidara Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998287","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0070","nameId":"antiviral-fc-conjugates"},{"sheetId":"71","name":"Unnamed","technology":"Antivirals","technologyDetails":"Antiviral compounds","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Cocrystal Pharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998327","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0071","nameId":"antiviral-compounds"},{"sheetId":"114","name":"Ruxolitinib","technology":"Other","technologyDetails":"Jakafi/jakavi (ruxolitinib)","developmentStage":"Clinical","nextSteps":"Novartis/Incyte Phase 3 trial started April 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["ChiCTR2000029580","NCT04334044","NCT04331665","NCT04337359","NCT04348071","NCT04338958","NCT04348695","NCT04355793","NCT04362137","NCT04377620","NCT04366232","NCT04359290","NCT04361903","NCT04374149","NCT04403243","EudraCT 2020-001963-10","NCT04414098","NCT04424056","NCT04477993","NCT04581954","x-NCT04354714"],"organizations":["Novartis","Incyte","Grupo Cooperativo de Hemopatías Malignas","University Health Network, Toronto","University of Colorado, Denver","University of Jena","Fundación de investigación HM","Tongji Hospital","Washington University School of Medicine","Assistance Publique Hopitaux De Marseille","Philipps University Marburg Medical Center","Azienda USL Toscana Nord Ovest","Prisma Health-Upstate","Lomonosov Moscow State University Medical Research and Educational Center","Centre Hospitalier Intercommunal de Toulon La Seyne-sur-mer","Vanderson Geraldo Rocha","University of Sao Paulo General Hospital","Imperial College London","Imperial College Healthcare NHS Trust","Rigel Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ruxolitinib is a janus kinase (JAK) 1 and 2 inhibitor. This interaction prevents signal transducers and activators of transcription (STATs) recruitment to cytokine receptors, which in turn modulates gene expression and might help to lower the hyper inflammation caused by SARS-CoV-2. This would prevent damage to the lungs and possibly other organs. \n","show":true,"date":"2021-04-05 11:05:09.998386","type":"Treatment","fdaApproved":"FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|20","Phase 2|294","Phase 2/3|80","Phase 3|NA","Phase 4|NA","Phase NA|134"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0114","nameId":"jakafi-jakavi-ruxolitinib"},{"sheetId":"74","name":"Unnamed","technology":"Antivirals","technologyDetails":"Antiviral drug combinations","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["SCORE consortium (universities of Aix-Marseille","Leuven","Utrecht","Bern","and Lubeck)","the Helmholtz Centre for Infection Research","and Janssen Pharmaceutica NV"],"funder":"EU Commission (Horizon 2020 Program)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998454","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0074","nameId":"antiviral-drug-combinations"},{"sheetId":"76","name":"Unnamed","technology":"Antivirals*","technologyDetails":"AB001*","developmentStage":"Pre-clinical","nextSteps":"Phase 1 to start in 2020*","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Agastiya Biotech*"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998499","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0076","nameId":"ab001"},{"sheetId":"77","name":"PLX-PAD","technology":"Cell-based therapies","technologyDetails":"PLX cell product, placenta-based cell therapy","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":["NCT04389450","NCT04614025"],"organizations":["Pluristem Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998536","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|180","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0077","nameId":"plx-cell-product-placenta-based-cell-therapy"},{"sheetId":"79","name":"Autologous Adipose-derived Stem Cells","technology":"Cell-based therapies","technologyDetails":"Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04428801"],"organizations":["Celltex Therapeutics Corporation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998593","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|200","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0079","nameId":"autologous-adipose-tissue-derived-mesenchymal-stem-cells-admscs"},{"sheetId":"80","name":"Remestemcel-L","technology":"Cell-based therapies","technologyDetails":"Ryoncil (remestemcel-L), allogenic mesenchymal stem cells","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04371393","NCT04366830","NCT04456439"],"organizations":["Mesoblast, Inc","Icahn School of Medicine at Mount Sinai"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Remestemcel-L is an off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells (MSC). MSCs are multipotent stromal cells that come from a diverse array of tissues (bone marrow, cord cells, molar cells, amniotic fluid, and adipose tissue) can differentiate into a diverse range of cell lineages. They have been shown to have immunomodulatory and tissue regenerative effects and thus are theorized to reduce or reverse the pathological lung changes and inhibit the cell-mediated immune-inflammatory response caused by SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:09.998658","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|300","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0080","nameId":"ryoncil-remestemcel-l-allogenic-mesenchymal-stem-cells"},{"sheetId":"116","name":"Novaferon","technology":"Other","technologyDetails":"Novaferon, Nova, interferon, licensed in China for Hepatitis B","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III/IV","clinicalTrials":["ChiCTR2000029573","ChiCTR2000029496","NCT04669015","NCT04708158"],"organizations":["The First Affiliated Hospital of Zhejiang University Medical School","Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd","The First Hospital of Changsha","The Second Xiangya Hospital of Central South University","Genova Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Novaferon is a new recombinant IFN alpha-like anti-viral protein with significantly higher activities than biological IFN-alpha. It was produced by artificial design technology combining DNA-shuffling and High Throughput Screening (HTS).","show":true,"date":"2021-04-05 11:05:09.998721","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|300","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3,4]},"inprogressClinicalTrials":[3,4],"completedClinicalTrials":[0,1,2],"phaseSortKey":6.5,"urlIdx":"d-0116","nameId":"novaferon-nova-interferon-licensed-in-china-for-hepatitis-b"},{"sheetId":"82","name":"Unnamed","technology":"Cell-based therapies","technologyDetails":"Allogeneic T-cell therapies","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["AlloVir","Baylor College of Medicine"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998786","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0082","nameId":"allogeneic-t-cell-therapies"},{"sheetId":"83","name":"Natural Killer Cell-based therapy","technology":"Cell-based therapies","technologyDetails":"Natural killer cell-based therapy","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04578210","NCT04634370"],"organizations":["Instituto de Investigación Hospital Universitario La Paz","Universidad Autonoma de Madrid","Universidad Miguel Hernandez de Elche","Asociación Instituto de Investigación Sanitaria BioCruces","Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","Hospital de Clinicas de Porto Alegre"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998831","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|58","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0083","nameId":"natural-killer-cell-based-therapy"},{"sheetId":"86","name":"Unnamed","technology":"Cell-based therapies","technologyDetails":"haNK, natural killer cells","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ImmunityBio","NantKwest"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998883","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0086","nameId":"hank-natural-killer-cells"},{"sheetId":"87","name":"Unnamed","technology":"Cell-based therapies","technologyDetails":"Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ImmunityBio","NantKwest"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998924","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0087","nameId":"bone-marrow-derived-allogenic-mesenchymal-stem-cells-bm-allo-msc"},{"sheetId":"89","name":"Astrostem-V","technology":"Cell-based therapies","technologyDetails":"Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)*","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04527224"],"organizations":["Naturecell"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.998983","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|10","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|100","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0089","nameId":"astrostem-v-allogenic-adipose-derived-mesenchymal-stem-cells-hb-admscs"},{"sheetId":"90","name":"AmnioBoost","technology":"Cell-based therapies*","technologyDetails":"AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid*","developmentStage":"Pre-clinical","nextSteps":"Phase 1 enrolling April 2020*","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Lattice Biologics*"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999051","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0090","nameId":"amnioboost-concentrated-allogeneic-mscs-and-cytokines-derived-from-amniotic-fluid"},{"sheetId":"91","name":"Unnamed","technology":"RNA-based treatments","technologyDetails":"RNAi - testing 150 RNAis","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Sirnaomics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999114","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0091","nameId":"rnai-testing-150-rnais"},{"sheetId":"92","name":"Unnamed","technology":"RNA-based treatments","technologyDetails":"siRNA candidates","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Vir Biotech","Alnylam Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999156","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0092","nameId":"sirna-candidates"},{"sheetId":"93","name":"Unnamed","technology":"RNA-based treatments","technologyDetails":"Ampligen; (rintatolimod)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["AIM ImmunoTech","National Institute of Infectious Diseases in Japan"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999195","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0093","nameId":"ampligen-rintatolimod"},{"sheetId":"94","name":"OT-101*","technology":"RNA-based treatments","technologyDetails":"OT-101, a TGF-Beta antisense drug candidate","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04801017"],"organizations":["Oncotelic Inc.","Mateon Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999238","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|18","Phase 2/3|NA","Phase 3|NA","Phase 4|100","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0094","nameId":"ot-101-a-tgf-beta-antisense-drug-candidate"},{"sheetId":"95","name":"Unnamed","technology":"RNA-based treatments","technologyDetails":"Inhaled mRNA","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Neurimmune","Ethris"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999295","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0095","nameId":"inhaled-mrna"},{"sheetId":"96","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning library of antiviral compounds","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Janssen Pharmaceutical Companies"],"funder":"Biomedical Advanced Research and Development Authority (BARDA)","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999331","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0096","nameId":"scanning-library-of-antiviral-compounds"},{"sheetId":"97","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning compounds to repurpose","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Novartis"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999380","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0097","nameId":"scanning-compounds-to-repurpose"},{"sheetId":"98","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning antiviral compounds previously in development","developmentStage":"Pre-clinical","nextSteps":"Lead candidate (protease inhibitor) to start Phase 1 trial in Q3 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Pfizer"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999426","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0098","nameId":"scanning-antiviral-compounds-previously-in-development"},{"sheetId":"99","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning compounds to repurpose","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Merck"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999516","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0099","nameId":"scanning-compounds-to-repurpose-68"},{"sheetId":"100","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Repurposing antiviral drug candidates","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Materia Medica","Cyclica"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999560","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0100","nameId":"repurposing-antiviral-drug-candidates"},{"sheetId":"101","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Screening new drugs + library of antiviral compounds","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Enanta Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999605","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0101","nameId":"screening-new-drugs-library-of-antiviral-compounds"},{"sheetId":"102","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Screening drug compounds","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Southwest Research Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999655","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0102","nameId":"screening-drug-compounds"},{"sheetId":"103","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning compounds to repurpose","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Takeda"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999694","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0103","nameId":"scanning-compounds-to-repurpose-73"},{"sheetId":"104","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning compounds to repurpose","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Queens University Belfast"],"funder":"UK Government","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999742","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0104","nameId":"scanning-compounds-to-repurpose-75"},{"sheetId":"105","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Scanning compound libraries","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["COVID-19 Therapeutics Accelerator (15 companies shared their compound libararies including BD","bioMérieux","Boehringer Ingelheim","Bristol-Myers Squibb","Eisai","Eli Lilly","Gilead","GSK","Johnson & Johnson","Merck [known as MSD outside the US and Canada]","Merck KGaA","Novartis","Pfizer","and Sanofi)"],"funder":"Gates Foundation / Wellcome / Mastercard Impact Fund","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999802","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0105","nameId":"scanning-compound-libraries"},{"sheetId":"106","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Artifical intellegence-based screening to identify repurposed drug combinations","developmentStage":"Pre-clinical","nextSteps":"Combinations will be ready for preclinical testing in May 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Healx"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999865","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0106","nameId":"artifical-intellegence-based-screening-to-identify-repurposed-drug-combinations"},{"sheetId":"107","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Identifying drugs to repurpose","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:09.999931","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0107","nameId":"identifying-drugs-to-repurpose"},{"sheetId":"108","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Screening for antiviral drug candidates","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Anixa Biosciences","OntoChem"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000008","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0108","nameId":"screening-for-antiviral-drug-candidates"},{"sheetId":"109","name":"Unnamed","technology":"Scanning Compounds to Repurpose","technologyDetails":"Identifying drugs to repurpose","developmentStage":"Pre-clinical","nextSteps":"Identified 30 known drugs that inhibit SARS-CoV-2 replication","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Sanford Burnham Prebys Medical Discovery Institute","the University of Hong Kong","Scripps Research","UC San Diego School of Medicine","the Icahn School of Medicine at Mount Sinai and UCLA"],"funder":"","publishedResults":["bioRxiv|https://doi.org/10.1101/2020.04.16.044016"],"relatedUse":["bioRxiv|https://doi.org/10.1101/2020.04.16.044016"],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000066","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0109","nameId":"identifying-drugs-to-repurpose-81"},{"sheetId":"110","name":"Unnamed","technology":"Scanning Compounds to Repurpose*","technologyDetails":"AI-based screening to identify a peptide cocktail*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Nuritas*"],"funder":"Partnership for Advanced Computing in Europe (PACE)*","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000115","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0110","nameId":"ai-based-screening-to-identify-a-peptide-cocktail"},{"sheetId":"118","name":"Interferon alpha","technology":"Other","technologyDetails":"Interferon alpha","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04320238","ChiCTR2000030535","NCT04273763","NCT04480138","NCT04379518","NCT04293887","NCT04275388","NCT04534725"],"organizations":["Shanghai Jiao Tong University School of Medicine","Mianyang Central Hospital","Wuhan Red Cross Hospital","West China Hospital of Sichuan University","Second Affiliated Hospital of Wenzhou Medical University","WanBangDe Pharmaceutical Group Co.,Ltd.","Cadila Healthcare Limited","Roswell Park Cancer Institute","National Cancer Institute (NCI)","AIM ImmunoTech Inc.","Tongji Hospital","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","Peter MacCallum Cancer Centre, Australia"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.04.11.20061473"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.04.11.20061473"],"countries":[],"description":"Interferon alpha proteins are cytokines mainly involved in innate immunity against viral infection. They are secreted by numerous cell types, including white blood cells and they function through the interferon regulatory factor (IRF) antiviral pathways within cells.","show":true,"date":"2021-04-05 11:05:10.000184","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|2944","Phase 4|100","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0118","nameId":"interferon-alpha"},{"sheetId":"115","name":"Unnamed","technology":"Other","technologyDetails":"PegIntron, Sylatron, IntronA, PegiHep (peginterferon alfa-2b)*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Zydus Cadila Group","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) (Schering)*"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000238","type":"Treatment","fdaApproved":"PegIntron - FDA-approved since 2001, approved to treat Hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat Hepatitis C and certain cancers","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0115","nameId":"pegintron-sylatron-introna-pegihep-peginterferon-alfa-2b"},{"sheetId":"121","name":"Ifenprodil","technology":"Other","technologyDetails":"Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04382924"],"organizations":["Algernon Pharmaceuticals","Novotech"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ifenprodil is an N-methyl-D-Aspartate (NDMA) inhibitor that is specific for the NR2B subunit of the NMDA Receptor and a potentially potent anti-inflammatory drug. This drug may reduce the recruitment of neutrophils to areas of inflammation and reduce T cell secretion of cytokines. These two cell types may play a role in the pathogenic inflammatory response observed in severe COVID-19 cases, and thus this drug may have therapeutic benefits under these circumstances. ","show":true,"date":"2021-04-05 11:05:10.000299","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|462","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0121","nameId":"cerocal-ifenprodil-np-120-an-ndma-receptor-glutamate-receptor-antagonist-targeting-glu2nb"},{"sheetId":"122","name":"APN01","technology":"Other","technologyDetails":"APN01; recombinant soluble human Angiotensin Converting Enzyme 2","developmentStage":"Clinical","nextSteps":"Phase 2 began in April 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04335136"],"organizations":["Apeiron Biologics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"APN01 is a recombinant human angiotensin-converting enzyme 2 (ACE2) molecule. ACE2 is the receptor that the SARS-CoV-2 spike protein binds in order for the virus to gain access to host cells. This treatment is thought to act as a competitive inhibitor against the virus by binding the spike protein and preventing binding to host cell ACE2.","show":true,"date":"2021-04-05 11:05:10.000380","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|200","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0122","nameId":"apn01-recombinant-soluble-human-angiotensin-converting-enzyme-2"},{"sheetId":"123","name":"Brilacidin","technology":"Other","technologyDetails":"Brilacidin, a defensin mimetic","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04784897"],"organizations":["Innovation Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000444","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|120","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0123","nameId":"brilacidin-a-defensin-mimetic"},{"sheetId":"124","name":"Unnamed","technology":"Other","technologyDetails":"BXT-25; glycoprotein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Bioxytran"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000495","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0124","nameId":"bxt-25-glycoprotein"},{"sheetId":"127","name":"Fingolimod","technology":"Other","technologyDetails":"Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator","developmentStage":"Clinical","nextSteps":"Primary trial ends July 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04280588"],"organizations":["The First Affiliated Hospital of Fujian Medical University","Novartis"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters white blood cells in lymph nodes, preventing them from contributing to an immune reaction. Patients with severe SARS-CoV-2 pneumonia are thought to have an abundance of over-active immune cells in their lungs, and thus reducing that number of cells is thought to be beneficial.","show":true,"date":"2021-04-05 11:05:10.000537","type":"Treatment","fdaApproved":"FDA-approved since 2010, approved to treat multiple sclerosis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|30","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0127","nameId":"gilenya-fingolimod-sphingosine-1-phosphate-receptor-modulator"},{"sheetId":"125","name":"Unnamed","technology":"Other","technologyDetails":"Peptides targeting the NP protein","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["CEL-SCI","University of Georgia Center for Vaccines and Immunology"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000604","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0125","nameId":"peptides-targeting-the-np-protein"},{"sheetId":"126","name":"Unnamed","technology":"Other","technologyDetails":"BIO-11006, inhaled peptide","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Biomarck Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000653","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0126","nameId":"bio-11006-inhaled-peptide"},{"sheetId":"130","name":"Nafamostat","technology":"Other","technologyDetails":"nafamostat, approved in Japan to treat pancreatitis and other diseases","developmentStage":"Clinical","nextSteps":"University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04352400","NCT04418128","NCT04473053","NCT04623021","NCT04628143","NCT04390594"],"organizations":["University Hospital Padova","Yokohama City University","University of Zurich","Gyeongsang National University Hospital","University of Edinburgh","University of Oxford","Chong Kun Dang Pharmaceutical","Institut Pasteur de Dakar","Fann Hospital, Senegal","Ministry of Health, Senegal","Diamniadio Children Hospital, Senegal","Dalal Jamm Hospital, Senegal","Institut Pasteur Korea"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Nafamostat is a serine protease inhibitor and short-acting anti-coagulant. To gain entry into cells, the SARS-CoV-2 virus requires spike protein binding to the angiotensin-converting enzyme 2 (ACE2) and activation of the protease TMPRSS2. Nafamostat can inhibit TMPRSS2 protease function and is thus thought to be able to prevent viral entry into cells.","show":true,"date":"2021-04-05 11:05:10.000707","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|256","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0130","nameId":"nafamostat-approved-in-japan-to-treat-pancreatitis-and-other-diseases"},{"sheetId":"128","name":"Unnamed","technology":"Other","technologyDetails":"WP1122, glucose decoy prodrug (and related drug candidates)","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Moleculin Biotech","University of Texas Medical Branch"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000780","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0128","nameId":"wp1122-glucose-decoy-prodrug-and-related-drug-candidates"},{"sheetId":"132","name":"Losartan*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04312009","NCT04311177","NCT04328012","NCT04335123","NCT04343001","NCT04340557","NCT04447235","NCT04606563","NCT04643691","x-NCT04330300"],"organizations":["University of Minnesota","The Minnesota Foundation","Bassett Healthcare","University of Kansas Medical Center","London School of Hygiene and Tropical Medicine","Bill and Melinda Gates Foundation","Sharp HealthCare","CORONACION","Instituto do Cancer do Estado de São Paulo","University of British Columbia","Canadian Institutes of Health Research","Assistance Publique Hopitaux De Marseille"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.","show":true,"date":"2021-04-05 11:05:10.000846","type":"Treatment","fdaApproved":"FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|780","Phase 2/3|2000","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0132","nameId":"-89"},{"sheetId":"131","name":"Unnamed","technology":"Other","technologyDetails":"A number of synthesized nanoviricide drug candidates","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["NanoViricides"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.000885","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0131","nameId":"a-number-of-synthesized-nanoviricide-drug-candidates"},{"sheetId":"133","name":"Tissue plasminogen activator","technology":"Other","technologyDetails":"Activase (alteplase), tissue plasminogen activator (tPA); Tenecteplase","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04356833","NCT04357730","NCT04453371","NCT04505592","NCT04558125","NCT04640194"],"organizations":["University College, London","Denver Health and Hospital Authority","Genentech, Inc.","University of Colorado Denver","Beth Israel Deaconess Medical Center","and Long Island Jewish Hospital","Negovsky Reanimatology Research Institute","Sklifosovsky Institute of Emergency Care","Genentech, Inc.","Icahn School of Medicine at Mount Sinai","Cedars-Sinai Medical Center","Boehringer Ingelheim"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"During severe COVID-19 disease, due to vascular leakage, tiny clots can form in the airways of infected individuals which may exacerbate breathing problems. Tissue plasminogen activators may assist in the breakdown of these clots which will help alleviate the breathing difficulties associated with COVID-19.\n","show":true,"date":"2021-04-05 11:05:10.000963","type":"Treatment","fdaApproved":"FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|84","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0133","nameId":"activase-alteplase-tissue-plasminogen-activator-tpa-tenecteplase"},{"sheetId":"134","name":"Granulocyte-Macrophage Colony-Stimulating Factor","technology":"Other","technologyDetails":"Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor, Molgramostim)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04326920","NCT04400929","NCT04411680","NCT04569877","NCT04642950","NCT04707664","EudraCT 2020-001254-22"],"organizations":["University Hospital, Ghent","Flanders Institute of Biotechnology","Singapore General Hospital","Partner Therapeutics, Inc.","University of Giessen","Nobelpharma","United States Department of Defense"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an important white blood cell growth factor known to play a key role in hematopoiesis, effecting the growth and maturation of multiple cell lineages as well as the immune functional activities of these cells. It has also been used to improve oxygenation in patients with disordered gas exchange in the lungs. This therapeutic is thus thought to be potentially beneficial to aid the host in fighting SARS-CoV-2  infection, as well as help with lung function which is a known complication in severe COVID-19 cases.","show":true,"date":"2021-04-05 11:05:10.001034","type":"Treatment","fdaApproved":"FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|80","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0134","nameId":"leukine-sargramostim-rhu-granulocyte-macrophage-colony-stimulating-factor-molgramostim"},{"sheetId":"135","name":"Anakinra*","technology":"Other","technologyDetails":"Kineret (anakinra), interleukin-1 receptor antagonist","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04324021","NCT02735707","NCT04366232","NCT04362943","NCT04364009","NCT04357366","NCT04339712","NCT04362111","NCT04341584","NCT04330638","NCT04408326","NCT04412291","NCT04424056","NCT04443881","NCT04462757","NCT04603742","NCT04643678","NCT04680949","EudraCT 2020-001246-18","EudraCT 2020-001039-29","EudraCT 2020-001825-29","EudraCT 2020-001734-36","EudraCT 2020-001466-11","EudraCT 2020-001754-21","EudraCT 2020-001963-10","EudraCT 2020-001500-41","EudraCT 2020-001739-28","EudraCT 2015-002340-14"],"organizations":["Swedish Orphan Biovitrum","REMAP-CAP global trial","INSERM","CORIMUNO-ANA","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","Hôpital d'instruction des armées Sainte-Anne","Assistance Publique Hopitaux De Marseille","Complejo Hospitalario Universitario de Albacete","University Hospital, Tours","Hellenic Institute for the Study of Sepsis","University of Alabama at Birmingham","Assistance Publique - Hôpitaux de Paris","University Hospital, Ghent","Guy's and St Thomas' NHS Foundation Trust","Australian and New Zealand Intensive Care Research Centre","Monash University","Royal Surrey County Hospital NHS Foundation Trust","NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET","CHRU de TOURS","TOCILIZUMAB","UZLeuven","University of Manchester","Weill Medical College of Cornell University","Hamad Medical Corporation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Interleukin (IL)-1 alpha and beta are important innate inflammatory proteins. Anakinra is a recombinant human decoy IL-1 receptor alpha and therefore blocks IL-1alpha and IL-1beta. Since severe COVID-19 case pathology can arise from an overabundance of inflammatory cytokines (like IL-1), anakinra may be an effective therapeutic to mitigate these effects. ","show":true,"date":"2021-04-05 11:05:10.001131","type":"Treatment","fdaApproved":"FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|360","Phase 2/3|27","Phase 3|488","Phase 4|617","Phase NA|576"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0135","nameId":"kineret-anakinra-interleukin-1-receptor-antagonist"},{"sheetId":"136","name":"AT-001","technology":"Other","technologyDetails":"AT-001, aldose reductase inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04365699"],"organizations":["NYU Langone Health"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"AT-001 is an aldose reductase inhibitor that has demonstrated potential therapeutic effects on diabetic cardiomyopathy. Given the involvement of the heart in individuals with severe COVID-19 complications, AT-001 is being tested to see how it can impact the cardiac structure, function, and survival of COVID-19 patients. ","show":true,"date":"2021-04-05 11:05:10.001197","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|500","Phase 2/3|NA","Phase 3|NA","Phase 4|617","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0136","nameId":"at-001-aldose-reductase-inhibitor"},{"sheetId":"139","name":"Recombinant Human Plasma Gelsolin","technology":"Other","technologyDetails":"recombinant human plasma gelsolin (rhu-pGSN)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04358406"],"organizations":["BioAegis Therapeutics Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Gelsolin is a highly conserved protein found abundantly in blood plasma. Its primary therapeutic function is to keep inflammation local to the source of insult and enhance the function of the innate immune system. Due to the overabundance of inflammatory mediators in severe COVID-19 cases, administration of recombinant human plasma gelsolin (rhu-pGSN) may help mitigate these effects as well as help fight off the SARS-CoV-2 viral infection.","show":true,"date":"2021-04-05 11:05:10.001248","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|60","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0139","nameId":"recombinant-human-plasma-gelsolin-rhu-pgsn"},{"sheetId":"137","name":"Plitidepsin","technology":"Other","technologyDetails":"Aplidin (plitidepsin), approved in Australia to treat multiple myeloma","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/III","clinicalTrials":["NCT04382066","NCT04784559"],"organizations":["PharmaMar","Apices Soluciones S.L."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Plitidepsin is a cyclic peptide isolated from the marine tunicate Aplidium albicans with broad spectrum of antitumor activities. It functions by releasing mitochondrial cytochrome c, initiating the Fas/DC95, JNK pathway, and activating caspase 3 activation which ultimately leads to apoptosis. Plitidepsin also interferes with protein synthesis by inhibiting elongation factor 1-a, and induces G1 arrest and G2 blockade. It has also demonstrated anti-coronaviral activity and thus it is being clinically tested to reduce COVID-19 morbidity and mortality.","show":true,"date":"2021-04-05 11:05:10.001305","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|27","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|609","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,2],"inprogress":[1,3]},"inprogressClinicalTrials":[1,3],"completedClinicalTrials":[0,2],"phaseSortKey":4,"urlIdx":"d-0137","nameId":"aplidin-plitidepsin-approved-in-australia-to-treat-multiple-myeloma"},{"sheetId":"141","name":"Nitric Oxide","technology":"Other","technologyDetails":"Nitric oxide","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04305457","NCT04312243","NCT04306393","NCT03331445","NCT04358588","NCT04338828","NCT04337918","NCT04383002","NCT04388683","NCT04397692","NCT04443868","NCT04456088","NCT04476992","NCT04606407","NCT04601077","x-NCT04290858","x-NCT04290871","x-NCT04398290"],"organizations":["Massachusetts General Hospital","Xijing Hospital","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","University of British Columbia","Sanotize Research and Development corp.","The Emmes Company, LLC","University Health Network, Toronto","Tufts Medical Center","Bellerophon","Sanotize Research and Development corp.","Beyond Air Ltd","Federal State Budgetary Scientific Institution, Research Institute of Cardiology","Nitric Oxide Innovations LLC"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Nitric oxide is a colorless, free radical gas composed of nitrogen and oxygen that has demonstrated antimicrobial effects. It is theorized to have anti-viral properties as well and thus may help prevent and/or treat severe forms of SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.001388","type":"Treatment","fdaApproved":"FDA-approved since 1999, approved to improve oxygenation in neonates","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|1390","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0141","nameId":"nitric-oxide"},{"sheetId":"140","name":"Solnatide","technology":"Other","technologyDetails":"solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["EudraCT 2020-001244-26"],"organizations":["Medical University of Vienna","Apeptico"],"funder":"EU Commission (Horizon 2020 Program)","publishedResults":[],"relatedUse":[],"countries":[],"description":"Solnatide is a synthetic peptide that inhibits Protein kinase C (PKC)-alpha activation and restores pulmonary epithelial sodium channels. This leads to the clearance of alveolar fluids and reduced leakage of blood and fluids from the capillaries in the air space. Additionally, solnatide inhibits the production of hypoxia-induced reactive oxygen species (ROS) and counteracts various ROS and toxin-mediated effects. Due to the increased pulmonary oedema and ROS observed in severe COVID-19 cases, this drug is hypothesized to be beneficial as a therapeutic in this scenario. ","show":true,"date":"2021-04-05 11:05:10.001434","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0140","nameId":"solnatide-synthetic-molecule-with-a-structure-based-on-the-lectin-like-domain-of-human-tumour-necrosis-factor-alpha"},{"sheetId":"144","name":"PUL-042 inhalation solution","technology":"Other","technologyDetails":"PUL-042 inhalation solution","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04312997","NCT04313023"],"organizations":["Pulmotect","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"PUL-042 Inhalation Solution consisting of a combination of two toll-like receptor (TLR) ligands: Pam2CSK4 acetate (a synthetic diacylated lipopeptide; TLR2/6 agonist) and oligodeoxynucleotide M362 (contains unmethylated CpG-based dinucleotides; TLR9 agonist) with potential immunostimulating activity. Upon administration, the components activate TLRs on lung epithelial cells which causes them to produce peptides and reactive oxygen species (ROS) against pathogens, including bacteria, fungi, and viruses.","show":true,"date":"2021-04-05 11:05:10.001516","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|300","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0144","nameId":"pul-042-inhalation-solution"},{"sheetId":"142","name":"Unnamed","technology":"Other","technologyDetails":"PP-001","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Panoptes Pharma GmbH"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.001567","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0142","nameId":"pp-001"},{"sheetId":"143","name":"Unnamed","technology":"Other","technologyDetails":"ARMS-1","developmentStage":"Pre-clinical","nextSteps":"Trial starts April 2020","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["ARMS Pharmaceutical","UH Cleveland Medical Center","Case Western Reserve University"],"funder":"Cleveland Foundation","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.001603","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0143","nameId":"arms-1"},{"sheetId":"146","name":"Tofacitinib","technology":"Other","technologyDetails":"Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04332042","NCT04415151","NCT04469114","NCT04750317","x-NCT04412252"],"organizations":["Pfizer","Università Politecnica delle Marche","Yale University","Hospital Israelita Albert Einstein","I.M. Sechenov First Moscow State Medical University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Tofacitinib is an inhibitor of Janus kinases (JAK). This inhibition prevents the activation of the signal transducers and activators of transcription (STAT) which may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both the inflammatory response and the inflammation-induced damage caused by certain disease such as severe COVID-19.\n","show":true,"date":"2021-04-05 11:05:10.001645","type":"Treatment","fdaApproved":"FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|50","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0146","nameId":"xeljanz-tofacitinib-janus-kinase-jak-inhibitor"},{"sheetId":"147","name":"Colchicine*","technology":"Other","technologyDetails":"colchicine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04350320","NCT04375202","NCT04355143","NCT04360980","NCT04367168","NCT04326790","NCT04328480","NCT04322565","NCT04363437","NCT04322682","NCT04403243","NCT04416334","NCT04472611","NCT04492358","NCT04324463","NCT04510038","NCT04516941","NCT04527562","NCT04539873","NCT04603690","NCT04654416","NCT04667780","NCT04724629","NCT04756128","NCT04762771","NCT04818489"],"organizations":["National and Kapodistrian University of Athens","Estudios Clínicos Latino América","Azienda Ospedaliero-Universitaria di Parma","Montreal Heart Institute","DACIMA Software","University Of Perugia","University of California, Los Angeles","Shahid Beheshti University of Medical Sciences","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Lomonosov Moscow State University Medical Research and Educational Center","Instituto de Investigación Marqués de Valdecilla","Yale University","Fundacion Clinic per a la Recerca Biomédica","Miami Cardiac and Vascular Institute","University Hospital Inselspital, Berne","Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","Dhaka Medical College","Fundación Universitaria de Ciencias de la Salud","Hospital de San Jose","Liaquat University of Medical & Health Sciences","Universidad de Murcia","Clínica Medellín - Grupo Quirónsalud","Ayub Teaching Hospital","University of Sao Paulo","Conselho Nacional de Desenvolvimento Científico e Tecnológico","Science Valley Research Institute","HealthPartners Institute","Baptist Health South Florida","University of California, Los Angeles","ClinAmygate"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Colchicine is an alkaloid isolated from colchicum autumnale with anti-inflammatory activities. The exact mechanisms of action are not completely known, but of migration of leukocytes and other inflammatory cells are inhibited, thereby reducing the inflammatory response. This therapeutic may be beneficial in severe cases of COVID-19 as an overreactive immune response is part of the pathology.","show":true,"date":"2021-04-05 11:05:10.001728","type":"Treatment","fdaApproved":"N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|75","Phase 2|798","Phase 2/3|NA","Phase 3|8500","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0147","nameId":"colchicine"},{"sheetId":"150","name":"Selinexor","technology":"Other","technologyDetails":"Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04355676","NCT04349098","NCT04534725","EudraCT 2020-001411-25"],"organizations":["Karyopharm Therapeutics","Peter MacCallum Cancer Centre, Australia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Selinexor is an inhibitor of chromosome region maintenance 1 (CRM1), the major export factor for proteins from the nucleus to the cytoplasm. Binding irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as growth regulatory proteins. ","show":true,"date":"2021-04-05 11:05:10.001780","type":"Treatment","fdaApproved":"FDA-approved since 2019, approved to treat multiple myeloma","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|310","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0150","nameId":"xpovio-selinexor-oral-selective-inhibitor-of-nuclear-export-sine-compound"},{"sheetId":"149","name":"Fenretinide","technology":"Other","technologyDetails":"LAU-7b (fenretinide)","developmentStage":"Clinical","nextSteps":"Phase 2 to start May 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04417257"],"organizations":["Laurent Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Fenretinide is a synthetic retinoid derivative with anti-inflammatory and potentially anti-viral properties. It works by modulating key membrane lipids and triggering the body’s own resolution of inflammation, a process involving certain signaling pathways that also play an essential role in the virus cellular entry, replication, and avoidance of host defense system. This ultimately leads to a lower level of pro-inflammatory cytokines such as interleukin (IL)-6 and IL-8.","show":true,"date":"2021-04-05 11:05:10.001854","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|300","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0149","nameId":"lau-7b-fenretinide"},{"sheetId":"151","name":"BLD-2660","technology":"Other","technologyDetails":"BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04334460"],"organizations":["Blade Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"BLD-2660, synthetic small-molecule inhibitor of calpain. Calpains are a class of non-lysosomal cysteine proteases involved in diverse cellular processes. Several publications indicate that specific host calpains are essential for the replication of multiple RNA viruses including Coronaviruses. BLD-2660 has also been shown to normalize interleukin (IL)-6, a pro-inflammatory cytokine demonstrated to be elevated in COVID-19 patients and is implicated in disease pathogenesis.","show":true,"date":"2021-04-05 11:05:10.001900","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|120","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0151","nameId":"bld-2660-synthetic-small-molecule-inhibitor-of-calpain-capn-1-2-and-9"},{"sheetId":"152","name":"Acalabrutinib","technology":"Other","technologyDetails":"Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04346199","NCT04380688","EudraCT 2020-001736-95","NCT04497948","NCT04564040","NCT04647669"],"organizations":["AstraZeneca","Acerta Pharma B.V.","University Hospital Southampton NHS Foundation Trust","Parexel","The University of The West Indies"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Acalabrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK), an important enzyme in B lymphocyte development, activation, signaling, proliferation, and survival.","show":true,"date":"2021-04-05 11:05:10.001973","type":"Treatment","fdaApproved":"FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|20","Phase 1/2|NA","Phase 2|200","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0152","nameId":"calquence-acalabrutinib-bruton-s-tyrosine-kinase-btk-inhibitor"},{"sheetId":"153","name":"CD24Fc","technology":"Other","technologyDetails":"CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)","developmentStage":"Clinical","nextSteps":"Phase 3 trial started in April 2020*","customClinicalPhase":"Phase III","clinicalTrials":["NCT04317040"],"organizations":["OncoImmune","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"CD24Fc is a recombinant fusion protein composed of the extracellular domain of the mature human glycoprotein CD24 linked to a human immunoglobulin G1 (IgG1) Fc domain, with potential immune checkpoint inhibitory and anti-inflammatory activities.","show":true,"date":"2021-04-05 11:05:10.002040","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|230","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0153","nameId":"cd24fc-biological-immunomodulator-nonpolymorphic-regions-of-cd24-attached-to-the-fc-region-of-human-igg1"},{"sheetId":"154","name":"Aviptadil","technology":"Other","technologyDetails":"Aviptadil, RLF-100, synthetic form of Vasoactive Intestinal Polypeptide","developmentStage":"Clinical","nextSteps":"Phase 2 trial started in April 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04311697","NCT04360096","NCT04453839","NCT04536350"],"organizations":["NeuroRx, Inc.","Relief Therapeutics Holding SA","Target Health Inc.","Lavin Consulting, LLC","Cavendish Impact Foundation","Impact Assets, Inc.","Global Emerging Markets Fund","Cantonal Hosptal, Baselland"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Aviptadil is a synthetic version of Vasoactive Intestinal Polypeptide (VIP). This protein is found throughout the body and contributes to numerous functions including vasodilation, increasing glycogenolysis, lowering arterial blood pressure, and relaxing the smooth muscles. VIP is highly concentrated in the lung, where it prevents NMDA-induced caspase-3 activation in the lung, inhibits IL6, and TNFa production. It is theorized that the delivery of this therapeutic will help with the serious lung complications associated with COVID-19.","show":true,"date":"2021-04-05 11:05:10.002125","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|120","Phase 2/3|144","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0154","nameId":"aviptadil-rlf-100-synthetic-form-of-vasoactive-intestinal-polypeptide"},{"sheetId":"155","name":"Vazegepant","technology":"Other","technologyDetails":"vazegepant, CGRP receptor antagonist","developmentStage":"Clinical","nextSteps":"Phase 2 to start April 2020","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04346615"],"organizations":["Biohaven Pharmaceuticals","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Vazegepant is a Calcitonin gene-related peptide (CGRP) receptor antagonist that may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation in patients with COVID-19.","show":true,"date":"2021-04-05 11:05:10.002193","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|120","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0155","nameId":"vazegepant-cgrp-receptor-antagonist"},{"sheetId":"156","name":"CM4620","technology":"Other","technologyDetails":"CM4620-IE, calcium release-activated calcium (CRAC) channel inhibtor; Auxora","developmentStage":"Clinical","nextSteps":"Phase 2 started in April 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04345614","NCT04661540"],"organizations":["CalciMedica, Inc.","Northwestern University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"CM4620 is a calcium release-activated channel (CRAC) inhibitor which ultimately inhibits the proliferation of immune cells and prevents the release of various inflammatory cytokines. This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases, such as those observed in severe cases of COVID-19. ","show":true,"date":"2021-04-05 11:05:10.002250","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|180","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0156","nameId":"cm4620-ie-calcium-release-activated-calcium-crac-channel-inhibtor-auxora"},{"sheetId":"157","name":"Ivermectin*","technology":"Other","technologyDetails":"ivermectin","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04381884","NCT04425707","NCT04445311","NCT04351347","NCT04392713","NCT04343092","NCT04360356","NCT04403555","NCT04373824","NCT04438850","NCT04422561","NCT04429711","NCT04391127","NCT04405843","NCT04399746","NCT04407130","NCT04392427","NCT04390022","NCT04447235","NCT04434144","NCT04435587","NCT04407507","NCT04425863","NCT04382846","NCT04425850","NCT04446104","NCT04374019","NCT04431466","NCT04345419","NCT04460547","NCT04472585","NCT04482686","NCT04510233","NCT04523831","NCT04527211","NCT04530474","NCT04529525","NCT04551755","NCT04591600","NCT04602507","NCT04632706","NCT04635943","NCT04646109","NCT04668469","NCT04681053","NCT04703205","NCT04703608","NCT04701710","NCT04716569","NCT04714515","NCT04712279","NCT04727424","NCT04723459","NCT04729140","NCT04739410","NCT04747678","NCT04746365","NCT04768179","NCT04784481","EudraCT 2020-001994-66","EudraCT 2020-002091-12","EudraCT 2020-001474-29"],"organizations":["University of Baghdad","Tanta University","Laboratorio Elea Phoenix S.A.","University of Kentucky","Combined Military Hospital, Pakistan","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","Tanta University","Zagazig University","Ministry of Health and Population, Egypt","Sheba Medical Center","Eurnekian Public Hospital","UHFPO","Universidade Federal de Sao Carlos","Mahidol University","IRCCS Sacro Cuore Don Calabria di Negrar","Istituto Di Ricerche Farmacologiche Mario Negri","Applied Biology, Inc.","Instituto do Cancer do Estado de São Paulo","Qassim University","Sheikh Zayed Federal Postgraduate Medical Institute","ProgenaBiome","Dhaka Medical College","Javeriana University","Temple University","Bangladesh Medical Research Council","Alkarkh Health Directorate-Baghdad","CES University","MedinCell S.A","MAC Clinical Research","Universidad Peruana Cayetano Heredia","Barcelona Institute for Global Health","Afyonkarahisar Health Sciences University","NeuTec Pharma","Benha University","Mansoura University","Kitasato University","London School of Hygiene and Tropical Medicine","Maria de los Angeles Peral de Bruno","Ministry of Public Health, Argentina","South Valley University","University of Sargodha","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","Shaukat Khanum Memorial Cancer Hospital & Research Centre","Shanghai Jiao Tong University School of Medicine","Teesside University","Corpometria Institute","Cardresearch","Max Health, Subsero Health","FMH College of Medicine and Dentistry","Menoufia University","Elaraby Hospital","Shebin-Elkom Teaching Hospital","Makerere University","Ministry of Health, Uganda","Mbarara University of Science and Technology","Joint Clinical Research Center","Ministry of Public Health, Argentina"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ivermectin is a macrocyclic lactone derived from Streptomyces avermitilis with antiparasitic activity. This functionality results via activating glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells which means they remain at either hyperpolarisation or depolarization state, thereby resulting in paralysis and death of the parasites. Ivermectin does not readily pass the mammal blood-brain barrier to the central nervous system where glutamate-gated chloride channels locate, hence the hosts are relatively resistant to the effects of this agent.  \n","show":true,"date":"2021-04-05 11:05:10.002376","type":"Treatment","fdaApproved":"FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|50","Phase 1/2|NA","Phase 2|NA","Phase 2/3|160","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0157","nameId":"ivermectin"},{"sheetId":"158","name":"Nitazoxanide*","technology":"Other","technologyDetails":"nitazoxanide, antiprotozoal*","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04351347","NCT04348409","NCT04343248","NCT04341493","NCT04345419","NCT04361318","NCT04359680","NCT04382846","NCT04360356","NCT04423861","NCT04435314","NCT04441398","NCT04459286","NCT04463264","NCT04486313","NCT04498936","NCT04523090","NCT04532931","NCT04552483","NCT04561063","NCT04561219","NCT04563208","NCT04605588","NCT04729491","NCT04788407"],"organizations":["Romark Laboratories L.C.","Tanta University","Azidus Brasil","Materno-Perinatal Hospital of the State of Mexico","Azidus Brasil","Farmoquimica S.A.","Hospital Casa de Saúde","Obafemi Awolowo University","University of Liverpool","African Centre of Excellence for Genomics of Infectious Diseases","Oyo State Ministry of Health","Laboratorios Roemmers S.A.I.C.F.","Assiut University","Helwan University","Medical Research Council, South Africa","University of Cape Town","Aurum Institute","National Institutes of Health (NIH)","Texas Tech University Health Sciences Center","University of KwaZulu","Perinatal HIV Research Unit of the University of the Witswatersrand","Shin Poong Pharmaceutical Co. Ltd.","Medicines for Malaria Venture","Universidade Federal do Rio de Janeiro","Ministry of Science and Technology, Brazil","National Research Council, Brazil","University of Witwatersrand, South Africa","Universidade Federal do Rio de Janeiro","Ministry of Science and Technology, Brazil","National Research Council, Brazil","Rutgers, The State University of New Jersey","SynaVir","Corpometria Institute","Fundación Huésped","Ministerio de Salud de Ciudad Autónoma de Buenos Aires","Laboratorios Roemmers S.A.I.C.F."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Nitazoxanide is a synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase (PFOR)-dependent electron transfer reaction, which is essential to anaerobic energy metabolism. Nitazoxanide also has a broad-spectrum antiviral activity and inhibits the production of pro-inflammatory cytokines TNF-α, IL-2, IL-4, IL-5, IL-6, IL-8 and IL-10, which may play a pathological role in severe COVID-19 cases.","show":true,"date":"2021-04-05 11:05:10.002449","type":"Treatment","fdaApproved":"FDA-approved since 2002, approved to treat diarrhea caused by Giardia lamblia or Cryptosporidum parvum*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|180","Phase 3|1400","Phase 4|86","Phase NA|50"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0158","nameId":"nitazoxanide-antiprotozoal"},{"sheetId":"159","name":"Eicosapentaenoic Acid Free Fatty Acid","technology":"Other","technologyDetails":"EPAspire, oral forumation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules; Icosapent ethyl","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04335032","NCT04412018","NCT04460651","NCT04505098"],"organizations":["S.L.A. Pharma AG","Canadian Medical and Surgical Knowledge Translation Research Group","Amarin Corporation","HLS Therapeutics, Inc","Estudios Clínicos Latino América","Kaiser Permanente"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Eicosapentaenoic Acid (EPA) is an omega-3 fatty acid and precursor to prostaglandin-3 (which inhibits platelet aggregation), thromboxane-3, and leukotriene-5 eicosanoids. Ingestion of this compound is thought to reduce harmful, excess inflammatory responses, such as those observed in serve COVID-19 cases.","show":true,"date":"2021-04-05 11:05:10.002507","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|100","Phase 2/3|NA","Phase 3|240","Phase 4|16500","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0159","nameId":"epaspire-oral-forumation-of-highly-purified-eicosapentaenoic-acid-free-fatty-acid-epa-ffa-in-gastro-resistant-capsules-icosapent-ethyl"},{"sheetId":"160","name":"Niclosamide*","technology":"Other","technologyDetails":"niclosamide; DWRX2003, UNI911","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04345419","NCT04372082","NCT04399356","NCT04436458","NCT04524052","NCT04541485","NCT04542434","NCT04558021","NCT04576312","NCT04592835","NCT04603924","NCT04644705","NCT04749173","NCT04750759","NCT04753619"],"organizations":["Tanta University","University Hospital, Lille","I-site University Lille North Europe","Tufts Medical Center","First Wave Bio, Inc.","Daewoong Pharmaceutical Co. LTD.","Imuneks Farma ilac San. Tic. A.S.","UNION therapeutics","Novotech (Australia) Pty Limited","ANA Therapeutics","Charité Research Organisation GmbH","Bayer","University of Baghdad"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Niclosamide is a bioavailable chlorinated salicylanilide, with potential antiviral and known anthelmintic activity. Antihelminth activity is achieved by inhibiting glucose uptake, oxidative phosphorylation, and anaerobic metabolism in the tapeworm. Anticoronaviral activity is not well understood, but it is possible that niclosamide inhibits S-phase kinase-associated protein 2 (SKP2). SKP2 is known to tag Benclin 1 (BECN1) for degradation and SKP2 inhibition increases the BENC1 level, enhances autophagy, and efficiently reduces coronavirus replication.","show":true,"date":"2021-04-05 11:05:10.002613","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|72","Phase 1/2|NA","Phase 2|248","Phase 2/3|40","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0160","nameId":"niclosamide-dwrx2003-uni911"},{"sheetId":"163","name":"Piclidenoson","technology":"Other","technologyDetails":"piclidenoson, A3 adenosine receptor agonist","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04333472"],"organizations":["Can-Fite BioPharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Piclidenoson is an A3 adenosine receptor agonist which ultimately de-regulates the Wnt/β-catenin pathway and inhibits inflammatory cytokine production. Since a major part of the pathophysiology of severe COVID-19 involves an overproduction of inflammatory cytokines, this therapeutic drug may mitigate this aspect of the disease.","show":true,"date":"2021-04-05 11:05:10.002712","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|40","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0163","nameId":"piclidenoson-a3-adenosine-receptor-agonist"},{"sheetId":"161","name":"Unnamed","technology":"Other","technologyDetails":"ADX-629, orally available reactive aldehyde species (RASP) inhibitor","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Aldeyra Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.002766","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0161","nameId":"adx-629-orally-available-reactive-aldehyde-species-rasp-inhibitor"},{"sheetId":"162","name":"N-803","technology":"Other","technologyDetails":"N-803, IL-15 \"superagonist\"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04385849"],"organizations":["ImmunityBio","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"N-803 is a recombinant human interleukin-15 (IL-15) superagonist. The IL-15 receptor plays a very important role in the immune system by affecting the maintenance, function, and development of natural killer and T- cells, key components of antiviral immunity. It is thus hypothesized that this therapeutic will help bolster the antiviral response against SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.002828","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|30","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-0162","nameId":"n-803-il-15-superagonist"},{"sheetId":"166","name":"MRx-4DP0004","technology":"Other","technologyDetails":"MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human*","developmentStage":"Clinical","nextSteps":"UK approval to start Phase 2 study in April 2020*","customClinicalPhase":"Phase II","clinicalTrials":["NCT04363372"],"organizations":["4D pharma plc"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"MRx-4DP0004 is an immunomodulating Live Biotherapeutic Product (LBP) comprised of the bacterium Bifidobacterium breve which was isolated from a healthy human gut. This LBP is expected to prevent or reduce the hyperinflammatory response to SARS-CoV-2 infection without impairing viral clearance ","show":true,"date":"2021-04-05 11:05:10.002880","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|90","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0166","nameId":"mrx-4dp0004-strain-of-bifidobacterium-breve-isolated-from-the-gut-microbiome-of-a-healthy-human"},{"sheetId":"164","name":"Unnamed","technology":"Other","technologyDetails":"Ryanodex (dantrolene sodium), skeletal muscle relaxant","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Eagle Pharmaceuticals","Amneal Pharmaceuticals","Alcami Corporation","Hackensack University Medical Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.002960","type":"Treatment","fdaApproved":"FDA-approved since 2014, approved to prevent and treat malignant hyperthermia","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0164","nameId":"ryanodex-dantrolene-sodium-skeletal-muscle-relaxant"},{"sheetId":"165","name":"Idronoxil","technology":"Other","technologyDetails":"Veyonda (idronoxil)*; NOX66","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04555213"],"organizations":["Noxopharm Limited"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.003014","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|40","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-0165","nameId":"veyonda-idronoxil-nox66"},{"sheetId":"170","name":"Dapagliflozin*","technology":"Other","technologyDetails":"Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor*","developmentStage":"Clinical","nextSteps":"Phase 3 study started in April 2020*","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04350593","NCT04393246"],"organizations":["Saint Luke's Health System","AstraZeneca","George Clinical Pty Ltd","Cambridge University Hospitals NHS Foundation Trust"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor which has previously been demonstrated to have potent heart and kidney-protective effects in patients with type 2 diabetes, heart failure and/or chronic kidney disease, and may afford protection of these vital organ systems in the setting of COVID-19.","show":true,"date":"2021-04-05 11:05:10.003067","type":"Treatment","fdaApproved":"FDA-approved since 2014, approved to improve glycemic controls in adults with type 2 diabetes and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|600","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0170","nameId":"farxiga-dapagliflozin-sodium-glucose-cotransporter-2-sglts-inhibitor"},{"sheetId":"167","name":"Unnamed","technology":"Other","technologyDetails":"roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Cyclacel Pharmaceuticals","University of Edinburgh*"],"funder":"LifeArc*","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.003137","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0167","nameId":"roscovitine-seliciclib-cyclin-dependent-kinase-cdk-2-9-inhibitor"},{"sheetId":"168","name":"Unnamed","technology":"Other","technologyDetails":"fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor*","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Cyclacel Pharmaceuticals","University of Edinburgh*"],"funder":"LifeArc*","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.003194","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0168","nameId":"fadraciclib-cyc065-cyclin-dependent-kinase-cdk-2-9-inhibitor"},{"sheetId":"169","name":"ATYR1923","technology":"Other","technologyDetails":"ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2*","developmentStage":"Clinical","nextSteps":"Phase 2 study ~ April/May 2020*","customClinicalPhase":"Phase II","clinicalTrials":["NCT04412668"],"organizations":["aTyr Pharma","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"ATYR1923 is a fusion protein of the immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody. It functions by downregulating the immune system during inflammatory disease states by modulating Neuropilin 2 (NRP2). Since COVID-19 disease pathologies arise from an overactive immune system in the lung, this therapy is hypothesized to be beneficial during SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.003254","type":"Treatment","fdaApproved":"N/A*","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|30","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0169","nameId":"atyr1923-fusion-protein-immuno-modulatory-domain-of-histidyl-trna-synthetase-fused-to-the-fc-region-of-a-human-antibody-modulator-of-neuropilin-2"},{"sheetId":"171","name":"Conestat alfa","technology":"Other","technologyDetails":"Ruconest (recombinant human C1 esterase inhibitor)*, Conestat alfa","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/IV","clinicalTrials":["NCT04414631","NCT04530136","NCT04705831"],"organizations":["University Hospital, Basel, Switzerland","Pharming Technologies B.V.","IMMUNOe Research Centers"],"funder":"","publishedResults":["Pharming|https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf"],"relatedUse":["Pharming|https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf"],"countries":[],"description":"Ruconest is a recombinant human C1 esterase inhibitor which makes it an anti-inflammatory compound. C1 is an important molecule in the early stages of the innate complement system cascade. Inhibiting C1 esterase reduces inflammation, and since COVID-19 disease pathogenesis is in part driven by an overreactive immune response, this therapy has the potential to reduce the severity of SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.003367","type":"Treatment","fdaApproved":"FDA-approved since 2014, approved to treat hereditary angioedema","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|120","Phase 2/3|NA","Phase 3|NA","Phase 4|40","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,3],"inprogress":[2,4]},"inprogressClinicalTrials":[2,4],"completedClinicalTrials":[0,1,3],"phaseSortKey":7,"urlIdx":"d-0171","nameId":"ruconest-recombinant-human-c1-esterase-inhibitor-conestat-alfa"},{"sheetId":"172","name":"CytoSorb","technology":"Device","technologyDetails":"CytoSorb (blood purification device, extracorporeal cytokine adsorber))","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04324528","ChiCTR2000030475","NCT04344080","NCT04518969"],"organizations":["CytoSorbents Corporation","University Hospital Freiburg","Universitätsklinikum Hamburg-Eppendorf","Brugmann University Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"CytoSorb is an extracorporeal blood purification procedure that can effectively reduce excessive levels of inflammatory mediators. It is comprised of porous polymer sorbent beads with a high binding capacity to a broad range of cytokines and other inflammatory mediators. It is known that a main pathological driver of severe COVID-19 is an overabundance of inflammatory cytokines, and it is thus believed that this therapeutic may remove excess factors from patients suffering from this disease.","show":true,"date":"2021-04-05 11:05:10.003438","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|78"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-0172","nameId":"cytosorb-blood-purification-device-extracorporeal-cytokine-adsorber"},{"sheetId":"176","name":"INOpulse","technology":"Device","technologyDetails":"INOpulse","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04358588","NCT04421508","x-NCT04398290"],"organizations":["Bellerophon"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"INOpulse is a device that delivers the anti-viral gas nitric oxide (NO) to patients in a targeted pulsatile portable format.  ","show":true,"date":"2021-04-05 11:05:10.003511","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|530","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0176","nameId":"inopulse"},{"sheetId":"173","name":"Unnamed","technology":"Device","technologyDetails":"Extracorporeal blood purification (EBP) devices","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Terumo BCT Inc","Marker Therapeutics AG"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.003558","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0173","nameId":"extracorporeal-blood-purification-ebp-devices"},{"sheetId":"CD1","name":"Plasma Adsorption Cartridge","technology":"Device","technologyDetails":"Plasma Adsorption Cartridge","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04358003"],"organizations":["Marker Therapeutics AG"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"PLasma adsorption cartridges simultaneously filter the blood and return it to the patient and reduce the number of cytokines and other inflammatory mediators. Since severe COVID-19 suffers have an overabundance of inflammatory molecules in their circulation, this therapeutic holds merit to help bring the levels of these proteins back to their appropriate baseline. ","show":true,"date":"2021-04-05 11:05:10.003610","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|2000"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-0CD1","nameId":"plasma-adsorption-cartridge"},{"sheetId":"174","name":"Seraph-100 Microbind Affinity Blood Filter","technology":"Device","technologyDetails":"Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04413955","NCT04361500","NCT04547257"],"organizations":["Children's Hospital Medical Center, Cincinnati","ExThera Medical Corporation","Hannover Medical School","Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.003664","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|200"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-0174","nameId":"seraph100microbindaffinity-blood-filter-seraphy-100-approved-in-the-eu-for-pathogen-reduction"},{"sheetId":"175","name":"Unnamed","technology":"Device","technologyDetails":"Oxiris Blood Purification Filter","developmentStage":"Pre-clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Baxter"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.003738","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-0175","nameId":"oxiris-blood-purification-filter"},{"sheetId":"CD2","name":"Cobicistat*","technology":"Antivirals","technologyDetails":"cobicistat, CYP3A inhibitor","developmentStage":"Clinical","nextSteps":"Primary study ends August 2021","customClinicalPhase":"Phase III","clinicalTrials":["ChiCTR2000029541","NCT04252274","NCT04425382"],"organizations":["Shanghai Public Health Clinical Center","Zhongnan Hospital of Wuhan University","Hamad Medical Corporation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Cobicistat inhibits the human CYP3A proteins, which are known to degrade important antiretroviral molecules. Cobicistat is thus importantly used in combination with other drugs to help enhance their efficacy. \n","show":true,"date":"2021-04-05 11:05:10.003796","type":"Treatment","fdaApproved":"FDA-approved since 2015, approved to treat HIV-1 infection","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|30","Phase 4|NA","Phase NA|40"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-0CD2","nameId":"cobicistat-cyp3a-inhibitor"},{"sheetId":"CD3","name":"NKG2D-ACE2 CAR-NK Cells","technology":"Cell-based therapies","technologyDetails":"NKG2D-ACE2 CAR-NK Cells","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04324996"],"organizations":["Chongqing Public Health Medical Center","Chongqing Sidemu Biotechnology Technology Co.,Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"NKG2D-ACE2 CAR-NK Cells are engineered natural killer (NK) cells made from chord blood. NK cells are part of the innate immune system that helps your body to kill virally-infected cells. These cells were then engineered to secrete an interleukin (IL)-15 superagonist (soluble IL-15 plus IL-15 receptor alpha chimeric protein; IL-15 is required for NK cell long-term survival in the body) and a single-chain variable fragment (scFv; a single-chain protein comprised of only the variable [specific] fragment of an antibody) that binds granulocyte-macrophage colony-stimulating factor (GM-CSF; a cytokine, that when neutralized, helps prevent a dangerous cytokine release syndrome associated with other cell therapies). Along with these secretable factors, these cells are chimeric antigen receptor (CAR) engineered to express the NKG2D membrane protein (an activating receptor of NK cells, which can recognize and thus clear virus-infected cells) and angiotensin-converting enzyme 2 (ACE2; the surface protein recognized by the SARS-CoV-2 spike protein) so that they can no only target and kill virally-infected cells, but also competitively inhibit SARS-CoV-2 infection of other cells through its ACE2 expression.\n","show":true,"date":"2021-04-05 11:05:10.003848","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|90","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0CD3","nameId":"nkg2d-ace2-car-nk-cells"},{"sheetId":"CD4","name":"TAK-981","technology":"Other","technologyDetails":"TAK-981","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT03648372"],"organizations":["Millennium Pharmaceuticals","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and anti-tumor activities.","show":true,"date":"2021-04-05 11:05:10.003896","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|80","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-0CD4","nameId":"tak-981"},{"sheetId":"CD5","name":"Interferon beta-1b*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04343768","NCT04350281","NCT04366245","NCT04276688","NCT04465695","NCT04469491","NCT04494399","NCT04324463","NCT04611243","NCT04647695"],"organizations":["Shahid Beheshti University of Medical Sciences","The University of Hong Kong","Andalusian Network for Design and Translation of Advanced Therapies","The University of Hong Kong","Centre Hospitalier Universitaire, Amiens","Hospital Authority, Hong Kong","Chinese University of Hong Kong","The University of Hong Kong","Health and Medical Research Fund"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Interferon beta-1b is an interferon-family cytokine produced by modified bacteria (Escherichia coli) that helps to balance pro- and anti-inflammatory environments.","show":true,"date":"2021-04-05 11:05:10.003948","type":"Treatment","fdaApproved":"FDA-approved since 2002, approved to treat multiple sclerosis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|72","Phase 2|140","Phase 2/3|NA","Phase 3|NA","Phase 4|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0CD5","nameId":"-99"},{"sheetId":"CD6","name":"Imatinib*","technology":"Other","technologyDetails":"aka: Gleevec, Glivec","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04346147","NCT04357613","NCT04356495","NCT04394416","NCT04422678","NCT04794088"],"organizations":["University Hospital, Bordeaux","University of Bordeaux","Versailles Hospital","Hospital Universitario de Fuenlabrada","Centro Nacional de Investigaciones Oncologicas CARLOS III","University of Maryland, Baltimore","Alexandria University","Science, Technology & Innovation Funding Authority (STIFA), Egypt","Simbec Orion","Exvastat Ltd.","KABS laboratories"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Imatinib is a tyrosine kinase (TK) inhibitor and a common Antitumor agent. It functions by binding the intracellular pocket located within TK, and thus inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. It has shown antiviral properties in early stages of infection against coronaviruses. In addition, it has been linked to reduced inflammation and improved endothelial barrier and pulmonary edema.","show":true,"date":"2021-04-05 11:05:10.003995","type":"Treatment","fdaApproved":"FDA-approved since 2002, approved to treat multiple types of cancer","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|264","Phase 2/3|NA","Phase 3|1057","Phase 4|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0CD6","nameId":"aka-gleevec-glivec"},{"sheetId":"CD7","name":"Rivaroxaban*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04351724","NCT04333407","NCT04416048","NCT04394377","NCT04324463","NCT04504032","NCT04508023","NCT04640181","NCT04662684","NCT04715295","NCT04736901","NCT04757857"],"organizations":["Imperial College London","ACOVACT","Charite University, Berlin, Germany","Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)","Bayer","COALIZAO ACTION Trial","Bill & Melinda Gates Medical Research Institute","Janssen Research & Development, LLC","St. David's HealthCare","Science Valley Research Institute","Yaounde Central Hospital","Ain Shams University","Misr International University","Hospital Alemão Oswaldo Cruz","Hospital Israelita Albert Einstein","Hospital do Coracao","Hospital Sirio-Libanes","Hospital Moinhos de Vento","Brazilian Research In Intensive Care Network","Brazilian Clinical Research Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Rivaroxaban is an orally bioavailable oxazolidinone derivative and anticoagulant. It functions by selectively binding to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. There is evidence that severe cases of COVID-19 suffer from an important infection-related coagulopathy and from elevated risks of thrombosis and thus anticoagulants may have positive effects here. ","show":true,"date":"2021-04-05 11:05:10.004061","type":"Treatment","fdaApproved":"FDA-approved since 2011, approved for prophylaxis of deep vein thrombosis and stroke prevention in people with non-valvular atrial fibrillation","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|110","Phase 3|NA","Phase 4|NA","Phase NA|3170"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0CD7","nameId":"-100"},{"sheetId":"CD8","name":"JS016","technology":"Antibodies","technologyDetails":"Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody)","developmentStage":"Clinical","nextSteps":"Phase 1 to start 2Q 2020","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04441918","NCT04780321"],"organizations":["Shanghai Junshi Bioscience Co.","Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.004101","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|40","Phase 1/2|90","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|3170"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0CD8","nameId":"combination-product-js016-anti-sars-cov-2-monoclonal-antibody"},{"sheetId":"CD9","name":"Rintatolimod*","technology":"RNA-based treatments","technologyDetails":"Ampligen; (rintatolimod)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04379518"],"organizations":["Roswell Park Cancer Institute","National Cancer Institute (NCI)"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Rintatolimod is double-stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving this, and other therapeutics in tandem,  may activate the immune system to limit the replication and spread of the virus.","show":true,"date":"2021-04-05 11:05:10.004163","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|80","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0CD9","nameId":"ampligen-rintatolimod-101"},{"sheetId":"CD10","name":"Tradipitant","technology":"Other","technologyDetails":"tradipitant, a neurokinin-1 receptor antagonist","developmentStage":"Clinical","nextSteps":"Phase 3 trial started in April 2020","customClinicalPhase":"Phase III","clinicalTrials":["NCT04326426"],"organizations":["Vanda Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Tradipitant is a neurokinin-1 receptor (NK-1R) antagonist that functions by blocking substance P interactions. Inhibitors of NK-1 can be used as antiemetic agents.","show":true,"date":"2021-04-05 11:05:10.004220","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|300","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD10","nameId":"tradipitant-a-neurokinin-1-receptor-antagonist"},{"sheetId":"CD12","name":"Avdoralimab","technology":"Antibodies","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04371367","x-NCT04333914"],"organizations":["Innate Pharma","Assistance Publique Hopitaux De Marseille","Centre Leon Berard"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Avdoralimab is a monoclonal antibody that binds and blocks the C5a receptor (C5aR) on myeloid cells (including monocytes, macrophages, and neutrophils). C5a is a proinflammatory molecule that is known to play a pathogenic role in severe COVID-19 disease. Blocking its receptor (C5aR) has the potential to reduce the inflammatory response in the lungs that is a hallmark of severe SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.004284","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|108","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD12","nameId":"-102"},{"sheetId":"CD13","name":"Azithromycin*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT02735707","NCT04381962","NCT04365231","NCT04329832","NCT04371406","NCT04359316","NCT04343092","NCT04374019","NCT04395768","NCT04359095","NCT04399746","NCT04383717","EudraCT 2020-001246-18","EudraCT 2015-002340-14","NCT04405921","NCT04365764","NCT04394182","NCT04434144","NCT04354428","NCT04458948","NCT04459702","NCT04457609","NCT04461925","NCT04501965","NCT04502342","NCT04590274","NCT04613271","NCT04622891","NCT04621461","NCT04699097","NCT04715295","NCT04729491","x-NCT04528927","x-NCT04341727","x-NCT04341870","x-NCT04329572","x-NCT04348474","x-NCT04363203","x-NCT04361461","x-NCT04345861","x-NCT04344379","x-NCT04575558","x-NCT04392128","Over 70 studies listed in clincialtrials.gov"],"organizations":["REMAP-CAP","ATOMIC2","Hospital St. Joseph, Marseille, France","Intermountain Health Care, Inc.","University of Utah","University of Oxford","Pfizer","Assistance Publique - Hôpitaux de Paris","Shahid Beheshti University of Medical Sciences","University of Baghdad","University of Kentucky","National Institute of Integrative Medicine, Australia","Catholic Health Initiatives","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","UHFPO","University of Washington","Bill and Melinda Gates Foundation","University of New Mexico","ProgenaBiome","Big Corona Ltd.","Indonesia University","Institute of Cell Therapy","Kyiv City Clinical Hospital # 4","Institute for Research and Development of Medicinal and Food Plants of Guinea","International Brain Research Foundation","Ina-Respond","Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia","South Valley University","St. Francis Hospital, New York","Kayseri City Hospital","Yaounde Central Hospital","Corpometria Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Azithromycin is a macrolide antibiotic that is used to treat a number of bacterial infections. It functions by binding the 50S subunit of the bacterial ribosome, thus inhibiting the translation of mRNA. Interestingly, azithromycin may also have immunomodulatory capabilities which could help with viral clearance. It is thus being considered as a possible therapeutic against COVID-19.","show":true,"date":"2021-04-05 11:05:10.004363","type":"Treatment","fdaApproved":"FDA-approved since 2002, approved to treat many types of infections affecting the lungs, sinuses, skin, and other parts of the body","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-CD13","nameId":"-103"},{"sheetId":"CD14","name":"DIBI","technology":"Other","technologyDetails":"DIBI, iron-binding polymer","developmentStage":"Pre-Clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Chelation Partners"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.004399","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-CD14","nameId":"dibi-iron-binding-polymer"},{"sheetId":"CD15","name":"Brensocatib","technology":"Other","technologyDetails":"Brensocatib (INS1007)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["EudraCT 2020-001643-13","NCT04817332"],"organizations":["Insmed Inc.","University of Dundee","NHS Tayside","Insmed Incorporated"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Brensocatib is a reversible inhibitor of the dipeptidyl peptidase 1 (DPP1) enzyme. This enzyme is crucial for neutrophil-associated destruction and Inflammation. Since severe Covid-19 complications are characterized by neutrophil influx into the lungs, this therapeutic is hypothesized to mitigate this aspect of severe SARS-CoV-2 infections.","show":true,"date":"2021-04-05 11:05:10.004445","type":"Treatment","fdaApproved":"","updatedOrNew":"Updated","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD15","nameId":"brensocatib-ins1007"},{"sheetId":"CD16","name":"DAS181","technology":"Antivirals","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04324489","NCT04460547","NCT03808922","NCT04298060","x-NCT04354389"],"organizations":["Ansun Biopharma, Inc.","Renmin Hospital of Wuhan University","Qassim University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"DAS181 is a sialidase fusion protein antiviral that cleaves both the Neu5Ac alpha(2,3)- and Neu5Ac alpha(2,6)-Gal linkages of sialic acid from respiratory endothelial cell surfaces. These linkages are important for the cell attachment and entry of some viruses and thus it is being explored as a therapeutic option against SARS-CoV-2. ","show":true,"date":"2021-04-05 11:05:10.004497","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD16","nameId":"-105"},{"sheetId":"CD16","name":"GP1681","technology":"Other","technologyDetails":"GP1681, small molecule inhibitor of cytokine release","developmentStage":"Pre-Clinical","nextSteps":"","customClinicalPhase":"Preclinical","clinicalTrials":[],"organizations":["Quotient Sciences","CytoAgents"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.004527","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[0],"completedClinicalTrials":[],"phaseSortKey":0,"urlIdx":"d-CD16","nameId":"gp1681-small-molecule-inhibitor-of-cytokine-release"},{"sheetId":"CD17","name":"LSALT peptide","technology":"Other","technologyDetails":"Metablok","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":[],"organizations":["Arch Biopartners"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"LSALT is a small peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH. It functions by binding to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. Among other things, DPEP-1 is crucial for leukocyte adhesion and recruitment to areas of inflammation. Thus, this molecule is thought to be beneficial during SARS-CoV-2 infection as it will prevent excessive leukocyte migration to the lung and the associated inflammation that causes mild and severe COVID-19.","show":true,"date":"2021-04-05 11:05:10.004577","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|60","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD17","nameId":"metablok"},{"sheetId":"CD18","name":"Pacritinib","technology":"Other","technologyDetails":"pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR","developmentStage":"Clinical","nextSteps":"Phase 3 to start in May 2020, results expected by the end of 2020","customClinicalPhase":"Phase III","clinicalTrials":["NCT04404361"],"organizations":["CTI Biopharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.004633","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|358","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD18","nameId":"pacritinib-oral-kinase-inhibitor-with-specificity-for-jak2-irak1-and-csfir"},{"sheetId":"15","name":"Gimsilumab","technology":"Antibodies","technologyDetails":"Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04351243"],"organizations":["Kinevant Sciences GmbH","Roivant Sciences, Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Gimsilumab is a monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that helps create more white blood cells such as neutrophils, macrophages, and eosinophils. Recent scientific evidence suggests that GM-CSF may contribute to the immunopathology of COVID-19, and thus neutralizing this factor with an antibody may prove beneficial to those suffering from the disease. ","show":true,"date":"2021-04-05 11:05:10.004704","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|270","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0015","nameId":"gimsilumab-anti-granulocyte-macrophage-colony-stimulating-factor-monoclonal"},{"sheetId":"24","name":"Ravulizumab","technology":"Antibodies","technologyDetails":"Ultomiris (ravulizumab-cwvz), complement inhibitor","developmentStage":"Clinical","nextSteps":"Phase 3 to start in May 2020","customClinicalPhase":"Phase III/IV","clinicalTrials":["NCT04369469","NCT04390464","NCT04570397"],"organizations":["Alexion Pharmaceuticals","Cambridge University Hospitals NHS Foundation Trust","Brigham and Women's Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ravulizumab is a humanized monoclonal antibody that binds and prevents the activation of complement component 5 (C5), an important inflammatory component of the complement system.","show":true,"date":"2021-04-05 11:05:10.004772","type":"Treatment","fdaApproved":"FDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|270","Phase 4|1167","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3,4]},"inprogressClinicalTrials":[3,4],"completedClinicalTrials":[0,1,2],"phaseSortKey":6.5,"urlIdx":"d-0024","nameId":"ultomiris-ravulizumab-cwvz-complement-inhibitor"},{"sheetId":"52","name":"IC14","technology":"Antibodies","technologyDetails":"IC14, recombinant chimeric anti-CD14 monoclonal antibody","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04346277","NCT04391309"],"organizations":["Implicit Bioscience","University of Washington"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"IC14 is a recombinant chimeric monoclonal antibody that binds human CD14. Binding of CD14 by this antibody prevents its interaction with pathogen and damage-associated molecular patterns (PAMPs and DAMPs, respectively) which contribute to inflammation during SARS-CoV-2 infection. \n","show":true,"date":"2021-04-05 11:05:10.004837","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|300","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0052","nameId":"ic14-recombinant-chimeric-anti-cd14-monoclonal-antibody"},{"sheetId":"78","name":"Mesenchymal stem cells","technology":"Cell-based therapies","technologyDetails":"Mesenchymal stem cells; cyp-001; PrimePro, PrimeMSK; MesenCure; COVI-MSC","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["ChiCTR2000029990","NCT04315987","NCT04302519","NCT04288102","NCT04313322","NCT04273646","NCT04348435","NCT04349631","NCT04362189","NCT04339660","NCT04346368","NCT04390152","NCT04399889","NCT04400032","NCT04416139","NCT04429763","NCT04437823","NCT04444271","NCT04445220","NCT04445454","NCT04447833","NCT04451291","NCT04452097","NCT04456361","NCT04457609","NCT04461925","NCT04466098","NCT04467047","NCT04490486","NCT04492501","NCT04494386","NCT04522817","NCT04522986","NCT04524962","NCT04525378","NCT04535856","NCT04537351","NCT04573270","NCT04615429","NCT04611256","NCT04625738","NCT04629105","NCT04684602","NCT04716998","NCT04713878","NCT04728698","NCT04780685","NCT04798066","x-NCT04341610","x-NCT04293692"],"organizations":["Numerous trials with global research sponsors","Azidus Brasil","CAR-T (Shanghai) Biotechnology Co., Ltd.","Stem Cells Arabia","Beijing 302 Hospital","Huoshenshan Hospital","Maternal and Child Health Hospital of Hubei Province","General Hospital of Central Theater Command","VCANBIO CELL & GENE ENGINEERING CORP.","Wuhan Union Hospital","Wuhan Hamilton Bio-technology Co.","Hope Biosciences","The Marcus Foundation","Duke University","Ottawa Hospital Research Institute","Stem Cell Network","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Trustem","Fundación Universitaria de Ciencias de la Salud","Hospital de San Jose","Hospital Infantil Universitario de San Jose","Jinnah Hospital","Johns Hopkins University","Armed Forces Bone Marrow Transplant Center, Pakistan","Pak Emirates Military Hospital","Sentien Biotechnologies, Inc.","University of Liege","Uppsala University","University Health Network, Toronto","Oslo University Hospital","Baylx Inc.","Instituto de Medicina Regenerativa","Indonesia University","Institute of Cell Therapy","Kyiv City Clinical Hospital # 4","Masonic Cancer Center, University of Minnesota","Hospital de Clinicas de Porto Alegre","University of Miami","UNICEF","Pak Emirates Military Hospital Rawalpindi","Restem, LLC.","Caladrius Biosciences, Inc.","Rohto Pharmaceutical Co., Ltd.","Cartesian Therapeutics","D'Or Institute for Research and Education","Ina-Respond","National Institute of Health Research and Development, Ministry of Health Republic of Indonesia","Daewoong Pharmaceutical Co. LTD.","Cynata Therapeutics Limited","Cerebral Palsy Alliance Research Institute","Thomas Advanced Medical LLC","HeartStem Institute","Puerta de Hierro University Hospital","Instituto de Terapia Celular","Central Hospital, Nancy, France","Longeveron LLC","NuStem","BonusBio Group Ltd","Kanuni Sultan Suleyman Training and Research Hospital","Sorrento Therapeutics, Inc.","Stemedica Cell Technologies, Inc.","bioRASI, LLC"],"funder":"","publishedResults":["Aging and Disease|http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml","ChinaXiv|http://chinaxiv.org/abs/202002.00084"],"relatedUse":["Aging and Disease|http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml","ChinaXiv|http://chinaxiv.org/abs/202002.00084"],"countries":[],"description":"Mesenchymal stem cells are multipotent stromal cells that come from a diverse array of tissues (bone marrow, cord cells, molar cells, amniotic fluid, and adipose tissue) can differentiate into a diverse range of cell lineages. They have been shown to have immunomodulatory and tissue regenerative effects and thus are theorized to reduce or reverse the pathological lung changes and inhibit the cell-mediated immune-inflammatory response caused by SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.005004","type":"Treatment","fdaApproved":"Unknown","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|104","Phase 1/2|5060","Phase 2|348","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|48"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-0078","nameId":"mesenchymal-stem-cells-cyp-001-primepro-primemsk-mesencure-covi-msc"},{"sheetId":"72","name":"Molnupiravir","technology":"Antivirals","technologyDetails":"EIDD-2801, oral ribonucleoside analog, Molnupiravir, MK-4482","developmentStage":"Clinical","nextSteps":"Phase 1 started April 2020","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04392219","NCT04405739","NCT04405570","NCT04575584","NCT04575597","NCT04746183"],"organizations":["Ridgeback Biotherapeutics","Drug Innovation Ventures at Emory (DRIVE)","Merck Sharp & Dohme Corp.","University of Liverpool","University of Southampton","Liverpool School of Tropical Medicine","Lancaster University","Liverpool University Hospitals NHS Foundation Trust"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Molnupiravir (Formerly MK-4482 and EIDD-2801) is an orally bioavailable prodrug of the synthetic nucleoside derivative N4-hydroxycytidine. It, therefore, exerts its antiviral function through the introduction of copying errors during viral RNA replication. Importantly, it has already been shown to demonstrate its antiviral effects against SARS-CoV-2 in vitro, and against the related SARS-CoV-1 in in vivo animal models. ","show":true,"date":"2021-04-05 11:05:10.005118","type":"Treatment","fdaApproved":"N/A","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|122","Phase 1/2|NA","Phase 2|124","Phase 2/3|2750","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-0072","nameId":"eidd-2801-oral-ribonucleoside-analog-molnupiravir-mk-4482"},{"sheetId":"117","name":"Interferon beta-1a*","technology":"Other","technologyDetails":"Traumakine; Rebif; SNG001","developmentStage":"Clinical","nextSteps":"Added to REMAP-CAP trial","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT02735707","NCT04315948","NCT04350671","NCT04343768","NCT04350684","NCT04385095","NCT04449380","NCT04460547","NCT01126177","NCT04492475","NCT04324463","NCT04521400","NCT04552379","NCT04647669","NCT04732949","EudraCT 2015-002340-14","EudraCT 2020-001023-14"],"organizations":["REMAP-CAP global trial","DisCoVeRy","Shahid Beheshti University of Medical Sciences","Synairgen Research Ltd.","IRCCS San Raffaele","Qassim University","National Institute of Allergy and Infectious Diseases","Pontificia Universidad Catolica de Chile","Telethon Kids Institute","The University of The West Indies"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Interferon beta-1a is an interferon-family cytokine produced by mammalian cells that helps to balance pro- and anti-inflammatory environments.","show":true,"date":"2021-04-05 11:05:10.005206","type":"Treatment","fdaApproved":"FDA-approved since 2002, approved to treat multiple sclerosis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0117","nameId":"traumakine-rebif-sng001"},{"sheetId":"120","name":"Pegylated Interferon Lambda","technology":"Other","technologyDetails":"Peginterferon lambda; Peginterferon Lambda-1a","developmentStage":"Clinical","nextSteps":"Phase 2 began in April 2020","customClinicalPhase":"Phase II","clinicalTrials":["NCT04331899","NCT04354259","NCT04344600","NCT04388709","NCT04534673"],"organizations":["Eiger BioPharmaceuticals, Inc.","Stanford University","University Health Network, Toronto","Johns Hopkins University","Icahn School of Medicine at Mount Sinai","Soroka University Medical Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Pegylated Interferon Lambda is a modified version of the antiviral protein interferon lambda. The modification includes the attachment of an inert and hydrophilic polymer known as polyethylene glycol (PEG) to increase the half-life of the protein in the blood as well as reduce the immunogenicity of the attached protein. The interferon lambda family of cytokines are well known to have strong anti-viral effects by activating the  Janus kinases (JAK)/signal transducer and activator of transcription proteins (STATs) leading to the expression of numerous interferon-stimulated genes with anti-viral effects.","show":true,"date":"2021-04-05 11:05:10.005261","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|490","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-0120","nameId":"peginterferon-lambda-peginterferon-lambda-1a"},{"sheetId":"138","name":"Dipyridamole","technology":"Other","technologyDetails":"dipyridamole (Persantine), anticoagulant","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04391179","NCT04410328","NCT04424901","NCT04433078"],"organizations":["Yogendra Kanthi","University of Michigan","Rutgers, The State University of New Jersey","Boehringer Ingelheim","UConn Health","Temple University"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.02.27.20027557"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.02.27.20027557"],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.005338","type":"Treatment","fdaApproved":"FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|80","Phase 2/3|NA","Phase 3|132","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-0138","nameId":"dipyridamole-persantine-anticoagulant"},{"sheetId":"145","name":"Baricitinib*","technology":"Other","technologyDetails":"Olumiant (baricitinib), Janus kinase (JAK) inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04321993","NCT04320277","NCT04340232","NCT04345289","NCT04358614","NCT04362943","NCT04346147","NCT04345289","NCT04365764","NCT04373044","NCT04390464","NCT04393051","NCT04399798","NCT04401579","NCT04421027","NCT04640168","NCT04693026","EudraCT 2020-001246-18"],"organizations":["Nova Scotia Health Authority","Dalhousie University","Hospital of Prato","University of Colorado","Hospital of Prato","Hvidovre University Hospital","Complejo Hospitalario Universitario de Albacete","Hospital Universitario de Fuenlabrada","CCAP","University of Southern California","National Cancer Institute (NCI)","Groupe Hospitalier Pitie-Salpetriere","Centre Hospitalier Intercommunal Robert Ballanger","Centre Hospitalier Intercommunal Montfermeil-Le Raincy","CMC Ambroise Paré","Cambridge University Hospitals NHS Foundation Trust","Azienda Ospedaliero, Universitaria Pisana","IRCCS Policlinico S. Matteo","National Institute of Allergy and Infectious Diseases (NIAID)","Assistance Publique - Hôpitaux de Paris","Eli Lilly and Company","M Abdur Rahim Medical College and Hospital","First affiliated Hospital Xi'an Jiaoting University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Baricitinib is an inhibitor of Janus kinases 1 and 2 (JAK1/2). This inhibition prevents the activation of the signal transducers and activators of transcription (STAT) signaling pathway and decreases the production of inflammatory cytokines. Since pathology in severe cases of COVID-19 is partially due to an overactive inflammatory response, this therapeutic may help in this circumstance. ","show":true,"date":"2021-04-05 11:05:10.005424","type":"Treatment","fdaApproved":"FDA-approved since 2018, approved to treat rheumatoid arthritis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|401","Phase 2/3|292","Phase 3|500","Phase 4|NA","Phase NA|288"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-0145","nameId":"olumiant-baricitinib-janus-kinase-jak-inhibitor"},{"sheetId":"148","name":"Low Molecular Weight Heparin*","technology":"Other","technologyDetails":"low molecular weight heparin, anticoagulant, enoxaparin, dalteparin, fondaparinux and tinzaparin; NADROPARIN; Bemiparin; Apixaban","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04344756","NCT04345848","NCT04367831","NCT04359212","NCT04366960","NCT04362085","NCT04351724","NCT04380818","NCT04359277","NCT04373707","NCT04354155","NCT04377997","NCT04372589","NCT04374539","NCT04393805","NCT04401293","NCT04400799","NCT04406389","NCT04409834","NCT04412304","NCT04420299","NCT04427098","NCT04394182","NCT04461925","NCT04466670","NCT04483830","NCT04485429","NCT04486508","NCT04487990","NCT04490239","NCT04492254","NCT04505774","NCT04507282","NCT04508439","NCT04511923","NCT04512079","NCT02735707","NCT04530578","NCT04528888","NCT04542408","NCT04545541","NCT04584580","NCT04593654","NCT04604327","NCT04600141","NCT04635241","NCT04640181","NCT04650087","NCT04646655","NCT04655586","NCT04723563","NCT04736901","NCT04730856","NCT04746339","NCT04743011","NCT04787510","NCT04801940","NCT04808882","EudraCT 2020-001736-95","EudraCT 2020-001739-28","x-NCT04520620"],"organizations":["Assistance Publique - Hôpitaux de Paris","University Hospital, Geneva","Columbia University","Quovadis Associazione","Niguarda Hospital","St. Michael's Hospital, Toronto","NYU Langone Health","ACOVACT","Grupo de Investigación Clínica en Oncología Radioterapia","University of Manitoba","University Health Network, Toronto","Hopital Montfort","Hamilton Health Sciences Corporation","University Hospital Southampton NHS Foundation Trust","Quovadis Associazione","University of Padova","Northwell Health","University of Zurich","University Hospital Inselspital, Berne","University Hospital, Geneva","Centre Hospitalier Universitaire Vaudois","University Hospital, Basel, Switzerland","Oncology Institute of Southern Switzerland","Clinica Luganese Moncucco","Weill Medical College of Cornell University","The TIMI Study Group","UZLeuven","Karolinska Institutet","Fundación de investigación HM","Syntax for Science, S.L","Institute of Cell Therapy","Kyiv City Clinical Hospital # 4","University of Sao Paulo General Hospital","Clinedem","Alfasigma S.p.A.","D'Or Institute for Research and Education","Rajaie Cardiovascular Medical and Research Center","University of Mississippi, Oxford","Thrombosis Research Institute","Sanofi","National Heart, Lung, and Blood Institute","University of Pittsburgh","Bursa Postgraduate Hospital","Hospital Regional de Alta especialidad de Ixtapaluca","University College Hospital Galway","Icahn School of Medicine at Mount Sinai","UMC Utrecht","Australian and New Zealand Intensive Care Research Centre","Medical Research Institute of New Zealand","Unity Health","Berry Consultants","Global Coalition for Adaptive Research","University of Pittsburgh Medical Center","Clinica San Camilo, Argentina","University of Modena","Universitätsklinikum Hamburg-Eppendorf","Australian National University","Ain Shams University","Clinica Universidad de Navarra, Universidad de Navarra","Conselho Nacional de Desenvolvimento Científico e Tecnológico","Australian National University","Helwan University","Clinica San Camilo, Argentina","St. David's HealthCare","Duke University","ASST Fatebenefratelli Sacco","ARCA Biopharma, Inc.","Colorado Prevention Center","Frederick Health","Misr International University","Hospital Universitario Infanta Leonor","Brazilian Clinical Research Institute","Hospital Israelita Albert Einstein","Hospital do Coracao","UPECLIN HC FM Botucatu Unesp","Universidade do Vale do Sapucai","Apsen Farmaceutica S.A.","Pfizer","Dermadia","Methodos Laboratory","Biofarma","University Hospital, Ioannina","Cambridge University Hospitals NHS Foundation Trust","University of Liverpool","The University of Cambridge"],"funder":"","publishedResults":["medRxiv|https://doi.org/10.1101/2020.03.28.20046144","medRxiv|https://doi.org/10.1101/2020.04.15.20067017"],"relatedUse":["medRxiv|https://doi.org/10.1101/2020.03.28.20046144","medRxiv|https://doi.org/10.1101/2020.04.15.20067017"],"countries":[],"description":"Low Molecular Weight Heparin is an anticoagulant that irreversibly inactivates thrombin and other activated clotting factors. There is evidence that severe cases of COVID-19 suffer from an important infection-related coagulopathy and from elevated risks of thrombosis and thus anticoagulants may have positive effects here. ","show":true,"date":"2021-04-05 11:05:10.005570","type":"Treatment","fdaApproved":"FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|808","Phase 2/3|NA","Phase 3|4374","Phase 4|100","Phase NA|80"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-0148","nameId":"low-molecular-weight-heparin-anticoagulant-enoxaparin-dalteparin-fondaparinux-and-tinzaparin-nadroparin-bemiparin-apixaban"},{"sheetId":"CD11","name":"Famotidine","technology":"Other","technologyDetails":"Pepcid (famotidine), histamine-2 (H2) receptor antagonist","developmentStage":"Clinical","nextSteps":"Phase 2 study underway in April 2020","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04370262","NCT04389567","NCT04504240","NCT04545008","NCT04621149","NCT04724720"],"organizations":["Northwell Health","Cold Spring Harbor Laboratory","Chattogram General Hospital","Prisma Health-Upstate","Clemson University","Profact, Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Famotidine is a histamine H2 antagonist that reduces acid secretion in the stomach by blocking H2 receptors located on parietal cells. Interestingly, famotidine was also found to have strong binding potential against the papain-like protease (Plpro) of SARS-CoV-2 during an in silico screen against the virus. Since Plpro is an early acting protease responsible for the initial processing of the SARS CoV2 polyprotein into active subunits and is implicated in early infection phase inhibition of innate (interferon) immune responses, a compound that interacts with and inhibits this protease would be a valuable therapeutic against COVID-19.","show":true,"date":"2021-04-05 11:05:10.005667","type":"Treatment","fdaApproved":"FDA-approved since 1986, approved to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, pathological hypersecretory conditions, and to reduce the risk of duodenal ulcer recurrence","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|1170","Phase 4|NA","Phase NA|10"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-CD11","nameId":"pepcid-famotidine-histamine-2-h2-receptor-antagonist"},{"sheetId":"CD24","name":"Alvelestat*","technology":"Other","technologyDetails":"Alvelestat (MPH996)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04396067","NCT04539795"],"organizations":["Kafrelsheikh University","Damietta University","University of Alabama at Birmingham","Mereo BioPharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"MPH996 is a potent, selective, and reversible, oral inhibitor of human neutrophil elastase (NE). During severe manifestations of COVID-19, neutrophils are some of the first cells to be recruited to the lungs, and they are known to contribute to the detrimental inflammatory effects. Thus, an inhibitor of NE is hypothesized to reduce lung damage and may slow disease progression in this circumstance.","show":true,"date":"2021-04-05 11:05:10.005732","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|15","Phase 2|360","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD24","nameId":"alvelestat-mph996"},{"sheetId":"CD25","name":"ABX464","technology":"Other","technologyDetails":"ABX-464","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04393038"],"organizations":["Abivax S.A."],"funder":"","publishedResults":["https://www.nature.com/articles/s41598-018-37813-y|https://www.nature.com/articles/s41598-018-37813-y"],"relatedUse":["https://www.nature.com/articles/s41598-018-37813-y|https://www.nature.com/articles/s41598-018-37813-y"],"countries":[],"description":"ABX464 is a small molecule that binds to the cap binding complex which is required for efficient cellular and viral pre-mRNA splicing. This molecule thus has proposed anti-viral activity against some viruses and anti-inflammatory properties and is hypothesized to be beneficial to those suffering from SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.005790","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|1034","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD25","nameId":"abx-464"},{"sheetId":"CD26","name":"FT516","technology":"Cell-based therapies","technologyDetails":"Natural killer cell-based therapy","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04363346"],"organizations":["Masonic Cancer Center","University of Minnesota"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"FT516 is an off-the-shelf cryopreserved natural killer (NK) cell product derived from induced pluripotent stem cells. Not only are NK cells naturally anti-viral, but these cells were also transduced with a high affinity, non-cleavable antibody receptor on their cell surface, which is expected to enhance their anti-viral effects by binding the naturally occurring anti-SARS-CoV-2 antibodies that the body produces during infection.","show":true,"date":"2021-04-05 11:05:10.005838","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|12","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD26","nameId":"natural-killer-cell-based-therapy-107"},{"sheetId":"CD27","name":"Natural Killer T cells","technology":"Cell-based therapies","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04280224"],"organizations":["Xinxiang Medical University","First Affiliated Hospital of Xinjiang Medical University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Natural killer (NK) cells are innate immune cells that kill virally infected and cancerous cells. They function primarily by recognizing membrane proteins that these unhealthy cells express, and then releasing small granules that contain cytotoxic proteins. These proteins cause the cells to undergo programmed cell death (apoptosis) which prevents viral spread and tumor growth.","show":true,"date":"2021-04-05 11:05:10.005903","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|30","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD27","nameId":"-108"},{"sheetId":"CD28","name":"Allogenic Natural Killer T cells","technology":"Cell-based therapies","technologyDetails":"agenT-797; KDS-1000","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04344548","NCT04582201","NCT04797975"],"organizations":["Universidad Nacional de Colombia","Fundación Salud de los Andes","AgenTus Therapeutics, Inc.","Kiadis Pharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Allogenic Natural killer (NK) cells are innate immune cells that kill virally infected and cancerous cells, and they originate in the same host that they are therapeutically administered to. NK cells function primarily by recognizing membrane proteins that unhealthy cells express, and then releasing small granules that contain cytotoxic proteins. These proteins cause the cells to undergo programmed cell death (apoptosis) which prevents viral spread and tumor growth.","show":true,"date":"2021-04-05 11:05:10.005944","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|10","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD28","nameId":"agent-797-kds-1000"},{"sheetId":"CD29","name":"Leflunomide","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04361214","NCT04532372"],"organizations":["University of Chicago","City of Hope Medical Center","National Cancer Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Leflunomide is an immunomodulatory drug that functions by inhibiting dihydroorotate dehydrogenase (DHODH) in mitochondria. DHODH plays a key role in uridine monophosphate synthesis, which is required for the creation of nucleic acids within cells. Hence, leflunomide inhibits the reproduction of rapidly dividing cells, especially lymphocytes, which are drivers of pathogenic inflammation in COVID-19.","show":true,"date":"2021-04-05 11:05:10.006051","type":"Treatment","fdaApproved":"FDA-approved since 1998, approved to treat adult moderate to severe rheumatoid arthritis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|20","Phase 1/2|30","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD29","nameId":"-109"},{"sheetId":"CD30","name":"Dociparastat sodium","technology":"Other","technologyDetails":"DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04389840"],"organizations":["Chimerix"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Dociparastat sodium is a glycosaminoglycan derivative of heparin. Heparin is an anticoagulant that irreversibly inactivates thrombin and other activated clotting factors. There is evidence that severe cases of COVID-19 suffer from an important infection-related coagulopathy and from elevated risks of thrombosis and thus anticoagulants may have positive effects here.\n","show":true,"date":"2021-04-05 11:05:10.006088","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|524","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD30","nameId":"dstat-dociparstat-sodium-glycosaminoglycan-derivative-of-heparin"},{"sheetId":"CD31","name":"EDP1815","technology":"Other","technologyDetails":"EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04393246","NCT04488575"],"organizations":["Cambridge University Hospitals NHS Foundation Trust","Evelo Biosciences, Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. This strain has been shown to have immunomodulatory effects, and since most tissue damage following infection with SARS-CoV-2 appears to be due to an exaggerated host immune response, this therapeutic may prove beneficial to those infected.","show":true,"date":"2021-04-05 11:05:10.006157","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|60","Phase 2/3|1407","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD31","nameId":"edp1815-is-an-orally-administered-pharmaceutical-preparation-of-a-single-strain-of-prevotella-histicola-isolated-from-the-duodenum-of-a-human-donor"},{"sheetId":"CD32","name":"Almitrine","technology":"Other","technologyDetails":"improves oxygenation (without combination with iNO) by selective pulmonary vasoconstriction of precapillary pulmonary arteries perfusing lung areas exposed to a hypoxic challenge with a slight increase in mean arterial pulmonary.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04380727","NCT04357457","EudraCT 2020-001909-22"],"organizations":["Central Hospital, Nancy, France","Assistance Publique - Hôpitaux de Paris","Centre Hospitalier de Chartres"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Almitrine is a diphenylmethylpiperazine derivative classified as a respiratory stimulant that functions by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. This leads to increased arterial oxygen tension and decreased arterial carbon dioxide tension in patients. In severe COVID-19 pulmonary failure, the profound hypoxemia is mainly related to pulmonary vasodilation, and thus this therapeutic may be a pharmacological option used in standard care to improve oxygenation.","show":true,"date":"2021-04-05 11:05:10.006260","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|212","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD32","nameId":"improves-oxygenation-without-combination-with-ino-by-selective-pulmonary-vasoconstriction-of-precapillary-pulmonary-arteries-perfusing-lung-areas-exposed-to-a-hypoxic-challenge-with-a-slight-increase-"},{"sheetId":"CD33","name":"Bemcentinib","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["EudraCT 2020-001736-95"],"organizations":["BerGenBio","University Hospital Southampton NHS Foundation Trust"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Bemcentinib is a small molecule inhibitor of the surface protein AXL kinase. It functions by binding to the intracellular catalytic kinase domain and inhibiting AXL kinase activity. This protein is one of several cell surface receptors used by enveloped viruses to enter cells, and thus its inhibition may prevent SARS-CoV-2 infection. Also, Bemcentinib prevents inhibition of Type I Interferon, a protein vital to anti-viral defence, again suggesting valuable utility in the treatment of SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.006391","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|212","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD33","nameId":"-110"},{"sheetId":"CD34","name":"MEDI3506","technology":"Antibodies","technologyDetails":"MEDI3506, monoclonal antibody targeting interleukin 33","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["EudraCT 2020-001736-95"],"organizations":["University Hospital Southampton NHS Foundation Trust"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"MEDI3506 is a human immunoglobulin (Ig) G1 monoclonal antibody (mAb) against interleukin (IL)-33. Biologically, IL-33 is a cytokine belonging to the IL-1 superfamily and induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. During hyperinflammatory conditions, such as those observed in COVID-19, IL-33 expression may be increased, and thus neutralizing it may be beneficial to those suffering from this disease. ","show":true,"date":"2021-04-05 11:05:10.006428","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD34","nameId":"medi3506-monoclonal-antibody-targeting-interleukin-33"},{"sheetId":"CD35","name":"Zilucoplan","technology":"Other","technologyDetails":"(complement C5 inhibitor)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04382755","EudraCT 2020-001736-96"],"organizations":["UCB Pharma","University Hospital, Ghent","University Hospital Southampton NHS Foundation Trust"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Zilucoplan is a synthetic macrocyclic peptide inhibitor of complement C5 with potential anti-inflammatory and cell-protective activities. It functions by binding to a unique site on the protein, which blocks its cleavage into C5a and C5b and prevents the C5b-dependent assembly of the membrane-attack complex (MAC). As a therapeutic, Zilucoplan may inhibit acute lung injury post-COVID-19, and promote lung repair mechanisms by reducing C5a-mediated inflammation. ","show":true,"date":"2021-04-05 11:05:10.006484","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD35","nameId":"complement-c5-inhibitor"},{"sheetId":"CD36","name":"Ulinastatin","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04393311"],"organizations":["Stanford University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.006533","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|150","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD36","nameId":"-111"},{"sheetId":"CD37","name":"AT-527","technology":"Antivirals","technologyDetails":"AT-527 is a novel modified guanosine nucleotide prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04396106","NCT04709835"],"organizations":["Atea Pharmaceuticals, Inc.","Hoffmann-La Roche"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.006570","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|180","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD37","nameId":"at-527-is-a-novel-modified-guanosine-nucleotide-prodrug-inhibitor-of-the-hepatitis-c-virus-hcv-ns5b-polymerase"},{"sheetId":"CD38","name":"Continuous Positive Airway Pressure Helmet","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04395807","NCT04381923","NCT04326075"],"organizations":["Region Skane","Lund University","University of Pennsylvania","Mario Negri Institute for Pharmacological Research"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.006663","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|1220"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-CD38","nameId":"-112"},{"sheetId":"CD39","name":"AMY-101","technology":"Other","technologyDetails":"a potent C3 inhibitor","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04395456"],"organizations":["Amyndas Pharmaceuticals S.A."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.006705","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|144","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD39","nameId":"a-potent-c3-inhibitor"},{"sheetId":"CD40","name":"Levilimab","technology":"Antibodies","technologyDetails":"Levilimab (BCD-089)","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04397562"],"organizations":["Biocad"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Levilimab is a fully human antibody acting against the interleukin-6 receptor (IL-6R). Interleukin 6 is a cytokine relevant to many inflammatory diseases including COVD-19, and thus blocking its effects may be beneficial to those suffering from the disease.","show":true,"date":"2021-04-05 11:05:10.006759","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|204","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD40","nameId":"levilimab-bcd-089"},{"sheetId":"CD41","name":"Mavrilimumab","technology":"Antibodies","technologyDetails":"KPL-301","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04397497","NCT04399980","NCT04447469","NCT04463004","NCT04492514"],"organizations":["Ospedale San Raffaele","The Cleveland Clinic","Kiniksa Pharmaceuticals, Ltd.","Virginia Commonwealth University","University of Cincinnati"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. GM-CSF is a cytokine that helps create more white blood cells such as neutrophils, macrophages, and eosinophils. Recent scientific evidence suggests that GM-CSF may contribute to the immunopathology of COVID-19, and thus neutralizing this factor with an antibody may prove beneficial to those suffering from the disease. ","show":true,"date":"2021-04-05 11:05:10.006817","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|110","Phase 2/3|573","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD41","nameId":"kpl-301"},{"sheetId":"CD42","name":"LungFit","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04397692","NCT04456088","NCT04606407"],"organizations":["Beyond Air Ltd"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"The LungFit system can generate nitric oxide from ambient air and deliver it to the lungs. Nitric Oxide (NO) is a small endogenously produced molecule with known antimicrobial and antiviral effects. It is thus thought that the delivery of NO to the lungs may help with infections with SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.006878","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|100","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD42","nameId":"-113"},{"sheetId":"CD43","name":"GNS651","technology":"Other","technologyDetails":"Chloroquine Analog","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04637828","x-NCT04333914"],"organizations":["Genoscience Pharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"GNS651 is a chloroquine analog and an inhibitor of autophagy. It is believed that inhibition of autophagy may prevent the SARS-CoV-2 virus from gaining entry into the cell, and thus prevent its pathogenic effects. GNS561 has been found to be 10- to 50-fold more potent than hydroxychloroquine and has minor manageable adverse events.\nNOTE: This trial is currently suspended (NCT04333914)","show":true,"date":"2021-04-05 11:05:10.006913","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|178","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD43","nameId":"chloroquine-analog"},{"sheetId":"CD44","name":"Carrimycin","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III/IV","clinicalTrials":["NCT04286503","NCT04672564"],"organizations":["Beijing YouAn Hospital","Shenyang Tonglian Group Co., Ltd.","Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences","Huangshi Central Hospital","Shenyang Pharmaceutical University","First Affiliated Hospital of Chongqing Medical University","The Second Affiliated Hospital of Harbin Medical University","No.2 People's Hospital of Fuyang City","First Affiliated Hospital Bengbu Medical College","Renmin Hospital of Wuhan University","The sixth people's hospital of Shenyang","Nanyang Central Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Carrimycin is a macrolide antibiotic with effects against some gram-positive bacteria and in vitro effects on Mycobacterium tuberculosis. Its mode of action against viruses is unknown at this time. ","show":true,"date":"2021-04-05 11:05:10.006964","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|520","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3,4]},"inprogressClinicalTrials":[3,4],"completedClinicalTrials":[0,1,2],"phaseSortKey":6.5,"urlIdx":"d-CD44","nameId":"-114"},{"sheetId":"CD45","name":"Levamisole*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04331470","NCT04360122","NCT04383717"],"organizations":["Fasa University of Medical Sciences","Ain Shams University","Cairo University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Levamisole is an antiparasitic agent that also has immunomodulatory effects. Interestingly, it appears to restore depressed immune function rather than to stimulate response to above-normal levels. Levamisole can stimulate the formation of antibodies to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte, and macrophage functions including phagocytosis and chemotaxis, and increase neutrophil mobility, adherence, and chemotaxis. For these reasons, it is being considered as a therapeutic to treat an infection with SARS-CoV-2.","show":true,"date":"2021-04-05 11:05:10.007004","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|30","Phase 3|160","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD45","nameId":"-115"},{"sheetId":"CD46","name":"Candesartan*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04351724","NCT04394117","x-NCT04330300"],"organizations":["Medical University of Vienna","Kaiser Franz Josef Hospital","SMZ-Ost Donauspital","Otto Wagner Hospital","Hospital Hietzing","Wilhelminenspital Vienna","Medical University Innsbruck","National University of Ireland, Galway, Ireland","The George Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Candesartan is an angiotensin II receptor blocker that functions by binding to the type-1 angiotensin II receptor. It is hypothesized that a buildup of angiotensin II interacting with its receptor drives COVID-19 pathology by increasing pulmonary vascular permeability. Blocking this interaction would help mitigate this facet of COVID-19 disease, and thus this therapeutic is currently being tested in clinical trials.","show":true,"date":"2021-04-05 11:05:10.007041","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-CD46","nameId":"-116"},{"sheetId":"CD47","name":"Angiotensin 1-7","technology":"Other","technologyDetails":"TXA127; USB002","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04332666","NCT04401423","NCT04570501","NCT04605887","NCT04633772","NCT04778059"],"organizations":["Erasme University Hospital","Fonds Erasme pour la Recherche Médicale","Columbia University","Stanford University","Rambam Health Care Campus","Federal University of Minas Gerais","Angitec","US Biotest, Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Angiotensin (1-7) is a heptapeptide vasodilator agent that plays important roles in cardiovascular organs, such as heart, blood vessels, and kidneys. It is downregulated in COVID-19 patients and thus therapeutic addition to those suffering from this disease may potentially improve respiratory function in this setting. Additionally, Angiotensin (1-7) has been shown to have antioxidant and anti-inflammatory effects which may prove beneficial during severe SARS-CoV-2 infections.","show":true,"date":"2021-04-05 11:05:10.007078","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|100","Phase 2/3|60","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-CD47","nameId":"txa127-usb002"},{"sheetId":"CD48","name":"Virus-Specific T cells","technology":"Cell-based therapies","technologyDetails":"IMP","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04401410","NCT04457726","NCT04578210","NCT04742595","NCT04762186","NCT04765449"],"organizations":["Baylor College of Medicine","Center for Cell and Gene Therapy, Baylor College of Medicine","The Methodist Hospital System","AlloVir","KK Women's and Children's Hospital","Duke-NUS Graduate Medical School","National University Hospital, Singapore","Singapore General Hospital","Sengkang General Hospital","Changi General Hospital","M.D. Anderson Cancer Center","Universitätsklinikum Köln","ZKS Köln","MMH Institute for Transfusion Medicine","Miltenyi Biomedicine GmbH","Thomas Jefferson University","Tevogen Bio Inc"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"T cells are important members of the adaptive immune system, including the response to viruses. This therapeutic utilizes T cells from individuals who have recovered from COVID-19 and administers them to infected patients with hopes that they will clear the virus faster and not require mechanical ventilation.","show":true,"date":"2021-04-05 11:05:10.007135","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|20","Phase 1/2|18","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD48","nameId":"imp"},{"sheetId":"CD49","name":"APL-9","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04402060"],"organizations":["Apellis Pharmaceuticals","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"APL-9 is a PEGylated peptide that inhibits the inflammatory complement C3 molecule. It is thought that SARS-CoV-2 activates the complement system and increases inflammation in the lungs. This therapeutic blocks activation of part of the complement pathway (C3), and thus may reduce inflammation in the lungs, which is a strong pathological driver of COVID-19. \n","show":true,"date":"2021-04-05 11:05:10.007179","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|66","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD49","nameId":"-117"},{"sheetId":"CD50","name":"DNases","technology":"Other","technologyDetails":"pulmozyme; rhDNase I; Tigerase; Dornase Alfa","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["EudraCT 2020-001492-33","NCT04402944","NCT04402970","NCT04359654","NCT04387786","NCT04355364","NCT04409925","NCT04432987","NCT04445285","NCT04459325","NCT04541979"],"organizations":["Hôpital Fondation Adolphe de Rothschild","University Hospital, Strasbourg, France","Centre Hospitalier Régional Metz-Thionville","Boston Children’s Hospital","Brigham and Women's Hospital","University of Missouri-Columbia","University College, London","Feinstein Institute for Medical Research","Cold Spring Harbor Laboratory","Northwell Health","Exactis Innovation","Jewish General Hospital","Hamilton Health Sciences Corporation","McGill University Health Centre/Research Institute of the McGill University Health Centre","Acibadem University","The Scientific and Technological Research Council of Turkey","University of South Alabama","AO GENERIUM","Region Skane"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Dornase alfa is a purified solution of recombinant human deoxyribonuclease I, an enzyme that selectively cleaves DNA. During COVID-19 hyperactive immune response, there is a deposition of cell-free DNA, primarily due to neutrophil extracellular traps (NETs). This buildup can increase the rigidity of mucus, clog airways, and exacerbate the development of acute respiratory distress. This therapy may thus aid in the degradation of DNA and help to prevent and reduce the time to recovery.","show":true,"date":"2021-04-05 11:05:10.007229","type":"Treatment","fdaApproved":"FDA-approved since 1993, approved for management of cystic fibrosis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|25","Phase 1/2|NA","Phase 2|60","Phase 2/3|NA","Phase 3|120","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-CD50","nameId":"pulmozyme-rhdnase-i-tigerase-dornase-alfa"},{"sheetId":"CD51","name":"TD-0903","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["EudraCT 2020-001807-18","NCT04350736","NCT04402866"],"organizations":["Theravance Biopharma"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"TD-0903 is a lung-selective Janus kinase inhibitor (JAKi). JAK is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals. Since severe lung pathologies during COVID-19 arise due to a cytokine storm, it is hypothesized that this therapy may be beneficial by damping the cytokine response during severe SARS-CoV-2 infections. ","show":true,"date":"2021-04-05 11:05:10.007287","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|54","Phase 1/2|NA","Phase 2|159","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD51","nameId":"-118"},{"sheetId":"CD52","name":"Secukinumab","technology":"Antibodies","technologyDetails":"Human IgG1κ monoclonal antibody that binds to the protein interleukin-17A","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["EudraCT 2020-001246-18","NCT04403243"],"organizations":["Assistance Publique - Hôpitaux de Paris","Lomonosov Moscow State University Medical Research and Educational Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.007325","type":"Treatment","fdaApproved":"FDA-approved since 2016, approved to treat moderate to severe plaque psoriasis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD52","nameId":"human-igg1k-monoclonal-antibody-that-binds-to-the-protein-interleukin-17a"},{"sheetId":"CD53","name":"Ozanimod","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04405102"],"organizations":["Celgene","Bristol-Myers Squibb","Laval University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ozanimod is a sphingosine-1-phosphate (S1P) receptor agonist that causes sequestering of lymphocytes to peripheral lymphoid organs and away from sites of inflammation. Since COVID-19 disease pathogenesis arises in part from a hyperinflammatory response, this therapeutic is hypothesized to reduce the morbidity and mortality associated with SARS-CoV-2 infection. ","show":true,"date":"2021-04-05 11:05:10.007400","type":"Treatment","fdaApproved":"FDA-approved since 2020, approved to treat relapsing forms of multiple sclerosis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|48","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD53","nameId":"-119"},{"sheetId":"CD54","name":"Interleukin-7","technology":"Other","technologyDetails":"CYT107; NT-17","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04407689","NCT04379076","NCT04426201","NCT04442178","NCT04476290","NCT04498325"],"organizations":["Revimmune","University Hospital, Limoges","Amarex Clinical Research","Memorial Sloan Kettering Cancer Center","Washington University School of Medicine","National Institute of Allergy and Infectious Diseases","National Institutes of Health Clinical Center","NeoImmune Tech"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Interleukin-7 (IL-7) is a cytokine that stimulates the differentiation of stem cells into lymphoid progenitor cells, as well as stimulates the proliferation of lymphoid cells (B cells, T cell, and natural killer cells). As a therapeutic, it has been shown to decreased local and systemic inflammation, and thus it is seen as beneficial for COVID-19 as many pathologies arise from an overactive (hyperinflammatory) immune response.","show":true,"date":"2021-04-05 11:05:10.007443","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|42","Phase 1/2|NA","Phase 2|96","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD54","nameId":"cyt107-nt-17"},{"sheetId":"CD55","name":"Merimepodib*","technology":"Antivirals","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04410354"],"organizations":["ViralClear Pharmaceuticals","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Merimepodib is an inhibitor of the enzyme inosine monophosphate dehydrogenase, which is required for the synthesis of nucleotide bases containing guanine. This results in the inhibition of DNA and RNA synthesis of both viruses and quickly dividing cells, such as lymphocytes. Thus, this therapeutic has potent antiviral and immunosuppressive effects, which are hypothesized to be beneficial during cases of COVID-19 due to SARS-CoV-2 infection and the pathogenic immune-mediated inflammatory response that follows.","show":true,"date":"2021-04-05 11:05:10.007491","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|40","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD55","nameId":"-120"},{"sheetId":"CD56","name":"RTB101","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04409327","NCT04584710"],"organizations":["Restorbio Inc.","National Institute on Aging"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"RTB101 is an inhibitor of target of rapamycin complex 1 (TORC1), an evolutionarily conserved pathway that contributes to the decline in function of multiple aging organ systems. Inhibition of TORC1 has been observed to extend lifespan and healthspan in aging preclinical species and to improve the function of aging organ systems, including the immune system. In other studies, prophylactic administration of RTB101 was shown to upregulate innate antiviral gene expression, and thus this therapeutic has the potential to benefit individuals at high risk for COVID-19.","show":true,"date":"2021-04-05 11:05:10.007533","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|60","Phase 2/3|NA","Phase 3|550","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD56","nameId":"-121"},{"sheetId":"CD57","name":"Garadacimab","technology":"Antibodies","technologyDetails":"CSL312","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04409509"],"organizations":["CSL Behring"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Garadacimab is a fully human recombinant monoclonal antibody against factor XIIa. It functions by inhibiting factor XIIa, which is an enzyme crucial in the coagulation cascade. There is evidence that severe cases of COVID-19 suffer from an important infection-related coagulopathy and thus anticoagulants may ameliorate some disease pathologies associated with SARS-CoV-2 infection.","show":true,"date":"2021-04-05 11:05:10.007567","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|124","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD57","nameId":"csl312"},{"sheetId":"CD58","name":"GLS-1200","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04408183"],"organizations":["GeneOne Life Science","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"GLS-1200 is a small molecule therapeutic that is delivered nasally and stimulates nasal cells to produce nitric oxide (NO). NO is a colorless, free radical gas composed of nitrogen and oxygen that has demonstrated antimicrobial effects. It is theorized to have anti-viral properties as well and thus stimulating its production at one of the sites of SARS-CoV-2 infection (the nose), it may help prevent and/or treat COVID-19.","show":true,"date":"2021-04-05 11:05:10.007611","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|225","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD58","nameId":"-122"},{"sheetId":"CD59","name":"Cyclosporine","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/IV","clinicalTrials":["NCT04412785","NCT04392531","EudraCT 2020-002123-11","EudraCT 2020-001262-11","NCT04451239","NCT04492891","NCT04540926"],"organizations":["University of Pennsylvania","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","Tatiana Cobo Ibáñez","Ministry of Health, Kuwait","Mansoura University","Brigham and Women's Hospital","Baylor College of Medicine","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Ciclosporin is an 11-amino acid immunosuppressive drug. It functions by binding cyclophilin in lymphocytes (primarily T cells) which inhibits calcineurin, the phosphatase normally responsible for activating the transcription of important activating cytokines such as interleukin 2. Since disease pathogenesis of COVID-19 is driven by an overactive immune response, immunosuppressive drugs are hypothesized to be beneficial to those suffering from this disease. ","show":true,"date":"2021-04-05 11:05:10.007658","type":"Treatment","fdaApproved":"FDA-approved since 2000, approved for treatment of organ rejection, rheumatoid arthritis, psoriasis, amyotrophic lateral sclerosis, nephrotic syndrome, graft vs. host disease, uveitis and Behcet disease","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|20","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|120","Phase NA|NA"],"clinicalPhases":{"completed":[0,3],"inprogress":[1,2,4]},"inprogressClinicalTrials":[1,2,4],"completedClinicalTrials":[0,3],"phaseSortKey":6.5,"urlIdx":"d-CD59","nameId":"-123"},{"sheetId":"CD60","name":"Tacrolimus*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04341038","EudraCT 2020-001445-39"],"organizations":["Hospital Universitari de Bellvitge","Institut d'Investigació Biomèdica de Bellvitge"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Tacrolimus is a macrolide calcineurin inhibitor. Calcineurin is responsible for activating the transcription of important activating cytokines in T cells such as interleukin 2. Since disease pathogenesis of COVID-19 is driven by an overactive immune response, immunosuppressive drugs are hypothesized to be beneficial to those suffering from this disease. ","show":true,"date":"2021-04-05 11:05:10.007695","type":"Treatment","fdaApproved":"FDA-approved since 2006, approved for treatment of organ rejection","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|84","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD60","nameId":"-124"},{"sheetId":"CD61","name":"Bamlanivimab","technology":"Antibodies","technologyDetails":"LY3819253; Bamlanivimab; LY-CoV555","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04411628","NCT04427501","NCT04497987","NCT04501978","NCT04518410","NCT04603651","NCT04634409","NCT04427501","NCT04656691","NCT04701658","NCT04748588","NCT04790786","NCT04796402"],"organizations":["Eli Lilly and Company","AbCellera Biologics Inc.","National Institute of Allergy and Infectious Diseases","International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)","University of Copenhagen","Medical Research Council","Kirby Institute","Washington D.C. Veterans Affairs Medical Center","AIDS Clinical Trials Group","National Heart, Lung, and Blood Institute (NHLBI)","US Department of Veterans Affairs","Prevention and Early Treatment of Acute Lung Injury (PETAL)","Cardiothoracic Surgical Trials Network (CTSN)","AIDS Clinical Trials Group","Shanghai Junshi Bioscience Co., Ltd.","Optum, Inc.","UnitedHealth Group","University of Calgary","Sunnybrook Research Institute","University of Pittsburgh Medical Center","University of Pittsburgh","Fraser Health","Fraser Health Authrority Department of Evaluation and Research Services","Surrey Memorial Hospital Clinical Research Unit","Centre for Health Evaluation and Outcome Sciences","Surrey Hospitals Foundation","BC Support Unit","University of British Columbia","Ministry of Health, British Columbia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"LY-CoV555 is a monoclonal antibody against the SARS-CoV-2 spike protein that was isolated from some of the first COVID-19 patients in North America. It is hypothesized that anti-spike protein antibodies will block the virus from being able to enter cells and will thus have beneficial effects for those with COVID-19.","show":true,"date":"2021-04-05 11:05:10.007750","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|40","Phase 1/2|NA","Phase 2|400","Phase 2/3|2000","Phase 3|2400","Phase 4|7500","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-CD61","nameId":"ly3819253-bamlanivimab-ly-cov555"},{"sheetId":"CD62","name":"Hyperbaric Chamber","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04409886","NCT04344431","NCT04477954","NCT04500626","NCT04619719","NCT04800120"],"organizations":["Direction Centrale du Service de Santé des Armées","Maimonides Medical Center","Asociación Argentina de Medicina Hiperbárica e Investigación","Hospital de Infecciosas Francisco Javier Muniz","Hospital General de Agudos D. F. Santojanni","Hospital Central de San Isidro Dr. Melchor Angel Posse","Ottawa Hospital Research Institute","Climate Foundation","NYU Langone Health","Steward St. Elizabeth's Medical Center of Boston, Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Hyperbaric chambers are devices that allow the administration of gases (such as oxygen) at increased concentrations and at levels above atmospheric pressure. It has been observed that individuals with COVID-19 have hypoxia, low levels of blood oxygen. This device would assist in delivering oxygen to these individuals which would help equilibrate oxygen levels in hypoxic tissues.","show":true,"date":"2021-04-05 11:05:10.007810","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|100","Phase 3|NA","Phase 4|NA","Phase NA|30"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD62","nameId":"-125"},{"sheetId":"CD63","name":"CERC-002","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04412057"],"organizations":["Aevi Genomic Medicine, LLC","Cerecor Inc"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.007848","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|82","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD63","nameId":"-126"},{"sheetId":"CD64","name":"KB109*","technology":"Other","technologyDetails":"A novel glycan","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04414124","NCT04486482","NCT04814914"],"organizations":["Kaleido Biosciences"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.007886","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|400"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-CD64","nameId":"a-novel-glycan"},{"sheetId":"CD65","name":"Axatilimab","technology":"Antibodies","technologyDetails":"Axatilimab (SNDX-6352) is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R)","developmentStage":"Withdrawn","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["x-NCT04415073"],"organizations":["Syndax Pharmaceuticals"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.007930","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|186","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD65","nameId":"axatilimab-sndx-6352-is-a-high-affinity-antibody-targeting-the-colony-stimulating-factor-1-receptor-csf-1r"},{"sheetId":"CD66","name":"Opaganib","technology":"Other","technologyDetails":"a sphingosine kinase-2 (SphK2) inhibitor,","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04414618","NCT04435106","NCT04467840","x-NCT04502069"],"organizations":["RedHill Biopharma Limited","Shaare Zedek Medical Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008012","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|50","Phase 2|40","Phase 2/3|270","Phase 3|NA","Phase 4|NA","Phase NA|23"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD66","nameId":"a-sphingosine-kinase-2-sphk2-inhibitor"},{"sheetId":"CD67","name":"TRV027","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04419610"],"organizations":["Imperial College London"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008070","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|60","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD67","nameId":"-127"},{"sheetId":"CD68","name":"Vielight RX Plus","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04418505"],"organizations":["Vielight Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008103","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|280"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-CD68","nameId":"-128"},{"sheetId":"CD69","name":"N-acetylcysteine","technology":"Other","technologyDetails":"N-Acetyl cysteine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04279197","NCT04370288","NCT04374461","NCT04419025","NCT04455243","NCT04545008","NCT04573153","NCT04755972","NCT04792021"],"organizations":["ShuGuang Hospital","Hubei Hospital of Traditional Chinese Medicine","Jingmen No.1 People’s Hospital","Tongji Hospital","Mashhad University of Medical Sciences","Memorial Sloan Kettering Cancer Center","Cambridge Health Alliance","King Saud University","Prisma Health-Upstate","Clemson University","ScandiBio Therapeutics AB","Istanbul Medipol University Hospital","Istanbul Umraniye Training and Research Hospital","Clinical Hospital Center, Split","Ain Shams University","Misr International University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008149","type":"Treatment","fdaApproved":"FDA-approved since 2004, approved for treatment of acetaminophen toxicity","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|200","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-CD69","nameId":"n-acetyl-cysteine"},{"sheetId":"CD70","name":"TL-895","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04419623"],"organizations":["Telios Pharma","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008199","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|146","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD70","nameId":"-129"},{"sheetId":"CD71","name":"Lactoferrin","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04421534","NCT04412395","NCT04427865","NCT04475120","NCT04526821"],"organizations":["Cairo University","National Research Center, Egypt","Egyptian Military Medical Services","University of Rome Tor Vergata","Universidad Peruana Cayetano Heredia"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008237","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|516","Phase 2/3|210","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD71","nameId":"-130"},{"sheetId":"CD72","name":"Lanadelumab","technology":"Antibodies","technologyDetails":"Lanadelumab is a human monoclonal antibody that targets plasma kallikrein in order to promote prevention of angioedema in patients with hereditary angioedema.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04422509","NCT04460105"],"organizations":["Radboud University","Takeda","Shire"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008277","type":"Treatment","fdaApproved":"FDA-approved since 2018, approved for treatment of types I and II hereditary angioedema","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|24","Phase 1/2|80","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD72","nameId":"lanadelumab-is-a-human-monoclonal-antibody-that-targets-plasma-kallikrein-in-order-to-promote-prevention-of-angioedema-in-patients-with-hereditary-angioedema"},{"sheetId":"CD73","name":"Prostacyclin","technology":"Other","technologyDetails":"Iloprost; epoprostenol","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04420741","NCT04445246","NCT04452669"],"organizations":["Pär Johansson","Rigshospitalet, Denmark","Hamad Medical Corporation","Aerogen Pharma Limited","Ohio State University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008380","type":"Treatment","fdaApproved":"FDA-approved since 2004, approved for treatment of pulmonary arterial hypertension, scleroderma and Raynaud's phenomenon","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|120","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD73","nameId":"iloprost-epoprostenol"},{"sheetId":"CD74","name":"Clazakizumab","technology":"Antibodies","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04381052","NCT04348500","NCT04363502","NCT04343989","NCT04351724","NCT04494724","NCT04659772"],"organizations":["Columbia University","NYU Langone Health","Vitaeris INC","Cedars-Sinai Medical Center","Johns Hopkins University","NYU Langone Health","ACOVACT","The Methodist Hospital System","Mayo Clinic"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Clazakizumab is an aglycosylated, humanized rabbit monoclonal antibody against interleukin (IL)-6. IL-6 is a cytokine relevant to many inflammatory diseases including COVD-19, and thus blocking its effects may be beneficial to those suffering from the disease.","show":true,"date":"2021-04-05 11:05:10.008436","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD74","nameId":"-131"},{"sheetId":"CD75","name":"Interleukin-2","technology":"Other","technologyDetails":"ILT101; Bempegaldesleukin; Proleukin; Aldesleukin","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04357444","NCT04646044","NCT04724629"],"organizations":["Assistance Publique - Hôpitaux de Paris","Iltoo Pharma","Nektar Therapeutics","University of Sao Paulo","Conselho Nacional de Desenvolvimento Científico e Tecnológico","Science Valley Research Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Interleukin (IL)-2 is an important cytokine for the regulation of lymphocytes, specifically, T cell subsets. One specific subset of T cells enhanced by IL-2 are the T regulatory (Treg) cells, which play a crucial role in the control of immune responses. Since it has been observed that COVID-19 disease pathogenesis in part arises from a dysregulated immune response, it is hypothesized that the administration of IL-2 may help expand the Treg population, which in turn would help control the pathogenic immune response.  ","show":true,"date":"2021-04-05 11:05:10.008474","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|30","Phase 1/2|NA","Phase 2|30","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-CD75","nameId":"ilt101-bempegaldesleukin-proleukin-aldesleukin"},{"sheetId":"CD76","name":"Doxycycline*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04371952","NCT04407130","NCT04403555","NCT04370782","NCT04349410","NCT04434144","NCT04433078","NCT04482686","NCT04523831","NCT04551755","NCT04584567","NCT04591600","NCT04715295","NCT04729140","x-NCT04528927"],"organizations":["Nantes University Hospital","International Centre for Diarrhoeal Disease Research, Bangladesh","Tanta University","St. Francis Hospital, New York","The Camelot Foundation","UHFPO","Temple University","ProgenaBiome","Dhaka Medical College","Bangladesh Medical Research Council","General Administration of Military Health, Tunisia","Alkarkh Health Directorate-Baghdad","Yaounde Central Hospital","Max Health, Subsero Health"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008650","type":"Treatment","fdaApproved":"Doxycycline is an FDA-approced antibiotic used to treat many different bacterial infections","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-CD76","nameId":"-132"},{"sheetId":"CD77","name":"Infliximab","technology":"Antibodies","technologyDetails":"Remicade","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04425538","NCT04593940","NCT04734678"],"organizations":["Tufts Medical Center","National Institutes of Health (NIH)","National Center for Advancing Translational Science","Biomedical Advanced Research and Development Authority","Duke University","Ain Shams University","Misr International University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.008783","type":"Treatment","fdaApproved":"FDA-approved since 2011, approved for treatment of ulcerative colitis in children over the age of 6 years old","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|17","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD77","nameId":"remicade"},{"sheetId":"CD78","name":"ensoETM","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04426344"],"organizations":["Washington University School of Medicine"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009027","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|20"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-CD78","nameId":"-133"},{"sheetId":"CD79","name":"Casirivimab/Imdevimab","technology":"Antibodies","technologyDetails":"REGN10933+REGN10987 Combination Therapy; REGN-COV2","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III","clinicalTrials":["NCT04425629","NCT04426695","NCT04452318","NCT04519437","NCT04617535","NCT04666441","NCT04790786"],"organizations":["Regeneron Pharmaceuticals","University of Pittsburgh Medical Center","University of Pittsburgh"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009149","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|420","Phase 1/2|1054","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3]},"inprogressClinicalTrials":[1,2,3],"completedClinicalTrials":[0],"phaseSortKey":3,"urlIdx":"d-CD79","nameId":"regn10933-regn10987-combination-therapy-regn-cov2"},{"sheetId":"CD80","name":"Brequinar","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04425252","NCT04575038"],"organizations":["Clear Creek Bio","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009231","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|24","Phase 2|100","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD80","nameId":"-134"},{"sheetId":"CD81","name":"Radiation Therapy","technology":"Other","technologyDetails":"Radiotherapy","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04427566","NCT04377477","NCT04414293","NCT04390412","NCT04394793","NCT04420390","NCT04393948","NCT04366791","NCT04381988","NCT04380818","NCT04394182","NCT04466683","NCT04493294","NCT04534790","NCT04572412"],"organizations":["Ohio State University Comprehensive Cancer Center","Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","Hospital Provincial de Castellon","Shahid Beheshti University of Medical Sciences","All India Institute of Medical Sciences, New Delhi","Hospital San Carlos, Madrid","Brigham and Women's Hospital","Emory University","Memorial Sloan Kettering Cancer Center","Grupo de Investigación Clínica en Oncología Radioterapia","Hospital Universitario Madrid Sanchinarro","Hospital del Mar","Hospital Universitari Sant Joan de Reus","Fundacion GenesisCare","Hospital La Milagrosa","Hospital Vithas Valencia Consuelo","Varian Medical Systems","International Geriatric Radiotherapy Group","Instituto Mexicano del Seguro Social","Lancashire Teaching Hospitals NHS Foundation Trust","NIHR Lancashire Clinical Research Facility"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009296","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|24","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD81","nameId":"radiotherapy"},{"sheetId":"CD82","name":"Nangibotide","technology":"Other","technologyDetails":"Nangibotide, a TREM-1 (triggering receptor expressed on myeloid cells-1) inhibitor, is a chemically synthesized peptide that acts as a decoy receptor interfering with the binding of TREM-1 and its ligand. Based on preclinical studies, the Company believes nangibotide will be able to restore a balanced inflammatory response, vascular function, and improve overall survival.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04429334"],"organizations":["Inotrem"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009347","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|60","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD82","nameId":"nangibotide-a-trem-1-triggering-receptor-expressed-on-myeloid-cells-1-inhibitor-is-a-chemically-synthesized-peptide-that-acts-as-a-decoy-receptor-interfering-with-the-binding-of-trem-1-and-its-ligand-"},{"sheetId":"CD83","name":"TY027","technology":"Antibodies","technologyDetails":"monoclonal antibody (mAb) that specifically targets SARS-CoV-2,","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/III","clinicalTrials":["NCT04429529","NCT04649515"],"organizations":["Tychan Pte Ltd."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009526","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|25","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|1305","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,2],"inprogress":[1,3]},"inprogressClinicalTrials":[1,3],"completedClinicalTrials":[0,2],"phaseSortKey":4,"urlIdx":"d-CD83","nameId":"monoclonal-antibody-mab-that-specifically-targets-sars-cov-2"},{"sheetId":"CD84","name":"MK-5475","technology":"Other","technologyDetails":"","developmentStage":"Withdrawn","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["X-NCT04425733"],"organizations":["Merck Sharp & Dohme Corp."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009594","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|64","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD84","nameId":"-135"},{"sheetId":"CD85","name":"Ibudilast","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04429555"],"organizations":["MediciNova"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009633","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|40","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD85","nameId":"-136"},{"sheetId":"CD86","name":"High Flow Nasal Cannula Device","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04424836","NCT04452708","NCT04560257"],"organizations":["Sisli Hamidiye Etfal Training and Research Hospital","Chinese University of Hong Kong","Health and Medical Research Fund","Lahore General Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009672","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|40"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-CD86","nameId":"-137"},{"sheetId":"CD87","name":"Bromhexine*","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/III/IV","clinicalTrials":["NCT04355026","NCT04273763","NCT04424134","NCT04405999","NCT04340349"],"organizations":["General and Teaching Hospital Celje","Second Affiliated Hospital of Wenzhou Medical University","WanBangDe Pharmaceutical Group Co.,Ltd.","Lomonosov Moscow State University Medical Research and Educational Center","Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","Instituto Nacional de Rehabilitacion"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009715","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":[],"clinicalPhases":{"completed":[],"inprogress":[0]},"inprogressClinicalTrials":[1,3,4],"completedClinicalTrials":[0,2],"phaseSortKey":6,"urlIdx":"d-CD87","nameId":"-138"},{"sheetId":"CD88","name":"CAStem","technology":"Cell-based therapies","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04331613"],"organizations":["Chinese Academy of Sciences","Beijing YouAn Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009746","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|9","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD88","nameId":"-139"},{"sheetId":"CD89","name":"Ambrisentan*","technology":"Other","technologyDetails":"Letairis, Volibris, Pulmonext. Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04393246","NCT04771000"],"organizations":["Cambridge University Hospitals NHS Foundation Trust","Noorik Biopharmaceuticals AG"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009790","type":"Treatment","fdaApproved":"FDA-approved since 2007, approved for treatment of pulmonary arterial hypertension","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|150","Phase 2/3|1407","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD89","nameId":"letairis-volibris-pulmonext-ambrisentan-is-an-endothelin-receptor-antagonist-and-is-selective-for-the-type-a-endothelin-receptor-eta-ambrisentan-was-approved-by-the-u-s-food-and-drug-administration-fd"},{"sheetId":"CD90","name":"Pamrevlumab","technology":"Antibodies","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04432298"],"organizations":["FibroGen"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009962","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|130","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD90","nameId":"-140"},{"sheetId":"CD91","name":"Pentoxifylline","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04433988"],"organizations":["Sadat City University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.009998","type":"Treatment","fdaApproved":"FDA-approved since 1999, approved to reduce pain, cramping, numbness, or weakness in the arms or legs which occurs due to intermittent claudication, a form of muscle pain resulting from peripheral artery diseases","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|200","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD91","nameId":"-141"},{"sheetId":"CD92","name":"BAT2020","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04432766"],"organizations":["Bio-Thera Solutions"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010036","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|174","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD92","nameId":"-142"},{"sheetId":"CD93","name":"PB1046","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04433546"],"organizations":["PhaseBio Pharmaceuticals Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010069","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|210","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD93","nameId":"-143"},{"sheetId":"CD94","name":"Maraviroc*","technology":"Other","technologyDetails":"Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV. CCR5 antagonism prior to the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and may alter cell trafficking of inflammatory cells, both increasing viral control capacity and dampening damage to lung tissue, respectively.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04435522","NCT04441385","NCT04475991","NCT04710199"],"organizations":["Rhode Island Hospital","Hospital Universitario Infanta Leonor","Hospital Clínic de Barcelona","ViiV Healthcare","Hospital General de México Dr. Eduardo Liceaga","CCINSHAE. Secretaría de Salud. México","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Centro de Investigación en. Enfermedades Infecciosas, Mexico","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010109","type":"Treatment","fdaApproved":"FDA-approved since 2007, approved for treatment of adults infected with CCR5-tropic HIV-1","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|16","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD94","nameId":"maraviroc-a-c-c-chemokine-receptor-5-ccr5-antagonist-is-well-tolerated-without-significant-side-effects-in-its-current-use-in-patients-with-hiv-ccr5-antagonism-prior-to-the-second-wave-of-inflammatory"},{"sheetId":"CD95","name":"Crizanlizumab","technology":"Antibodies","technologyDetails":"Crizanlizumab is a monoclonal antibody that targets P-selectin. Crizanlizumab can decrease inflammation by binding to P-selectin, blocking leucocyte and platelet adherence to the vessel wall.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04435184"],"organizations":["Johns Hopkins University","Novartis","Socar Research SA","Brigham and Women's Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010309","type":"Treatment","fdaApproved":"FDA-approved since 2019, approved for to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|40","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD95","nameId":"crizanlizumab-is-a-monoclonal-antibody-that-targets-p-selectin-crizanlizumab-can-decrease-inflammation-by-binding-to-p-selectin-blocking-leucocyte-and-platelet-adherence-to-the-vessel-wall"},{"sheetId":"CD96","name":"VibroLUNG","technology":"Device","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase NA","clinicalTrials":["NCT04435353"],"organizations":["Astana Medical University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010422","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|200"],"clinicalPhases":{"completed":[],"inprogress":[-1]},"inprogressClinicalTrials":[-1],"completedClinicalTrials":[],"phaseSortKey":-0.5,"urlIdx":"d-CD96","nameId":"-144"},{"sheetId":"CD97","name":"Abivertinib Maleate","technology":"Other","technologyDetails":"Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. abivertinib, AC0010, avitinib, STI-5656","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04440007","NCT04528667"],"organizations":["Sorrento Therapeutics","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010459","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|80","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD97","nameId":"abivertinib-maleate-is-a-third-generation-egfr-tyrosine-kinase-inhibitor-and-btk-inhibitor-abivertinib-ac0010-avitinib-sti-5656"},{"sheetId":"CD98","name":"PTC299","technology":"Other","technologyDetails":"PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.\n","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04439071"],"organizations":["PTC Therapeutics"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010551","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|380","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD98","nameId":"ptc299-is-a-novel-orally-administered-small-molecule-designed-to-inhibit-the-production-of-vascular-endothelial-growth-factor-vegf-in-tumors-overexpression-of-vegf-plays-a-key-role-in-multiple-disease"},{"sheetId":"CD99","name":"Ibrutinib","technology":"Other","technologyDetails":"Ibrutinib is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04375397","NCT04439006"],"organizations":["AbbVie","Janssen Research & Development, LLC","National Cancer Institute (NCI)","Ohio State University Comprehensive Cancer Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010758","type":"Treatment","fdaApproved":"FDA-approved since 2014, approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|118","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD99","nameId":"ibrutinib-is-a-small-molecule-drug-that-binds-permanently-to-a-protein-bruton-s-tyrosine-kinase-btk-that-is-important-in-b-cells-it-is-used-to-treat-b-cell-cancers-like-mantle-cell-lymphoma-chronic-ly"},{"sheetId":"CD100","name":"Therapeutic Plasma Exchange","technology":"Other","technologyDetails":"OCTAPLAS","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/IV","clinicalTrials":["NCT04441996","NCT04457349","NCT04485169","NCT04492501","NCT04623255","NCT04634422","NCT04751643"],"organizations":["Emory University","Alexandria University","UNICEF","Pak Emirates Military Hospital Rawalpindi","University College, London","Aalborg University Hospital","Aarhus University Hospital","Odense University Hospital","Zealand University Hospital","Hospices Civils de Lyon"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010906","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|20","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,3],"inprogress":[2,4]},"inprogressClinicalTrials":[2,4],"completedClinicalTrials":[0,1,3],"phaseSortKey":7,"urlIdx":"d-CD100","nameId":"octaplas"},{"sheetId":"CD101","name":"Sofosbuvir*","technology":"Antivirals","technologyDetails":"\"Sofosbuvir inhibits the hepatitis C NS5B protein.[10] Sofosbuvir appears to have a high barrier to the development of resistance.[27]\n\nSofosbuvir is a prodrug of the Protide type, whereby the active phosphorylated nucleotide is granted cell permeability and oral bioavailability. It is metabolized to the active antiviral agent GS-461203 (2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate). GS-461203 serves as a defective substrate for the NS5B protein, which is the viral RNA polymerase, thus acts as an inhibitor of viral RNA synthesis.\"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04443725","NCT04460443","NCT04468087","NCT04497649","NCT04498936","NCT04530422","NCT04532931","NCT04535869","NCT04561063","NCT04773756"],"organizations":["Cairo University","Tanta University","Hospital do Coracao","Assiut University","Helwan University","Almaza Military Fever Hospital","Shin Poong Pharmaceutical Co. Ltd.","Medicines for Malaria Venture","Mansoura University","University of Witwatersrand, South Africa","Alexandria University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.010995","type":"Treatment","fdaApproved":"FDA-approved since 2013, approved for the treatment of patients with Chronic Hepatitis C","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|160","Phase 3|NA","Phase 4|54","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-CD101","nameId":"sofosbuvir-inhibits-the-hepatitis-c-ns5b-protein-10-sofosbuvir-appears-to-have-a-high-barrier-to-the-development-of-resistance-27-sofosbuvir-is-a-prodrug-of-the-protide-type-whereby-the-active-phospho"},{"sheetId":"CD102","name":"Daclatasvir*","technology":"Antivirals","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III/IV","clinicalTrials":["NCT04443726","NCT04468087","NCT04497649","NCT04532931","NCT04535869","NCT04561063","NCT04773756"],"organizations":["Cairo University","Hospital do Coracao","Tanta University","Shin Poong Pharmaceutical Co. Ltd.","Medicines for Malaria Venture","Mansoura University","University of Witwatersrand, South Africa","Alexandria University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.011451","type":"Treatment","fdaApproved":"FDA-approved since 2015, approved for the treatment of patients with Chronic Hepatitis C","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|100","Phase 3|NA","Phase 4|54","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3,4]},"inprogressClinicalTrials":[2,3,4],"completedClinicalTrials":[0,1],"phaseSortKey":5.5,"urlIdx":"d-CD102","nameId":"-145"},{"sheetId":"CD103","name":"Prasugrel","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04445623"],"organizations":["Azienda Ospedaliera Universitaria Integrata Verona","University of Milan"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.011528","type":"Treatment","fdaApproved":"FDA-approved since 2009, approved for the treatment of acute coronary syndrome","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|128","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD103","nameId":"-146"},{"sheetId":"CD104","name":"Bivalirudin","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase IV","clinicalTrials":["NCT04445935"],"organizations":["Hamad Medical Corporation"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.011589","type":"Treatment","fdaApproved":"FDA-approved since 2000, approved as an anticoagulant in unstable angina patient","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|100","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2,3],"inprogress":[4]},"inprogressClinicalTrials":[4],"completedClinicalTrials":[0,1,2,3],"phaseSortKey":8,"urlIdx":"d-CD104","nameId":"-147"},{"sheetId":"CD105","name":"LAM-002A","technology":"Other","technologyDetails":"Apilimod Dimesylate","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04446377"],"organizations":["AI Therapeutics, Inc.","Yale University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.011648","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|142","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD105","nameId":"apilimod-dimesylate"},{"sheetId":"CD106","name":"Dutasteride","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04729491"],"organizations":["Corpometria Institute"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.011733","type":"Treatment","fdaApproved":"FDA-approved since 2010, approved for the treatment of benign prostatic hyperplasia","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD106","nameId":"-148"},{"sheetId":"CD107","name":"M5049","technology":"Other","technologyDetails":"M5049 is a potentially first-in-class small molecule that blocks the activation of Toll-like receptor (TLR)7 and TLR8, two innate immune sensors that detect single-stranded (ss) RNA from viruses such as SARS-CoV-2. Activation of TLR7/8 leads to immune cell activation and inflammation, which when not properly controlled can cause severe immunopathology.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04448756"],"organizations":["EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany","EMD Serono"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.011802","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|150","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD107","nameId":"m5049-is-a-potentially-first-in-class-small-molecule-that-blocks-the-activation-of-toll-like-receptor-tlr-7-and-tlr8-two-innate-immune-sensors-that-detect-single-stranded-ss-rna-from-viruses-such-as-s"},{"sheetId":"CD108","name":"DUR-928","technology":"Other","technologyDetails":"is an endogenous, orally bioavailable small molecule that has been shown in nonclinical studies to modulate the activity of nuclear receptors playing an important regulatory role in cellular functions such as lipid homeostasis, inflammation, and cell survival.\nDUR-928 is a sulfated oxysterol—representing a new class of therapeutics with a novel mechanism of action. DUR-928 epigenetically modifies gene activity without changing the DNA sequence itself.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04447404"],"organizations":["Durect"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.012125","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|80","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD108","nameId":"is-an-endogenous-orally-bioavailable-small-molecule-that-has-been-shown-in-nonclinical-studies-to-modulate-the-activity-of-nuclear-receptors-playing-an-important-regulatory-role-in-cellular-functions-"},{"sheetId":"CD109","name":"BDB-001","technology":"Other","technologyDetails":"A toll-like receptor (TLR) agonist with potential immunostimulating and antineoplastic activities. Upon administration, TLR agonist BDB001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha (IFNa); production of proinflammatory cytokines; upregulation of co-stimulatory molecules; enhanced T- and B-cell stimulatory responses; T-cell proliferation; and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing. ","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04449588"],"organizations":["Staidson (Beijing) Biopharmaceuticals Co., Ltd","Beijing Defengrui Biotechnology Co. Ltd"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.012519","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|368","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD109","nameId":"a-toll-like-receptor-tlr-agonist-with-potential-immunostimulating-and-antineoplastic-activities-upon-administration-tlr-agonist-bdb001-activates-one-or-more-not-yet-disclosed-tlrs-which-may-result-in-"},{"sheetId":"CD110","name":"Povidone-Iodine","technology":"Other","technologyDetails":"Povidone-iodine (PVP-I), also known as iodopovidone, is an antiseptic used for skin disinfection before and after surgery.[1][2] It may be used both to disinfect the hands of healthcare providers and the skin of the person they are caring for.[2] It may also be used for minor wounds.[2] It may be applied to the skin as a liquid or a powder.[2]","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II/III/IV","clinicalTrials":["NCT04449965","NCT04371965","NCT04364802","NCT04410159","NCT04347954","NCT04344236","NCT04446104","NCT04393792","NCT04341688","NCT04478019","NCT04510402","NCT04517162","NCT04517188","NCT04549376","NCT04603794"],"organizations":["St. Paul's Hospital, Canada","Poitiers University Hospital","University of Kentucky","Universiti Sains Islam Malaysia","Universiti Kebangsaan Malaysia Medical Centre","Stanford University","National University Hospital, Singapore","Hampshire Hospitals NHS Foundation Trust","Aga Khan University","University of Karachi","University of Wisconsin, Madison","Brigham and Women's Hospital","3M","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Halodine LLC","Pi Research Consultancy Center, Bangladesh","Dhaka Medical College","Ohio State University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013085","type":"Treatment","fdaApproved":"FDA-approved for the prophylaxis of surgical handrub, aseptic handwash","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|81","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0],"inprogress":[1,2,3,4]},"inprogressClinicalTrials":[1,2,3,4],"completedClinicalTrials":[0],"phaseSortKey":5,"urlIdx":"d-CD110","nameId":"povidone-iodine-pvp-i-also-known-as-iodopovidone-is-an-antiseptic-used-for-skin-disinfection-before-and-after-surgery-1-2-it-may-be-used-both-to-disinfect-the-hands-of-healthcare-providers-and-the-ski"},{"sheetId":"CD111","name":"C21","technology":"Other","technologyDetails":"VP01; a small molecule Selective Agonist of Angiotensin AT2 Receptors","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04452435"],"organizations":["Vicore Pharma AB","Orphan Reach"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013281","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|100","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD111","nameId":"vp01-a-small-molecule-selective-agonist-of-angiotensin-at2-receptors"},{"sheetId":"CD112","name":"Olokizumab","technology":"Antibodies","technologyDetails":"Whole human antibody to IL-6","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04380519","NCT04452474"],"organizations":["R-Pharm","Data Management 365 LLC","K-Research, LLC","Cromos Pharma, LLC","Covance"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013363","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|376","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD112","nameId":"whole-human-antibody-to-il-6"},{"sheetId":"CD113","name":"NA-831*","technology":"Other","technologyDetails":"a.k.a. TRANEUROCIN. europrotective drug that is in clinical study for the treatment of Alzheimer's Disease","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04452565","NCT04480333"],"organizations":["NeuroActiva","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013426","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|525","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD113","nameId":"a-k-a-traneurocin-europrotective-drug-that-is-in-clinical-study-for-the-treatment-of-alzheimer-s-disease"},{"sheetId":"CD114","name":"Atazanavir*","technology":"Antivirals","technologyDetails":"Atazanavir binds to the active site HIV protease and prevents it from cleaving the pro-form of viral proteins into the working machinery of the virus","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04452566","NCT04459286","NCT04468087"],"organizations":["NeuroActiva, Inc.","Obafemi Awolowo University","University of Liverpool","African Centre of Excellence for Genomics of Infectious Diseases","Oyo State Ministry of Health","Hospital do Coracao"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013514","type":"Treatment","fdaApproved":"FDA-approved since 2003, approved for the treatment and prevention of HIV/AIDS","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|525","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD114","nameId":"atazanavir-binds-to-the-active-site-hiv-protease-and-prevents-it-from-cleaving-the-pro-form-of-viral-proteins-into-the-working-machinery-of-the-virus"},{"sheetId":"CD115","name":"RPH-104","technology":"Other","technologyDetails":"RPH-104 is a macromolecular compound that is capable of binding human interleukin-1 beta (IL-1β). inhibitor of IL-1β signalling pathway,","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04380519"],"organizations":["R-Pharm International, LLC","Data Management 365 LLC","K-Research, LLC"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013621","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|372","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD115","nameId":"rph-104-is-a-macromolecular-compound-that-is-capable-of-binding-human-interleukin-1-beta-il-1b-inhibitor-of-il-1b-signalling-pathway"},{"sheetId":"CD116","name":"Chlorhexidine","technology":"Other","technologyDetails":"a disinfectant and antiseptic that is used for skin disinfection before surgery and to sterilize surgical instruments","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/IV","clinicalTrials":["NCT04344236","NCT04603794"],"organizations":["NYU Langone Health","Ohio State University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013718","type":"Treatment","fdaApproved":"FDA-approved since 2005, approved for use as a disinfectant and antiseptic that is used for skin disinfection before surgery and to sterilize surgical instruments","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|48","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|254"],"clinicalPhases":{"completed":[0,1,3],"inprogress":[2,4]},"inprogressClinicalTrials":[2,4],"completedClinicalTrials":[0,1,3],"phaseSortKey":7,"urlIdx":"d-CD116","nameId":"a-disinfectant-and-antiseptic-that-is-used-for-skin-disinfection-before-surgery-and-to-sterilize-surgical-instruments"},{"sheetId":"CD117","name":"XAV-19","technology":"Antibodies","technologyDetails":"A new polyclonal humanized anti-SARS-CoV2 antibodies","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04453384"],"organizations":["Nantes University Hospital","BPIfrance","Xenothera SAS"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013807","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|368","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD117","nameId":"a-new-polyclonal-humanized-anti-sars-cov2-antibodies"},{"sheetId":"CD118","name":"Tramadol","technology":"Other","technologyDetails":"opioid pain medication used to treat moderate to moderately severe pain","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04454307"],"organizations":["Tanta University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013878","type":"Treatment","fdaApproved":"FDA-approved since 1995, approved to treat moderate to moderately severe pain in adults","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|100","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD118","nameId":"opioid-pain-medication-used-to-treat-moderate-to-moderately-severe-pain"},{"sheetId":"CD119","name":"COVI-Guard","technology":"Antibodies","technologyDetails":"a COVID-19 targeting monoclonal antibody; STI-1499","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04454398"],"organizations":["Sorrento Therapeutics","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.013959","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|24","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD119","nameId":"a-covid-19-targeting-monoclonal-antibody-sti-1499"},{"sheetId":"CD120","name":"Enzalutamide","technology":"Other","technologyDetails":"Enzalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents the effects of these hormones in the prostate gland and elsewhere in the body.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04456049","NCT04475601"],"organizations":["Oncology Institute of Southern Switzerland","Institute of Oncology Research","Institute for Research in Biomedicine","Umeå University\nSahlgrenska University Hospital, Sweden","University Hospital, Umeå","Uppsala University Hospital","Skane University Hospital","Jonkoping County Hospital","Sundsvall Hospital","Helsingborgs Hospital","Göteborg University","Astellas Pharma Europe Ltd.","Norrlands University Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014026","type":"Treatment","fdaApproved":"FDA-approved since 2018, approved to treat patients with castration-resistant prostate cancer","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|90","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD120","nameId":"enzalutamide-is-an-antiandrogen-and-acts-as-an-antagonist-of-the-androgen-receptor-the-biological-target-of-androgens-like-testosterone-and-dihydrotestosterone-in-doing-so-it-prevents-the-effects-of-t"},{"sheetId":"CD121","name":"Atovaquone","technology":"Other","technologyDetails":"chemical compound that belongs to the class of naphthoquinones. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity. ","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04456153"],"organizations":["University of Texas Southwestern Medical Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014172","type":"Treatment","fdaApproved":"FDA-approved since 1999, approved for the treatment and prevention of pneumocystic carinii pneumonia","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|560","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD121","nameId":"chemical-compound-that-belongs-to-the-class-of-naphthoquinones-atovaquone-is-a-hydroxy-14-naphthoquinone-an-analog-of-ubiquinone-with-antipneumocystic-activity"},{"sheetId":"CD122","name":"Ampion","technology":"Other","technologyDetails":"Ampion is a low molecular weight fraction of human serum albumin (HSA) currently being developed for the treatment of pain due to osteoarthritis of the knee.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04456452","NCT04606784"],"organizations":["Ampio Pharmaceuticals. Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014278","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|10","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD122","nameId":"ampion-is-a-low-molecular-weight-fraction-of-human-serum-albumin-hsa-currently-being-developed-for-the-treatment-of-pain-due-to-osteoarthritis-of-the-knee"},{"sheetId":"CD123","name":"ANG-3777","technology":"Other","technologyDetails":"ANG-3777, is potentially a first-in-class hepatocyte growth factor (HGF) mimetic. We engineered ANG-3777 to mimic the biological activity of HGF in activating critical pathways in the body’s natural organ repair process following an acute organ injury.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04459676"],"organizations":["Angion Biomedica Corp","CTI Clinical Trial and Consulting Services"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014379","type":"Treatment","fdaApproved":"FDA-approved since 2010, approved for fast track and orphan drug status for the treatment of acute renal failure","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|100","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD123","nameId":"ang-3777-is-potentially-a-first-in-class-hepatocyte-growth-factor-hgf-mimetic-we-engineered-ang-3777-to-mimic-the-biological-activity-of-hgf-in-activating-critical-pathways-in-the-bodys-natural-organ-"},{"sheetId":"CD124","name":"RESP301","technology":"Other","technologyDetails":"RESP301, a Nitric Oxide generating solution","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04460183"],"organizations":["Thirty Respiratory Limited"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014517","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|300","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD124","nameId":"resp301-a-nitric-oxide-generating-solution"},{"sheetId":"CD125","name":"OP-101","technology":"Other","technologyDetails":"Dendrimer N-acetyl-cysteine","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04458298"],"organizations":["Orpheris","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014580","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|24","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD125","nameId":"dendrimer-n-acetyl-cysteine"},{"sheetId":"CD126","name":"Monalizumab","technology":"Antibodies","technologyDetails":"Monalizumab is a monoclonal antibody targeted at NKG2A. It is a checkpoint inhibitor.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["x-NCT04333914"],"organizations":["Centre Leon Berard"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014635","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|384","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD126","nameId":"monalizumab-is-a-monoclonal-antibody-targeted-at-nkg2a-it-is-a-checkpoint-inhibitor"},{"sheetId":"CD127","name":"Rapamycin","technology":"Other","technologyDetails":"Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and treat a rare lung disease called lymphangioleiomyomatosis. It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/II","clinicalTrials":["NCT04461340","NCT04341675","NCT04371640","NCT04482712"],"organizations":["Alexandria University","University of Cincinnati","Thomas Jefferson University","The University of Texas Health Science Center at San Antonio","Claude D. Pepper Older Americans Independence Center"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014715","type":"Treatment","fdaApproved":"FDA-approved since 1999, approved for use as an immunosuppressive drug, and since 2015 to treat lymphangioleiomyomatosis.","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|40","Phase 1/2|NA","Phase 2|70","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1,2]},"inprogressClinicalTrials":[1,2],"completedClinicalTrials":[0],"phaseSortKey":1.5,"urlIdx":"d-CD127","nameId":"sirolimus-also-known-as-rapamycin-is-a-macrolide-compound-that-is-used-to-coat-coronary-stents-prevent-organ-transplant-rejection-and-treat-a-rare-lung-disease-called-lymphangioleiomyomatosis-it-has-i"},{"sheetId":"CD128","name":"Desidustat","technology":"Other","technologyDetails":"Desidustat is a prolyl hydroxylase domain (PHD) inhibitor. treatment of anemia of chronic kidney disease","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04463602"],"organizations":["Cadila Healthcare Limited"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.014873","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|24","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD128","nameId":"desidustat-is-a-prolyl-hydroxylase-domain-phd-inhibitor-treatment-of-anemia-of-chronic-kidney-disease"},{"sheetId":"CD129","name":"CPI-006","technology":"Antibodies","technologyDetails":"a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I/III","clinicalTrials":["NCT04464395","NCT04734873"],"organizations":["Corvus Pharmaceuticals","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015008","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|30","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|1000","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,2],"inprogress":[1,3]},"inprogressClinicalTrials":[1,3],"completedClinicalTrials":[0,2],"phaseSortKey":4,"urlIdx":"d-CD129","nameId":"a-humanized-monoclonal-antibody-targeting-the-cd73-cell-surface-ectonucleotidase-as-immunotherapy-for-stable-hospitalized-mild-or-moderately-symptomatic-covid-19-patients"},{"sheetId":"CD130","name":"TAK-671","technology":"Other","technologyDetails":"SB26; ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04464460"],"organizations":["Takeda"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015116","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|40","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD130","nameId":"sb26-ulinastatin-fc-uti-fc-fusion-protein-intended-to-treat-severe-acute-pancreatitis"},{"sheetId":"CD131","name":"Clofazimine","technology":"Other","technologyDetails":"Clofazimine works by binding to the guanine bases of bacterial DNA, thereby blocking the template function of the DNA and inhibiting bacterial proliferation.[7][8] It also increases activity of bacterial phospholipase A2, leading to release and accumulation of lysophospholipids,[7][8] which are toxic and inhibit bacterial proliferation.[9][10]\n\nClofazimine is also a FIASMA (functional inhibitor of acid sphingomyelinase).[11]","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04465695"],"organizations":["The University of Hong Kong"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015192","type":"Treatment","fdaApproved":"FDA-approved since 1986, approved to treat leprosy. The drug is currently no longer commercially available in the United States","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|81","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD131","nameId":"clofazimine-works-by-binding-to-the-guanine-bases-of-bacterial-dna-thereby-blocking-the-template-function-of-the-dna-and-inhibiting-bacterial-proliferation-7-8-it-also-increases-activity-of-bacterial-"},{"sheetId":"CD132","name":"Atorvastatin","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04380402","NCT04466241","NCT04333407","NCT04486508","NCT04631536","NCT04801940"],"organizations":["Mount Auburn Hospital","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Université de Bordeaux","Programme PACCI","Imperial College London","Rajaie Cardiovascular Medical and Research Center","Lebanese American University Medical Center","Cambridge University Hospitals NHS Foundation Trust","University of Liverpool","The University of Cambridge"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015395","type":"Treatment","fdaApproved":"FDA-approved since 2001, approved for the prevention of cardiovascular disease","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|300","Phase 2/3|294","Phase 3|NA","Phase 4|NA","Phase NA|3170"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD132","nameId":"-149"},{"sheetId":"CD133","name":"Acetylsalicylic acid","technology":"Other","technologyDetails":"Aspirin*","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II/III","clinicalTrials":["NCT04368377","NCT04466670","NCT04324463","NCT04333407","NCT04343001","NCT04363840","NCT04365309","NCT04410328","NCT04498273","NCT04808895"],"organizations":["University of Milan","University of Sao Paulo General Hospital","Population Health Research Institute","Bayer","Imperial College London","London School of Hygiene and Tropical Medicine","Louisiana State University Health Sciences Center in New Orleans","Xijing Hospital","Rutgers, The State University of New Jersey","Boehringer Ingelheim","National Heart, Lung, and Blood Institute","University of Pittsburgh","Azienda Ospedaliera Universitaria Integrata Verona"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015449","type":"Treatment","fdaApproved":"FDA-approved as a medication to reduce pain, fever, or inflammation","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|5","Phase 2/3|NA","Phase 3|310","Phase 4|NA","Phase NA|3170"],"clinicalPhases":{"completed":[0,1],"inprogress":[2,3]},"inprogressClinicalTrials":[2,3],"completedClinicalTrials":[0,1],"phaseSortKey":3.5,"urlIdx":"d-CD133","nameId":"aspirin"},{"sheetId":"CD134","name":"NK-1R antagonist","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04468646"],"organizations":["University of Lahore","Bahria International Hospital"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"Neurokinin-1 receptor (NK-1R) antagonists function by blocking substance P interactions. Inhibitors of NK-1 can be used as antiemetic agents.","show":true,"date":"2021-04-05 11:05:10.015532","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|100","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1,2],"inprogress":[3]},"inprogressClinicalTrials":[3],"completedClinicalTrials":[0,1,2],"phaseSortKey":4.5,"urlIdx":"d-CD134","nameId":"-150"},{"sheetId":"CD135","name":"CK0802","technology":"Cell-based therapies","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04468971"],"organizations":["Cellenkos","Inc."],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015569","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|45","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD135","nameId":"-151"},{"sheetId":"CD136","name":"SAR443122","technology":"Other","technologyDetails":"a RIPK1 inhibitor (collaboration with Denali) entered into phase 1.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase I","clinicalTrials":["NCT04469621"],"organizations":["Sanofi"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015606","type":"Treatment","fdaApproved":"","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|67","Phase 1/2|NA","Phase 2|NA","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0],"inprogress":[1]},"inprogressClinicalTrials":[1],"completedClinicalTrials":[0],"phaseSortKey":0.5,"urlIdx":"d-CD136","nameId":"a-ripk1-inhibitor-collaboration-with-denali-entered-into-phase-1"},{"sheetId":"CD137","name":"Ramelteon","technology":"Other","technologyDetails":"","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04470297"],"organizations":["Associação Fundo de Incentivo à Pesquisa"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015676","type":"Treatment","fdaApproved":"FDA-approved since 2005, approved for the treatment of insomnia","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|100","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD137","nameId":"-152"},{"sheetId":"CD138","name":"Trimethoprim*","technology":"Other","technologyDetails":" dihydrofolate reductase inhibitor antibacterial","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04470531","NCT04357366"],"organizations":["Hellenic Institute for the Study of Sepsis","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","Anwar Khan Mordern Medical College and Hospital, Dhaka","Mugda Medical College and Hospital, Dhaka"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015714","type":"Treatment","fdaApproved":"FDA-approved since 1981, approved for the treatment of certain bacteria","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|194","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD138","nameId":"dihydrofolate-reductase-inhibitor-antibacterial"},{"sheetId":"CD138","name":"Sulfamethoxazole*","technology":"Other","technologyDetails":" sulfonamide antimicrobial","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04470531","NCT04357366"],"organizations":["Hellenic Institute for the Study of Sepsis","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","Anwar Khan Mordern Medical College and Hospital, Dhaka","Mugda Medical College and Hospital, Dhaka"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015776","type":"Treatment","fdaApproved":"FDA-approved since 1981, approved for the treatment of certain bacteria","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|194","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD138","nameId":"sulfonamide-antimicrobial"},{"sheetId":"CD139","name":"Nelfinavir*","technology":"Antivirals","technologyDetails":"Nelfinavir is an antiretroviral drug used in the treatment of the human immunodeficiency virus. Nelfinavir belongs to the class of drugs known as protease inhibitors and like other PIs is almost always used in combination with other antiretroviral drugs.","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04471662"],"organizations":["Tanta University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015828","type":"Treatment","fdaApproved":"FDA-approved since 1997, approved for the treatment of pediatric HIV infection","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|50","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD139","nameId":"nelfinavir-is-an-antiretroviral-drug-used-in-the-treatment-of-the-human-immunodeficiency-virus-nelfinavir-belongs-to-the-class-of-drugs-known-as-protease-inhibitors-and-like-other-pis-is-almost-always"},{"sheetId":"CD140","name":"Abatacept","technology":"Other","technologyDetails":"Abatacept is a drug used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. It is a modified antibody. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase II","clinicalTrials":["NCT04472494","NCT04593940","x-NCT04477642"],"organizations":["Bristol-Myers Squibb","National Center for Advancing Translational Science","Biomedical Advanced Research and Development Authority","Duke University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.015964","type":"Treatment","fdaApproved":"FDA-approved since 2005, approved for the treatment of adults with active psoriatic arthritis","updatedOrNew":"None","template":[[]],"templateLink":"https://app.biorender.com/biorender-templates/figures/t-5e8f2617bbf15200b1d93310-remdesivir-potential-repurposed-drug-candidate-for-covid-19","participants":["Phase 1|NA","Phase 1/2|NA","Phase 2|129","Phase 2/3|NA","Phase 3|NA","Phase 4|NA","Phase NA|NA"],"clinicalPhases":{"completed":[0,1],"inprogress":[2]},"inprogressClinicalTrials":[2],"completedClinicalTrials":[0,1],"phaseSortKey":2,"urlIdx":"d-CD140","nameId":"abatacept-is-a-drug-used-to-treat-autoimmune-diseases-like-rheumatoid-arthritis-by-interfering-with-the-immune-activity-of-t-cells-it-is-a-modified-antibody-abatacept-is-a-fusion-protein-composed-of-t"},{"sheetId":"CD141","name":"Rosuvastatin*","technology":"Other","technologyDetails":"statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is recommended to be used together with dietary changes, exercise, and weight loss. It is taken by mouth","developmentStage":"Clinical","nextSteps":"","customClinicalPhase":"Phase III","clinicalTrials":["NCT04472611"],"organizations":["Yale University"],"funder":"","publishedResults":[],"relatedUse":[],"countries":[],"description":"","show":true,"date":"2021-04-05 11:05:10.016114","type":"Treatment","fdaApproved":"FDA-approved since 2003, approved for the prevention of cardiovascular events","updatedOrNew":"None","template":[[]],"templateLink":"https://a